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ABSTRACT  
 
Metastasis is the process by which tumour cells disseminate to distant organ sites. 
Aberrant expression of stem cell-associated proteins within tumours is associated with 
metastasis and poor patient prognosis. One example of a stem cell factor that is 
associated with cancer progression is Nodal, a member of the TGF-β superfamily. 
Nodal is normally limited to pluripotent stem cells during embryonic development, and 
to specialized dynamic adult tissue (such as the cycling endometrium), but is 
aberrantly re-expressed in multiple cancer types, including melanoma, glioma, 
prostate cancer, and pancreatic cancer. The central objective of this thesis is to 
determine the role of Nodal during various aspects of the metastatic cascade in breast 
cancer. First, I determined that Nodal inhibition in aggressive breast cancer cell lines 
impairs tumour growth in an orthotopic nude mouse model, concomitant with reduced 
proliferation and enhanced apoptosis. Furthermore, in an experimental metastasis 
assay in NOD/SCID/MPSVII mice, I determined that Nodal knockdown prevents the 
transition from lung micrometastases to macrometastes, by supporting a positive ratio 
of proliferation to apoptosis. Using numerous animal models, I then discovered that 
Nodal promotes angiogenesis, and that knocking down its expression in established 
tumours reduces vascularization and causes necrosis.  Notably, Nodal  protein was 
positively correlated with vascular density in human breast cancer lesions.  
Mechanistically, Nodal induced a pro-angiogenic profile in breast cancer cells by 
upregulating VEGF and PDGF. Finally, I investigated the role of Nodal in the 
iii 
regulation of EMT and invasion; phenotypes that are classically associated with this 
morphogen. Specifically, since Nodal is implicated in mammary gland remodeling and 
placentation, I examined its effects on cellular invasion in these contexts. Nodal 
overexpression in poorly metastatic breast cancer and choriocarcinoma cell lines 
enhanced invasion and EMT-associated changes in gene expression, and this effect 
was in part mediated by ERK signaling. Nodal inhibition in metastatic breast cancer 
cell lines reduced spontaneous metastasis to the liver (but not the lung) in 
NOD/SCID/IL2γR- mice. The results presented herein suggest that Nodal promotes 
several pro-metastatic processes. Given its restriction to embryonic or highly 
specialized adult contexts, targeting Nodal in breast cancer poses an exciting avenue 
for therapeutic intervention. 
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If you’re out to describe the truth, leave elegance to the tailor. 
- Albert Einstein 
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CHAPTER 1 
General Introduction and Literature Review 
1
1.0 General Introduction and Literature Review 
In Canada, 40% of women and 45% of men will develop cancer during 
their lifetimes. Unimaginably, 1/4 Canadians will die from cancer or a cancer-
related death (1). Unfortunately, cancer is not a single disease; rather, it is a 
dynamic orchestrated phenomenon that involves multiple divergent cell types, 
communication between cells and their microenvironments, rearrangement and 
turnover of extracellular components, genomic instability and epigenetic 
alterations, and complex signalling networks between primary and pre-secondary 
sites (2-5). Furthermore, just as breast cancer is wildly divergent from a brain 
tumour, breast cancer in one patient behaves and arises differently than breast 
cancer in another patient (6-8), rendering the fight for the “cure” difficult to 
resolve. Accordingly, research geared towards elucidating the intricate molecular 
mechanisms that regulate the initiation and progression of this multifaceted 
disease is imperative in order to develop strategies for improved patient outcome. 
Breast cancer, in particular, directly afflicts one-in-nine Canadian women 
(1). The cause of death during breast cancer progression is primarily metastasis 
to secondary organs, most often involving liver, lung and bone. Consequently, 
understanding the mechanisms that underlie the transition from local to 
metastatic disease is of interest to both cancer scientists and the general public, 
and is the central focus of this thesis. 
2
1.1 Normal breast anatomy and development 
The mammary gland is a complex network of cell types and 
microenvironmental factors, which mediate lactation and transfer of milk, fat and 
protein between a mother and infant. Our knowledge of mammary gland 
development in humans is largely based on observations of mammary gland 
development in mice. In both rodents and humans, there are three key phases of 
mammary gland development, during embryonic development, puberty, and 
reproductive life (9,10): 
In mice, the first phase of mammary gland development occurs mid-
gestation, and is marked by the development of epithelial disc-like placodes 
(9,11). These placodes develop from multilayered ectoderm “milk lines” that arise 
from proliferation of basal cells in the epidermis, stimulated by signals from the 
underlying mesenchyme, such as bone morphogenetic protein 4 (BMP4) and 
fibroblast growth factor 10 (FGF10) (9,11). Overtime, the placodes develop into 
mammary buds, via elongation and invagination to form a luminal space (10-12). 
The mammary buds then undergo phases of proliferation and expansion, and 
give rise to a rudimentary gland (9).  
Postnatally, mammary development remains quiescent until puberty (9). 
During puberty, secondary branching morphogenesis of the ducts occurs in 
response to hormonal signals, such as estrogen, from the hypothalamic-ovarian-
pituitary axis (9,11). These hormonal signals cause the ends of the early ductal 
structures to transform into terminal end buds (9). The terminal end buds 
elongate and branch to eventually form full ductal networks throughout the entire 
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mammary fat pad, a specialized stromal compartment composed of multiple cell 
types including fibroblasts, adipocytes, endothelial cells, and immune cells (10). 
The primary role of the mammary gland during adult life is to 
accommodate pregnancy by responding to hormones that regulate lactation. The 
mature breast ducts are composed of two layers of cells that radiate from the 
nipple: an outer layer of basal myoepithelial cells, and an inner layer of luminal 
epithelial cells (Figure 1.1) (10). The myoepithelial cells have multiple 
responsibilities in the breast duct. First, they are responsible for production of 
basement membrane, which anchors the duct to the extracellular matrix (ECM), 
and separates epithelial and stromal compartments within the mammary fat pad 
(12). Second, the myoepithelial cells are involved in mediating differentiation, 
polarity and reorganization events of the luminal epithelial cells (12). For 
example, studies by Bissell, Peterson and colleagues have shown that in vitro 
culture of normal human luminal epithelial cells on Matrigel, a reconstituted 
source of basement membrane derived from Englebreth-Holm-Swarm sarcomas 
in mice, supports normal expression of polarity markers including epithelial 
specific antigen (ESA) and MUC1 (which demarcate the apical membrane), and 
integrin β4 (which demarcates the basolateral membrane) (13). In contrast, 
culture on Collagen Type 1 does not support this differentiation process (13). 
Interestingly, introduction of a myoepithelial co-culture restores epithelial polarity 
even in the absence of Matrigel (13), demonstrating the importance of this cell 
type in maintaining normal duct structure. 
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Figure 1.1 Human breast anatomy. The lobes of the breast are
connected to the nipple through the ducts, supported by a surrounding
stroma. The mature breast ducts are composed of two layers of cells
that radiate from the nipple: an outer layer of basal myoepithelial cells,
and an inner layer of luminal epithelial cells. The myoepithelial cells are
responsible for basement membrane production, and organization of the
luminal epithelial cells, which produce milk.
Adapted from Ali and Coombes (2002) Nat Rev Cancer, 2:101-112
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The luminal epithelial cells of the breast duct are responsible for milk 
production (10). One key hallmark of mammary gland development during 
pregnancy is proliferation and differentiation of the terminal end buds in response 
to hormone signals (predominantly progesterone and prolactin) to form secretory 
milk-producing alveoli (14,15). These alveoli are organized into structures called 
lobules. Following lactation, the alveoli undergo involution and apoptosis to 
remove 80% of the epithelium (9). This cycle continues in women with each 
pregnancy.  
 
1.2 The acquisition and progression of breast cancer 
Given that mammary epithelial cells are capable of continual and repetitive 
differentiation and remodelling events in response to various microenvironmental 
signals, it is not surprising that they are likewise receptive to signals that may 
contribute to the generation of cancer. Breast cancer arises from the epithelial 
cells of the ducts or the lobes of the breast, called ductal carcinoma and lobular 
carcinoma, respectively. The ducts are the most common origin of breast cancer 
and will be of primary focus here (Figure 1.2).  
In response to genetic or epigenetic alterations within cells, epithelial cells 
display intraductal proliferation of three non-invasive varieties, including usual 
ductal hyperplasia (UDH), atypical ductal hyperplasia (ADH), and ductal 
carcinoma in situ (DCIS) (16). Both UDH and ADH are considered “pre-
cancerous”, and there is conflicting evidence about whether they necessitate 
progression to cancer (16,17). DCIS is the first official stage of breast cancer, 
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Figure 1.2 Breast cancer progression. Breast cancer starts in the
lobe or the duct of the breast. During ductal carcinoma progression,
cells become hyperplastic and/or atypical, and eventually progress to
ductal carcinoma in situ (DCIS). DCIS is characterized by an intact
basement membrane and layer of myoepithelial cells. During invasive
dutal carcinoma (IDC), the basement membrane and myoepithelial cell
layer is breached, as tumour cells undergo metastatic dissemination.
Adapted from website: http://ftsask.ca/Christine/BC_Types.html
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and is characterized by an intact basement membrane and myoepithelial cell 
layer, and occupation of the intraluminal space by tumour cells (16). DCIS are 
relatively easy to treat with excision and radiation therapy; however, they are 
difficult to diagnose and are usually only found using mammography (18).  
DCIS lesions are classified into low-, medium-, or high-grade largely 
based on histological criteria. Low-grade DCIS is characterised by monomorphic 
cells that are evenly spaced, with small central nuclei. They have few mitoses 
and do not often display necrosis. In contrast, high-grade DCIS is characterised 
by pleomorphic cells that are unevenly spaced, with large nuclei. They have 
many mitoses and often display necrosis. Medium-grade DCIS are more difficult 
to define as they display features in between low- and high-grade, for example, 
mild to moderate pleomorphism (16).  
Invasive ductal carcinoma (IDC) is characterised by tumour invasion 
through the basement membrane, the myoepithelial cell layer, and the 
extracellular matrix (ECM). The transition from DCIS to IDC is typified by a 
drastic phenotypic transformation, whereby epithelial cells lose many hallmark 
features that define them as “epithelial”, and adopt a poorly-differentiated 
phenotype. For example, loss of epithelial (E)-Cadherin, a key cell-cell adhesion 
molecule expressed on epithelial cells, is associated with the transition from 
DCIS to IDC, and also with high histological grade, negative estrogen receptor 
status, and shorter disease-free-survival (19). In patients, acquisition of IDC is 
associated with an elevated risk of metastasis, even in lymph node-negative 
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lesions (20). Understanding the mechanisms that mediate this pivotal transition 
during disease progression is a central focus of cancer research worldwide.  
Interestingly, it has been postulated that breast cancer progression may 
not follow a linear disease course from DCIS to IDC. Rather, studies have 
described evidence for non-linear mechanisms of cancer progression. This 
concept is based largely on observations that (a) abnormal molecular 
characteristics in IDC are often present in DCIS (6,21,22), and (b) tumours are 
heterogeneous, whereby independent clones can co-exist and progress 
differently within the same lesion (reviewed in (23)). In order to characterize how 
breast cancer progresses from DCIS to IDC, one study generated mathematical 
algorithms to evaluate which of several candidate models of breast cancer 
progression most accurately recapitulated clinical observations (24). Results 
indicated that models describing a parallel evolution of cancer (i.e. DCIS and IDC 
lesions progress in parallel from a common progenitor) mirrored clinical 
observations better than models describing a linear-type progression (i.e. DCIS is 
a progenitor of IDC) (24). Their results explain why some breast cancers display 
features of both DCIS and IDC, and suggest that these types of cancers may 
arise from a common progenitor rather than by linear evolution, adding another 
layer of complexity to understanding breast cancer progression.  
 
1.3 Breast cancer classifications 
Breast cancer is classified based on stage (25) and grade (26). The TNM 
classification system of breast cancer stage is based on the size of the tumour 
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(T), lymph node involvement (N), and the presence/absence of distant 
metastases (M) (27,28). Generally, stage 1 includes small tumours (<2 cm) with 
or without micrometastasis involvement in the axillary lymph nodes (under the 
arm). Stage 2 tumours are slightly larger, (2-5 cm), with or without 
micrometastasis involvement in the axillary lymph nodes. Stage 3 tumours range 
in size, and are more locally advanced in that they have lymph node involvement 
under the arm, near the breastbone, or around the collarbone, and/or have 
spread to the chest wall, or the skin. Stage 3 tumours are sometimes inoperable 
by radical mastectomy, especially in cases of inflammatory breast cancer, in 
which lymph and skin metastases are significant. Stage 4 tumours show signs of 
metastases in other organs, most often including lung, liver or bone, and require 
treatment regimens that will simply maintain disease (27,28). 
While tumour stage is a measure of size and extent, tumour grade is a 
measure of histological features. Histological grade is based on three main 
criteria, including tubular formation, nuclear atypia, and mitotic counts, of which 
nuclear atypia has been reported to be the best predictor of recurrence following 
treatment (29-31). Each criterion is independently graded: Grading of tubular 
formation is based on whether the tumour is papillary, tubular or cribriform (grade 
1), or exhibits a solid nest pattern (grade 3). Grading of nuclear atypia is based 
on whether the tumour cells have nuclei that are uniform (grade 1) or 
pleomorphic (grade 3). (Note that grade 2 for both tubular formation and nuclear 
atypia is “in between” respective grade 1 and grade 3 features.) Finally, grading 
of mitosis is based on whether there are less than 5 mitoses per 10 high-power 
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fields of view (grade 1), between 5-10 mitoses (grade 2), or more than 10 
mitoses (grade 3). After each criterion is graded, a final tumour grade is assigned 
based on the sum of all grades (Tumour Grade 1= sum 3-4; Grade 2= 5-7, Grade 
3= 8-9), where grade 1 is well-differentiated and associated with good prognosis, 
and grade 3 is poorly-differentiated and associated with poor prognosis (29-31).
In addition to traditional histological and clinical classifications of breast 
cancer, DNA microarray analyses have uncovered several molecular subtypes of 
breast cancer that have helped predict patient-specific survival, and contributed 
to the development of targeted therapies. In a widely influential article published 
in Nature, Perou et al. defined four molecular subtypes of human breast cancer 
based on gene expression patterns in 42 different human breast tumour 
samples, using cDNA microarrays reflecting 8,102 human genes (6). From this 
study, four molecular subtypes of breast cancer were defined, including normal 
breast-like, ER+/luminal-like, ErbB2+, and basal-like (6). Normal-like tumours 
exhibit high expression of epithelial and adipocyte markers, and low expression 
of luminal epithelial markers. ER+/luminal-like tumours are estrogen receptor 
(ER) positive (+) and overexpress luminal cell markers. Recent studies have 
reported that the ER+/luminal-like subtype should be split into Luminal A (which 
is the most common subtype) and Luminal B (7,8), based on low and high 
histological grade, respectively. Patients bearing luminal-like tumours tend to 
have a good prognosis compared to other molecular subtypes. ErbB2+ (also 
known as HER2+) tumours overexpress the ERBB2 oncogene and are 
progesterone receptor (PR) negative (-) and ER-. Basal-like tumours (also 
13
known as Triple Negative) are PR-/ER-/HER2-, and exhibit high gene expression 
of Keratins 5, 6, and 17 (6). Interestingly, studies have revealed that carriers of 
the BRCA1 mutation, or the TP53 mutation, are predisposed to the basal-like 
subtype (7,8). Furthermore, basal-like and ErbB2+ subtypes are associated with 
shortest overall patient survival, and shortest relapse-free survival (7). More 
recently, another subtype has been identified as Claudin-low. This subtype is 
often triple negative (PR-/ER-/HER2-) and has low expression of cell-cell 
adhesion proteins, such as E-cadherin (32,33), making it an aggressive subtype 
of breast cancer.  
1.4 The metastatic cascade
IDC is a trigger and initiation step for the onset of the metastatic cascade. 
Metastasis is the process by which cancer cells spread and establish a 
secondary tumour at a distant organ site. Before metastasis occurs, breast 
cancer is generally considered to be “curable” by successful surgical resection 
and chemotherapy (16,18). However, once cancer has spread beyond the breast 
and lymph nodes, treatment modalities are usually geared towards disease 
maintenance and prolonging survival. Given the association between metastasis 
and poor prognosis, understanding the metastatic cascade poses an intriguing 
and challenging problem for scientists. 
In breast cancer, metastasis to lung, liver and bone are the most common 
causes of death (34,35). During metastasis, primary tumour cells must acquire 
the capacity to invade the basement membrane and myoepithelial cell layer 
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surrounding the breast duct. They proceed to degrade and invade through the 
ECM, and recruit a vasculature. Once metastatic cancer cells reach the vascular 
network, they intravasate into circulation, migrate through the bloodstream, and 
extravasate into secondary tissue sites. Alternatively, the cancer cells may 
spread through the lymphatics. At the secondary site, metastatic cancer cells 
must be able to sustain their growth in order to successfully form a secondary 
tumour mass (Figure 1.3) (2,36-38). 
The metastatic process is extremely delicate and inefficient, and some 
steps are “easier” to complete than others (36). As eloquently described by 
Hanahan and Weinberg in The hallmarks of cancer (39), and more recently in 
Hallmarks of cancer: The next generation (3), there are several cellular functions 
that are essential for successful metastasis, and not every tumour cell is capable 
of all of these functions. Examples include enhanced proliferation, evasion of 
apoptosis, tumour angiogenesis, and cellular invasion, which will constitute the 
main chapters of this thesis.  
 
1.4.1 Enhanced proliferation and evasion of apoptosis 
Under normal physiological conditions, cell fate is determined by incoming 
signals from the microenvironment. These signals bind to cell surface receptors 
to initiate a cascade of intracellular communication events that ultimately end in a 
change in gene expression and, subsequently, cellular behaviour. Two 
fundamental behavioural hallmarks of cancer include enhanced proliferation and 
evasion of apoptosis (3,39). Indeed, while most normal cells will not assume a 
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Figure 1.3 The metastatic cascade. During breast cancer metastasis,
primary tumour cells must acquire the capacity to invade the basement
membrane and myoepithelial cell layer surrounding the breast duct.
They proceed to degrade and invade through the extracellular matrix,
and recruit a vasculature. Once metastatic cancer cells reach the
vascular network, they intravasate into circulation, migrate through the
bloodstream, and extravasate into secondary tissue sites. At the
secondary site, metastatic cancer cells must be able to sustain their
growth in order to successfully form a secondary tumour mass.
Metastasis to lung, liver and bone are the most common causes of
death.
Adapted from Fidler (2003) Nat Rev Cancer, 3:453-458
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proliferative phase unless instructed to do so, cancer cells tend to be self-
sufficient in their ability to sustain mitogenic signalling. Furthermore, cancer cells 
can harbour mutations that render them insensitive to normal apoptotic signals 
from their microenvironments. Not surprisingly, mutations in genes associated 
with the cell cycle or with apoptosis are frequent in cancer. An understanding of 
these hallmarks and how their cycles are regulated is crucial to preventing 
progression of disease.  
 
1.4.1.1 The cell cycle 
The mammalian cell cycle consists of four phases that accommodate for 
DNA replication and cellular division, including G1, S, G2 (together known as 
interphase), and mitosis (Figure 1.4). G1 (“first gap”) is the first phase after a cell 
division. RNA and protein are produced immediately after the emergence of 
daughter cells, however, DNA synthesis rests, while cells decide whether to 
continue to divide, become quiescent or differentiate. At this point, cells can enter 
a quiescent phase, G0, before proceeding with the cell cycle. The decision to 
maintain G0 is often governed by an absence of mitogenic signals, a loss of 
adhesion, or cell density contact-inhibition (40). Entrance into Go is usually 
reversible, as cells re-enter the cell cycle in the presence of mitogenic signals 
(40). However, entrance into G0 can also be irreversible, in which case cells are 
said to be “post-mitotic” (41). For example, terminally differentiated neurons of 
the central nervous system are post-mitotic, and re-entrance back into the cell 
cycle upon de-regulation of this post-mitotic state is associated with the 
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Figure 1.4 The cell cycle. The mammalian cell cycle consists of four
phases that accommodate for DNA replication and cellular division,
including G1, S, G2 (together known as interphase (I)), and mitosis (M).
Progression through the cell cycle is regulated by protein complexes
(ex. cyclin and cyclin-dependent kinase complexes) or epigenetic
alterations (ex. phosphorylation of Histone H3) that cycle with phase-
entry and -exit events.
Adapted from website:
http://en.wikipedia.org/wiki/File:Cell_Cycle_2-2.svg
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acquisition of neurodegenerative diseases such as Alzheimer’s Disease (41,42). 
Re-entrance into the cell cycle from G0 or G1 permits entry into S (“synthesis”) 
phase during which DNA is copied. Following S phase is G2 (“second gap”), 
which is the final rest phase before mitosis (43).  
 Mitosis is the process of cell division, and consists of four phases, 
prophase, metaphase, anaphase and telophase. During prophase, the loosely 
bundled chromatin condenses to form chromosomes. Centrosomes, composed 
of two centrioles, move apart around the nuclear envelop in preparation for 
microtubule organization (44,45). During metaphase, the chromosomes line up 
along the equatorial plane, and when the nuclear envelop breaks down, 
microtubules from the polar centrosomes “search-and-capture” kinetochores on 
sister chromatids (44). During anaphase, the proteins that link sister chromatids 
are cleaved, and microtubules begin to shorten and cause segregation of sister 
chromatids towards opposite poles of the cell (43). Abnormal segregation of 
sister chromatids can cause irreversible damage to cells, therefore tight 
checkpoints exist to ensure normal segregation (43). During telophase, a 
nuclear membrane assembles around daughter chromosomes, and 
chromosomes decondense back into chromatin. Following mitosis, cytokinesis 
occurs, whereby a contractile ring, called a cleavage furrow, develops at the 
equatorial plane to finally split the cytoplasm to make two daughter cells (46). 
The daughter cells proceed to exit mitosis and enter back into G1 in response to 
anaphase-promoting complex/cyclosome (APC/C) assembly (43), and repeat the 
cell cycle to sustain proliferation.  
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The cell cycle is regulated by several mechanisms. First, cyclins and 
cyclin-dependent kinases (CDKs) mediate many of the phase-entry and -exit 
events during the cell cycle. For example, transition from G1 to S phase involves 
activation of the cyclinD-CDK4/6 complex (47), and transition from G2 to mitosis 
involves activation of the cyclinB-CDK1 complex (Figure 1.4) (48,49). Second, 
the cell cycle has several “checkpoints” that ensure each step is completed 
before proceeding to the next step. For example, during metaphase, in order to 
ensure proper segregation of sister chromatids, the spindle assembly checkpoint 
ensures that all chromosomes are lined up at the equatorial plane and bound to 
the mitotic spindle before anaphase can occur (44). The cell cycle is also 
regulated epigenetically. For example, phosphorylation of histone H3 fluctuates 
at various stages of mitosis, and is most prevalent during metaphase (Figure
1.4) (50). Furthermore, phosphorylation of histone H3 drops abruptly upon mitotic 
exit, and thus serves as a good marker for mitogenic activity (50). Together, 
these regulatory mechanisms are critical to ensure proper cellular division. 
 
1.4.1.2 Cancer cells exhibit self-sufficient proliferative programmes 
 There are several mechanisms that cells hijack to autoregulate their own 
proliferative programmes, rather than relying on regulated microenvironmental 
cues. First, cancer cells can aberrantly produce and secrete mitogenic signals 
themselves that signal back in an autocrine fashion. One example of this 
phenomenon is the production and secretion of WNT proteins from breast cancer 
cells (51). WNT proteins are a highly conserved family of secreted glycoproteins 
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that are heavily studied in developmental biology. Mutations in WNT pathway 
members are common in various types of cancer, most notably colorectal and 
skin cancers (52,53), to induce constitutive and aberrant WNT signalling; 
however, these mutations are not as common in breast cancer. Rather, breast 
cancer exhibits constitutive autocrine mitogenic WNT signalling, whereby WNT 
signals are upregulated via inhibition of sFRP1 expression, a secreted factor that 
competes with WNT ligands for receptor-binding (51,54,55). Interestingly, 
autocrine WNT signals in breast cancer are not only capable of activating 
canonical WNT signalling, but also activate ERK1/2 through transactivation of 
epidermal growth factor receptor (EGFR; also known as HER1) to mediate its 
mitogenic effects (51).  
Another example of how cells regulate their own proliferative programs is 
through altered receptor expression to improve receptivity to growth signals. One 
example is human EGFR expression during cancer progression. Similar to HER2 
(which defines an aggressive molecular subtype of breast cancer as described in 
section 1.2.1), EGFR is part of the ErbB-family of receptor tyrosine kinases, and 
its overexpression has been linked to various types of cancer, including breast, 
ovarian, stomach, and urterine cancers (56). Upon ligand activation, EGFR can 
stimulate a plethora of signalling cascades that are involved in activating 
proliferative programmes, including ERK MAPKs, PI3K/Akt, and STAT (57,58). 
Overexpression of ErbB-family receptors can also cause ligand-independent 
receptor activation to propagate these mitogenic pathways (39,58).  
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Lastly, cells can autoregulate their proliferation through mutations in 
intracellular signalling components that support proliferative programmes. For 
example, mutations in the small GTPase RAS result in enhanced proliferation in 
many types of human cancers including colon, bladder, and lung, among others 
(59-62). Furthermore, several studies by Clevers, Vogelstein, Kinzler and 
colleagues reported that mutations in β-catenin or APC (which mediate WNT 
signalling) play a significant role in the acquisition of colon cancer (52,63). 
Mutational alterations in these pathway components lead to constitutive, 
unregulated signalling propagation, and ultimately, the acquisition of disease.  
 
1.4.1.3 Programmed Cell Death 
Apoptosis, or programmed cell death, is a highly regulated and conserved 
mechanism amongst multicellular organisms that ensures tissue homeostasis. In 
contrast to necrosis, which results from cell trauma or injury, apoptosis is vital to 
an organism’s normal development and sustainability. Apoptosis is most often 
mediated by executioner proteins called caspases, a group of cysteine proteases 
that contain a pro-domain in their latent form. Activation of caspases is mediated 
by several mechanisms, including, but not limited to, (i) inhibition of caspase-
inhibitors, (ii) assembly of the apoptosome, or (iii) death receptor activation 
(Figure 1.5). There are two types of caspases, initiator caspases (ex. caspases 
8, 9, and 10) and effector caspases (ex. caspases 3, 6, and 7). In general, 
caspase-8 is the main initiator for cell death receptor-induced apoptosis, while 
caspase-9 mediates mitochondria-induced apoptosis (39). Upon activation, 
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Figure 1.5 Mechanisms of Apoptosis. Apoptosis is mainly mediated
by one of three mechanisms: (i) Inhibition of caspase inhibitors (such as
Inhibitor of Apoptosis Protein, or IAP), which allows for activation of
latent caspases, including pro-caspase-9, in response to mitochondria-
secreted Small Mitochondria-derived Activator of Caspases (SMAC). (ii)
Apoptosome assembly, which is initiated by the release of cytochrome c
from the inner membrane of the mitochondria, via formation of the
Mitochondrial Apoptosis-induced Channel (MAC). MAC formation is
normally regulated by an interplay between Bcl-2 (which inhibits channel
formation), and Bax (which promotes channel formation). (iii) Death
Receptor activation, which initiates apoptosis through mitochondria-
independent signal transduction and/or caspase activation. In all cases,
activation of caspases results in degradation of cellular components and
organelles to cause death.
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initiator caspases cleave and activate effector caspases, which proceed to cleave 
organelles or proteins within the cell to induce apoptosis, such as Poly-ADP-
ribose polymerase-1 (PARP-1) (64). Of note, PARP-1 can also induce apoptosis 
in the absence of caspases, by mediating translocation of Apoptosis Inducing 
Factor (AIF) from the mitochondria to the nucleus (64).  
Activation of caspases often occurs through mitochondrial release of pro-
apoptotic proteins that enable caspase activity. For example, in response to nitric 
oxide (NO), the mitochondrial membrane becomes more permeable to pro-
apoptotic proteins that are secreted into the cytosol (65). One such mitochondria-
derived protein is Second Mitochondria-derived Activator of Caspases (SMAC). 
SMAC binds to Inhibitor of Apoptosis Protein (IAP) to prevent it from inhibiting 
caspase-9 activity, thereby activating apoptosis (66). Indeed, addition of SMAC 
mimetics to cell lines (including breast, colon, lung, pancreas, skin and prostate 
cancer cell lines) increases sensitization to chemotherapy-induced apoptosis 
(67). 
Another mechanism of mitochondrial-induced apoptosis is through 
formation of the apoptosome complex. The apoptosome is initiated by the 
release of cytochrome c from the inner membrane of the mitochondria, via 
formation of the Mitochondrial Apoptosis-induced Channel (MAC) (68). MAC 
formation is normally regulated by an interplay between Bcl-2 (which inhibits 
channel formation), and Bax (which promotes channel formation) (68-70). Once 
MAC has been formed, cytochrome c is released from the inner membrane of the 
mitochondria, and forms the apoptosome by binding to Apoptotic Protease 
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Activating Factor-1 (APAF1) and pro-caspase-9 (68). The caspase pro-domain is 
subsequently cleaved off, and caspase-9 becomes activated to induce apoptosis. 
In addition to mitochondria-mediated apoptosis, signal transduction in 
response to ligand binding to death receptors can initiate apoptosis through 
mitochondria-independent caspase activation. For example, interactions between 
members of the Tumour Necrosis Factor (TNF) receptor family and their ligands 
induce apoptosis through activation of the TNF receptor-associated death 
domain (TRADD), and subsequent activation of caspase-8 (71).  Indeed, 
treatment of cell lines (ex. Hodgkin’s lymphoma and breast cancer cell lines) with 
TNF-α or related ligands has been shown to induce sensitization to 
chemotherapy-induced apoptosis (72,73). 
 
1.4.1.4 Alterations associated with apoptosis evasion 
In cancer, apoptotic programmes are often deregulated to render the cell 
unreceptive to initiation of cell death pathways. Like proliferation, apoptotic 
programmes can be altered on several levels, including altered mitochondrial 
function, or mutations in apoptotic signalling pathways. For example, 
mitochondria-induced apoptosis can be deregulated in cancer through altered 
expression of Bcl-2 or Bax proteins. Specifically, in breast cancer cells, the pro-
tumourigenic progesterone metabolite 5-α-dihydroprogesterone causes an 
increase in the ratio of Bcl-2:Bax mRNA expression concomitant with decreased 
apoptosis, while the anti-tumourigenic progesterone metabolite 3-α-
dihydroprogesterone has the opposite effect (74).   
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Mutations in genes associated with apoptosis are additional mechanisms 
of apoptosis evasion in cancer. One example that has received great attention is 
the tumour suppressor p53 (encoded by the TP53 gene). The normal function of 
p53 is to prevent damaged cells from replicating. Therefore, mutated p53 permits 
replication of cells with DNA damage, which can lead to an accumulation of 
genetic mutations and the initiation of cancer (39,75,76). Another example of a 
common mutation in cancer is deactivation of the BCL2 oncogene, which renders 
cells unable to initiate the apoptosome (39,68,69).  
1.4.2 Tumour vascularization 
As tumours proliferate, they eventually require a larger supply of oxygen 
and resources to sustain their growth. Accordingly, tumour vascularization is a 
rate-limiting step in the metastatic cascade. In addition to supporting growth, 
tumour-associated vessels facilitate cancer progression by acting as conduits for 
tumour cells to travel to secondary sites. Tumour vascularization involves co-
operation between multiple cell types within the local microenvironment, and 
recruitment of bone marrow-derived cells (BMDCs) from distant sites through 
chemokine signalling axes (77). Together, these cell types work in concert within 
a pro-angiogenic niche that is conducive to vascular development, to “feed” the 
growing tumour and promote disease progression. Of note, high microvascular 
density is associated with poor prognosis in cancer patients (78,79), and is 
therefore an interesting target for therapy.  
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1.4.2.1 Structure of blood vessels and the importance of vessel integrity 
Blood vessels are made of multiple cell types, including an external layer 
of pericytes, a basement membrane, and an internal layer of endothelial cells 
(Figure 1.6) (80). Endothelial cells are the main components of the vessel walls 
and are tightly assembled to ensure vessel integrity, while pericytes play a role in 
vessel maturity (80). Blood vessels can become “leaky” during cancer 
progression, largely due to destabilization of the vessel structure (77,80). For 
example, during hypoxia, there is an upregulation of vascular endothelial growth 
factor (VEGF) that causes endothelial cells to exhibit looser cell-cell adhesions 
(81). Furthermore, hypoxia causes an upregulation of Angiopoietin-2, which is 
associated with a depletion of pericyte coverage, reduced basement membrane 
integrity, and loosening of the endothelial cell layer (77,82). Lastly, hypoxia 
inducible factor (HIF) proteins have been shown to recruit BMDCs that secrete 
proteases that degrade extracellular matrix and basement membrane 
components, such as matrix metalloproteinases (MMPs) and  cathepsins (83). 
Together, deregulation of vessel integrity supports elevated intra/extravasation of 
tumour cells across the vessel wall, and reduces drug delivery to the tumour site. 
As a result, “vessel normalization”  has been proposed as a potential mechanism 
of improving drug delivery during treatment, involving increasing pericyte 
coverage, basement membrane deposition, and tightening of endothelial cells 
(80,84). 
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Figure 1.6 Structure of blood vessels. Blood vessels are made of
multiple cell types, including an external layer of pericytes, a basement
membrane, and an internal layer of endothelial cells. Endothelial cells
are the main components of the vessel walls and are tightly assembled
to ensure vessel integrity, while pericytes play a role in vessel maturity.
Blood vessels can become leaky during cancer progression, due to
destabilization of the vessel structure.
Adapted from Bergers and Benjamin (2003) Nat Rev Cancer, 3:401-410
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1.4.2.2 Mechanisms of tumour vascularization 
Tumour vascularization occurs through a combination of vasculogenesis 
(the de novo growth of blood vessels), vasculogenic mimicry (cancer cells mimic 
endothelial cells and make their own vessels) and angiogenesis (the sprouting of 
new vessels from existing vessels) (85-87). Although each of these processes 
will be discussed, angiogenesis is the primary mechanism of tumour 
vascularization, and will be of primary focus. 
In adult systems, vasculogenesis is mediated by mobilization of BMDCs, 
which contain a variety of progenitor populations that give rise to cells that 
constitute the blood, vasculature, supportive tissue and bone. BMDC populations 
are mobilized into the blood stream in response to chemokine signals, and home 
to tissues that require stem cell populations for tissue regeneration, repair, and 
vascularization.  Likewise, studies by Rafii, Lyden, Kaplan and colleagues have 
demonstrated that  BMDCs are  recruited to  both pre-metastatic and primary 
tumour sites in response to factors secreted by tumour cells to aid in 
vascularization (88,89). In one such study, they report that bone marrow-derived 
endothelial and hematopoietic cell types are required for tumour vascularization 
in vivo (90).  
Vasculogenic mimicry is another mechanism that yields de novo vessels
that contribute to tumour vascularization (86,87). Vasculogenic mimicry is 
characterized by the ability of aggressive cancer cells to express endothelial cell 
markers and form functional endothelial-like vascular networks (86,91). Hendrix 
and colleagues have shown evidence for vasculogenic mimicry in melanoma, 
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ovarian and prostate cancer (92,93), and other groups have demonstrated the 
same phenomenon in  lung and breast cancer (94,95). Vasculogenic mimicry will 
be discussed in more detail, as an example of how tumour cells display plasticity 
during disease progression (Section 1.5.1).  
Tumour angiogenesis, on the other hand, is a more widely studied 
phenomenon that involves sprouting of vessels from pre-existing networks (c.f. 
de novo vessel formation). In fact, as first proposed by Judah Folkman over 40 
years ago in the New England Journal of Medicine (96), many current cancer 
therapies target mediators of tumour angiogenesis, such as VEGF 
(Avastin/Bevacizumab). During normal tissue repair, such as during tissue 
ischemia, angiogenesis is initiated in response to low oxygen (hypoxia) (97,98). 
Subsequently, HIF proteins induce the upregulation of pro-angiogenic proteins, 
such as VEGF, FGF, or platelet-derived growth factor (PDGF), in order to induce 
vessel branching and oxygen delivery (97,98). Angiogenesis is similarly initiated 
in cancer when tumours become large enough that oxygen cannot permeate all 
the way through (approximately 1-2 mm (87)). The resulting hypoxia gradient 
ignites a signalling cascade that induces the expression of pro-angiogenic 
proteins (99).   
 
1.4.3 Cellular invasion 
During cancer progression, epithelial organization is disrupted when 
cancer cells become invasive. Cellular invasion is not a single process, but rather 
a composite of multiple cellular functions and alterations that work together in 
34
synchrony. One pivotal alteration that occurs during the acquisition of an invasive 
phenotype is epithelial-to-mesenchymal transition (EMT) (3,100). EMT is a 
key aspect of tissue remodelling in normal physiological processes including 
gastrulation, lactational involution, and wound healing (100). Equally, EMT 
contributes to tissue remodelling during cancer invasion, by mediating changes in 
cell-cell adhesions, including downregulation of E-Cadherin and upregulation of 
N-Cadherin (101,102). These alterations allow cancer cells to break free of their 
site-of-origin.  
A second process involved in cellular invasion is proteolytic degradation of 
extracellular matrices. Similar to EMT, proteolytic degradation is not limited to 
cancer invasion, but rather is a common characteristic of tissue remodelling. For 
example, matrix metalloproteinases (MMPs) are a family of proteases that are 
essential during tissue remodelling in both normal and pathological contexts. 
During mammary gland development, MMP activity is important in supporting the 
invasive events that are required for branching and alveolar morphogenesis 
(103-106). In cancer, MMPs have been shown to promote invasive phenotypes. 
For example, MMP activity is upregulated by insulin-like growth factor-1 (IGF-1) 
in human breast cancer cell lines, through MAPK and Akt pathways leading to 
increased invasive potential (107).  
Once cell-cell adhesions have been disrupted and the surrounding ECM 
has been sufficiently degraded, cancer cells are free to migrate away from their 
site-of-origin. It has been proposed that cellular migration is mediated by 
guidance interactions between multiple cell types in the tumour milieu. For 
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example, Condeelis and colleagues have shown that tumour cell migration 
through the ECM and into the blood stream (intravasation) is mediated by a 
paracrine interaction between tumour cells and infiltrating macrophages, 
involving a protein called MENA that is expressed on tumour cells (108).  Using 
intravital multiphoton imaging, this group was able to observe interactions 
between alternating macrophages and migratory cancer cells in vivo in real time 
(109), illustrating the importance of stromal compartments in supporting migratory 
phenotypes in cancer. 
1.5 Cellular plasticity as a mechanism for metastasis 
(See copyright release Appendix 1)
Given the inefficiency of the metastatic cascade, it is believed that tumour 
cells that successfully metastasize display phenotypic plasticity. Studies in the 
field of induced pluripotent stem cell (iPSC) biology support this concept, as 
alterations which support tumourigenesis also promote the induction of 
pluripotency (110-112). In cancer, cellular plasticity is characterized by a loss of 
lineage-specific markers and an ability to mimic embryonic cell types, yielding 
cells that are highly resilient and self-sufficient, and that can survive in multiple 
dynamic foreign microenvironments throughout the metastatic cascade (113). A 
few examples of how cells display plasticity during cancer progression include 
vasculogenic mimicry, EMT, endothelial-to-mesenchymal transition (EndMT), and 
phenotypic switching: 
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1.5.1 Vasculogenic mimicry 
Several studies have demonstrated the importance of cellular plasticity in 
cancer.  A clear example is vasculogenic mimicry, characterized by the ability of 
aggressive cancer cells to express endothelial cell markers and contribute to the 
formation of de novo endothelial-like vascular networks (86,91). These networks 
develop via a process similar to normal embryonic vasculogenesis, and are 
thought to be functional conduits for circulation throughout the tumour (86). One 
mediator of vaculogenic mimicry in cancer is VE-Cadherin. Notch4 and Nodal 
have been shown to cooperate to induce VE-Cadherin expression and the 
transendothelial phenotype in aggressive melanoma cells (114). Indeed,  
knockdown of VE-Cadherin, Notch4, or Nodal in melanoma cells impairs the 
formation of vasculogenic networks (114-117). Vasculogenic mimicry has been 
observed in melanoma, breast cancer, prostate cancer, ovarian cancer and lung 
cancer, and exemplifies the ability of cancer cells to alter their gene expression to 
resemble cell types that are not part of their own lineage (92-95). 
 
1.5.2 Epithelial-to-mesenchymal transition (EMT) 
EMT is another example of plasticity, and can be seen both during normal 
development and in cancer (118). EMT is characterised by a loss of epithelial cell 
markers, such as E-Cadherin, and the acquisition of mesenchymal markers, such 
as Vimentin and N-Cadherin (118). During development, EMT is required for 
gastrulation and serves an essential morphogenic function (119). In mammalian 
embryogenesis, the primitive streak is the site of involution during gastrulation, 
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mediated by signals from the node including Nodal and FGF (119). Signals from 
the node induce the expression of transcription factors that are essential for EMT, 
including Snail and Twist, which in turn alter expression of E-Cadherin both at the 
gene and protein level to facilitate motility (119). In cancer, EMT is likewise 
correlated with a broad upregulation of pluripotency markers, including Snail and 
Twist transcription factors (118-121). Functionally, EMT is associated with 
increased migration and invasion, changes in cell adhesion, intravasation of 
cancer cells into the blood stream, and spontaneous metastasis, all attributable 
to robust changes to cell-cell adhesion molecules during this transition (118).  
 
1.5.3 Endothelial-to-mesenchymal transition (EndMT) 
Another interesting example of cellular plasticity similar to EMT is EndMT, 
a transdifferentiation event (122). EndMT is characterized by a loss of endothelial 
cell markers such as vascular endothelial (VE)-Cadherin and CD31, and the 
acquisition of mesenchymal markers such as SNAI1 to yield an invasive cellular 
phenotype (122). EndMT occurs in normal embryogenesis, such as during heart 
valve development, whereby myocardial-derived TGF-β induces SNAI1 
expression and subsequent downregulation of VE-Cadherin in endocardial 
endothelial cells of the heart tube (123).  This EndMT event allows endothelial 
cells to delaminate, activate proteolytic enzymes and invade the ECM to initiate 
valve formation (123). Similarly, in response to tumourigenic signals within the 
tumour microenvironment, EndMT is believed to cause delamination of 
endothelial cells from local blood vessels. These endothelial cells are thought to 
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contribute to the population of cancer-associated fibroblasts (CAFs) that are 
present in the tumour stroma, which are a major source of fibronectin, secreted 
oncoproteins and growth factors (122,124).  
 
1.5.4 Phenotypic “switching” 
Several interesting studies have shown that sorted tumour cell 
subpopulations exhibit phenotypic switching, and display dynamic cell surface 
marker expression. Meyer et al. found that non-invasive epithelial-like 
CD44+/CD24+ breast cancer populations gave rise to highly-invasive 
mesenchymal-like CD44+/CD24- cells both in vitro and in vivo (125). 
Interestingly, the phenotypic switching events that occurred in each population 
were dependent on Activin/Nodal signalling (125). Consistently, Morrison and 
colleagues showed that melanomas sorted for ABCB5+ versus ABCB5- were 
able to re-establish cell surface marker expression ratios that recapitulated the 
original tumour population in vivo (126). This switching phenomenon was also 
true for many other markers, including CD166, A2B5, CD151, CD54, CD44, CD9, 
CD29, N-Cadherin, and CD271. Phenotypic switching is another emerging 
example of how tumours cells display plasticity.   
1.6 Embryonic proteins promote plasticity in cancer
One commonality between the aforementioned examples of cellular 
plasticity is that these processes frequently involve embryonic programmes. 
Recently, there has been a surge of research dedicated toward identification of 
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embryonic factors that are aberrantly expressed in cancer, and responsible for 
promoting cellular plasticity during cancer progression. Hendrix and colleagues 
elegantly tackled this problem by using the zebrafish embryo as a functional in 
vivo reporter to gain insight about what embryonic pathways might be activated in 
cancer cells (127). In their study, aggressive melanoma cells (versus poorly 
aggressive melanoma cells) were injected into the animal pole of zebrafish 
embryos at the blastula stage, and the effect of the melanoma cells on host 
development was observed after 6-8 hours. Interestingly, the aggressive 
melanoma cells were able to induce an almost-complete secondary axis, but the 
poorly aggressive melanoma cells were not. The pressing question was, what
embryonic factor is able to induce a secondary axis? 
Several studies implicated the embryonic protein Nodal as a top candidate 
for the observed phenomenon (128,129). It had been previously shown that 
injection of Nodal RNA into zebrafish embryos could induce a secondary 
notochord (128).  Furthermore, an article had been published in Nature 
demonstrating that misexpression of Nodal homologue, Znr1, could induce an 
ectopic outgrowth in zebrafish embryos (129). Together, these findings were 
similar to those observed in response to aggressive melanoma cell injections (by 
the Hendix group), and therefore pointed to Nodal as a fundamental embryonic 
protein with a putative role in cancer progression.  
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1.6.1 Nodal: An early embryonic protein 
(See copyright release Appendix 1)
Nodal is an embryonic morphogen that promotes mesendoderm 
specification and left-right asymmetry during embryogenesis (127,130,131). This 
embryonic protein is also essential for maintaining the pluripotent quality of stem 
cells during development, and is down-regulated as stem cells differentiate 
(127,130). Nodal is part of the TGF-β superfamily, and its actions are initiated by 
binding Activin-Like Kinase Receptor type I (ALK4/7) and type II (ActRIIB) 
(Figure 1.7). Upon activating this receptor complex (ALK receptor complex), 
SMAD2 (and possibly SMAD3) is phosphorylated intracellularly and interacts with 
SMAD4 before translocating to the nucleus (130). In the nucleus, transcription 
factors, such as forkhead box HI (FOXH1), are activated to increase Nodal 
expression and create a positive feedback loop (127). In a normal adult cell, 
Nodal expression and subsequent signalling is thought to be silenced (130).  
Nodal signalling is enhanced by the epidermal growth factor-
cripto/FRL1/cryptic (EGF-CFC) family co-receptor, Cripto (TDGF1) (127). Cripto 
has an N-terminal signal peptide, an EGF-like domain which directly interacts 
with Nodal, a conserved cysteine-rich (CFC) domain which interacts with ALK4, 
and a hydrophobic C-terminal containing sequence information for a glycosyl-
phosphatidylinositol (GPI) anchor (132). The adjacent positioning of the EGF-like 
domain and the CFC domain helps bring Nodal into proximity with ALK4 to 
facilitate enhanced binding (132). Cripto is either linked to the cell membrane 
through its GPI-anchor, or exists as a soluble factor in the extracellular space 
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Figure 1.7 The Nodal signalling pathway. In the extracellular
environment, Nodal binds the activin-like kinase type I (ALK4/7) and
type II (ActRIIB) heterodimeric receptor complex and subsequently
triggers the phosphorylation and activation of ALK4/7 by ActRIIB.
Intracellularly, ALK4/7 phosphorylates SMAD2/3, which in turn forms a
complex with SMAD4. The SMAD2/3-SMAD4 complex translocates to
the nucleus where it associates with transcription factors, such as
forkhead box HI (FOXHI), to initiate transcription of target genes. Target
genes include Nodal (for autoregulation of its own expression), or Lefty
(a Nodal inhibitor). Like other TGF-β superfamily proteins, Nodal is a
pro-protein that requires cleavage by convertase enzymes, such as
Furin (SPC1) and Pace4 (SPC4), in order to become active. Nodal
signalling is enhanced by the epidermal growth factor-coreceptor Cripto
(TDGF1), which binds to the ALK4/7-ActRIIB receptor on the cell
membrane, and is known to be associated with tumourigenesis. The
small molecule inhibitor SB431542 interferes with the Nodal signalling
cascade by inhibiting the ALK4/7 subunit of the ALK4/7-ActRIIB
heterodimeric receptor complex.
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(133,134). Studies have shown that GPI-linked Cripto is required for its role as a 
Nodal co-receptor (135,136). Studies in Xenopus embryos show that Cripto 
enhances Nodal signalling through direct interactions with ALK-4 that facilitate 
nodal-receptor binding, or with ALK-7 to enhance receptivity to nodal activation 
(137,138).  
Nodal signalling is inhibited spatially and temporally during development 
by inhibitors such as LeftyA/B, and Cerberus-like (CER1) (130,139). These 
inhibitors are transcribed in response to Nodal signalling, and act as a negative 
feedback mechanism to control Nodal localization and action in the developing 
embryo (130). Lefty, in particular, is also regulated by alternate SMAD pathways, 
WNT, and Oct4 (POU5F1) signalling, and is upregulated during differentiation 
events (140). It inhibits Nodal signalling through interactions with Nodal and/or 
Cripto in the cellular microenvironment or at the cell surface (130).  
The Nodal gene is located on chromosome 10 in humans, and contains 3 
exons. In mice, Nodal is transcriptionally regulated at 3 different sites: the left 
side-specific enhancer, (LSE), the asymmetric enhancer (ASE), and the node-
specific enhancer (NDE) (141,142). The LSE and ASE, located 4kb upstream of 
the translation start site and in the first intron, respectively, are involved in 
autoregulation of Nodal signalling through activation of FOXH1 transcription 
factor (131,141,142). The NDE, located 10 kb upstream of the gene locus, is 
Notch-responsive (143,144). Similar enhancer regions exist between mice and 
humans, suggesting similar mechanisms of transcriptional regulation. As 
expected, human melanoma cells utilize a positive feedback mechanism that 
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sustains Nodal signalling, and data suggests that Notch regulates Nodal in this 
cancer type as well (4,114,127,145). Most of the literature surrounding Nodal 
regulation and signalling is based on murine, zebrafish, and Xenopus model 
systems; the details of Nodal transcriptional regulation in human cancer and 
development are currently being investigated. 
Nodal transcription may also be regulated by epigenetic mechanisms, 
such as methylation. The Nodal gene contains a CpG island near the 
transcription start site, and the methylation of this region has been correlated with 
gene expression in melanoma cells (145). MicroRNA regulation has also been 
implicated to play a role in post-transcriptional regulation of Nodal. Specifically, 
miR-430 is able to inhibit translation of the Nodal agonist, Squint, in zebrafish 
(146). The role of miRNA in the regulation of human Nodal has not yet been 
described.  
In addition to transcriptional and post-transcriptional mechanisms of 
regulation, Nodal is also subject to post-translational regulation. Studies in 
murine embryos have determined that Nodal is a pro-protein that is subject to 
activation by subtilisin-like proprotein convertase (SPC) enzymes, SPC1 (FURIN) 
and SPC4 (PCSK6; previously known as PACE4) (147). SPC1 and SPC4 cleave 
and activate Nodal upon secretion, and are necessary for Nodal signalling and 
Cripto induction in vivo (147). Nodal is also post-translationally modified through 
glycosylation events. Human Nodal has 2 glycosylation sites within its 
propeptide, and murine Nodal has 1 glycosylation site within its propeptide. In 
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murine Nodal, N-glycosylation acts to stabilize the pro-domain, and inhibit 
proteolytic maturation (148).
Biochemical studies using murine Nodal expression constructs have 
demonstrated that Nodal is trafficked within the cell through both Cripto-
dependent and Cripto-independent mechanisms. Previous studies examining the 
Cripto-dependent mechanism of Nodal trafficking have shown that GPI-anchored 
Cripto recruits uncleaved Nodal and soluble convertase enzymes to flotillin lipid 
rafts on the cell membrane, to facilitate pro-domain processing and endocytosis 
to the early endosome (133,134,149-152). In the early endosome, Nodal can 
interact with its ALK receptor complex to propagate its signal, and eventually 
progress to the lysosome (133). Interactions between ALK4 and dapper-2 
(DACT2), a dishevelled-associated protein that interacts with the Nodal pathway 
at the late endosome marked by RAB7, accelerates trafficking to the lysosome 
(133).
Cripto-independent mechanisms of trafficking can follow several 
modalities (133,139,153). For instance, unidentified GPI-anchored receptors can 
behave like Cripto by recruiting uncleaved Nodal and soluble convertase 
enzymes into proximity to facilitate cleavage (133). It is also possible that 
uncleaved Nodal interacts with its ALK receptor complex on caveolin lipid rafts to 
initiate GPI-anchor-receptor-independent endocytosis (133,149). Nodal may also 
interact with soluble convertases directly in the extracellular microenvironment. 
Once the pro-domain is cleaved, active Nodal can bind unidentified GPI-
anchored receptors (besides Cripto) on the cell membrane to initiate endocytosis 
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(133). Within the cell, Nodal can be sequestered in intraluminal vesicles, to inhibit 
or delay signalling activity (134). Nodal trafficking has been studied using murine 
Nodal in an artificial expression system. Trafficking of endogenous human Nodal 
has not yet been defined. Furthermore, the requirement of Cripto in Nodal-
mediated signalling in cancer has not yet been established. Regardless, this 
complex mode of intracellular trafficking intricately controls Nodal signalling via 
compartmentalization and degradation. 
Nodal signalling range is determined by its stability, which is effected by 
cleavage of the Nodal N-terminal pro-domain by SPC1 and SPC4, and/or N-
glycosylation (148). The presence of the N-terminal pro-domain normally 
functions to reduce uptake by endocytic compartments for protein trafficking 
(133,148). Studies by Constam and colleagues have shown that cleavage of the 
Nodal precursor in conditioned media triggers clearance within 24 hours via 
increased receptor-mediated uptake into endocytic vessels, and that intracellular 
mature-Nodal is degraded within 1 hour (148). Given that Nodal is an embryonic 
morphogen and therefore requires regulated signalling range, Constam has 
proposed that convertase processing is likely a mechanism for autocrine 
signalling (133,149).  On the other hand, Nodal is stabilized by the presence of 
its pro-domain, and also by N-glycosylation, which is likely a mechanism for 
paracrine signalling (133,148). Constam has shown that N-glycosylation 
increases the stability of Nodal in conditioned media by reducing intracellular 
degradation (without affecting intracellular uptake) (148). Post-translational 
protein modifications are therefore important to maintain Nodal’s role as a 
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morphogen during embryonic patterning and development. Moreover, regulation 
of Nodal is very complex with numerous targets for aberrant activation.  
The primary role of Nodal during embryonic development is to establish 
anterior-posterior axis patterning and left-right asymmetry (130). It is first 
expressed in the murine epiblast shortly after implantation, and is maintained and 
enhanced by autoregulation (154). Convertases expressed in the adjacent 
extraembryonic ectoderm process Nodal predominantly in the proximal epiblast 
(130,147). Activated Nodal signalling subsequently induces gene expression of 
Lefty1 (note: Lefty1 and Lefty2 are murine orthologs of human LeftyB and LeftyA, 
respectively) and CER1 in the distal visceral endoderm, which later becomes the 
anterior visceral endoderm (130).  Nodal signalling is required for the 
displacement of the anterior visceral endoderm, determining the position of the 
anterior-posterior axis (130). Eventually, Nodal signalling becomes restricted by 
Lefty1 and CER1 to the proximal posterior region of the epiblast where the 
embryonic ectoderm and primitive endoderm are developing, and where the 
primitive streak will form (Figure 1.8) (131,133,139,155,156).  Interestingly, 
signalling by a cleavage-resistant mutant of Nodal has been shown to induce 
mesoderm and EMT (133). 
As development proceeds and cells undergo gastrulation, Nodal becomes 
restricted to the node at the anterior of the primitive streak, hence the name 
“Nodal” (130). The node initiates left-right axis formation (130,155,157,158). 
Nodal and growth differentiation factor 1 (GDF1) from the ventral node pattern 
the left side of the embryo through interactions with Cryptic in lateral plate 
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Figure 1.8 Nodal initiates anterior-posterior axis formation in
mouse embryos. Nodal is activated in the proximal epiblast by
convertase enzymes, such as Furin (SPC1) and PACE-4 (SPC4), from
the extraembryonic ectoderm. Nodal is maintained through
autoregulation, and eventually signals the distal visceral endoderm
(DVE) to induce feedback inhibitors, such as Lefty1 and Cerberus-like
(cerl).The DVE becomes the anterior visceral endoderm (AVE), whose
displacement requires Nodal signalling in order to form the anterior-
posterior axis. Lefty1 and cerl inhibit Nodal signalling in the anterior
region of the embryo. Nodal therefore becomes restricted to the
posterior region, where it plays a pivotal role in primitive streak
formation.
Adapted from Schier, 2003.
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mesoderm (139). On the right side of the embryo, Nodal inhibitors such as CER1 
and Lefty1/2, and physical leftward flow from cilia restrict Nodal signalling (Figure 
1.9) (139).  During somitogenesis, Nodal becomes more specifically restricted to 
mesoderm cells on the left side of the embryo, and is downregulated with 
differentiation until it is no longer present at approximately 8 dpc (156). 
Several studies with human embryonic stem cells have sought to elucidate 
the role of Nodal in human development. It is known that Nodal promotes 
pluripotency in human embryonic stem cells (159,160). Vallier and colleagues 
(2009) showed that Nodal signalling maintained pluripotency in human 
embryonic stem cells through SMAD2/3-induced activation of Nanog gene 
transcription (161). In turn, Nanog protein was shown to interact with SMAD2/3 to 
limit transcriptional activity of the Nodal signalling pathway, and inhibit endoderm 
differentiation (161). Several studies have also shown that inhibition of 
Activin/Nodal signalling in human embryonic stem cells by receptor inhibition with 
SB431542 induces neuroectoderm specification (161-163). Together, these 
studies exemplify the role of Nodal in maintaining pluripotency by inhibiting 
differentiation into neuroectoderm and mesendoderm lineages in human 
embryonic stem cells.  
 
1.6.2 Nodal is expressed in placenta and dynamic adult tissues 
 As outlined, Nodal plays a primary role during embryonic development; 
however, there are a few (understudied) examples of Nodal-expressing 
extraembryonic and normal adult tissues, including the placenta, the involuting 
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Figure 1.9 Nodal initiates left-right axis formation in mouse
embryos. Cilia-induced leftward flow within the embryo causes Nodal to
localize to the left side of the node. Furthermore, Cerl and Lefty
expression restrict Nodal to the left side of the node. On the left side of
the embryo, Nodal signalling is facilitated by Gdf1 from the ventral node,
and Cryptic, a Cripto-like co-receptor for Nodal in the lateral plate
mesoderm. This results in a morphogenic gradient that inhibits Nodal in
the right side of the embryo, and restrict its expression to the left side of
the embryo and yield the left-right axis.
Adapted from Constam, 2009.
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mammary gland, and the cycling endometrium. Interestingly, each of these 
systems is highly dynamic, and undergoes widespread remodelling events. 
 In the developing mammalian blastocyst, the trophectoderm cell layer 
surrounding the inner cell mass and blastocoel gives rise to the fetal portion of 
the placenta (164). Upon implantation, fetal trophoblast cells invade the maternal 
decidua and spiral arteries in order to gain access to the maternal blood supply. 
Given the role of Nodal in promoting invasive events during embryogenesis, 
recent studies have explored whether Nodal plays a role during placentation. In 
mice, insertional null Nodal mutants exhibit disrupted embryonic development 
concomitant with abnormal placentation (165). Similarly, SPC1 and SPC4 double 
knockout mice show accelerated differentiation of trophoblast stem cells during 
placentation (166). In vitro studies have demonstrated that Nodal-overexpression 
in HTR-8/SVneo trophoblast cells decreases cellular invasion and migration 
(167).  Together these studies implicate a role for Nodal in mediating invasive 
trophoblast cell functionality both in vivo and in vitro. 
 As previously mentioned, during pregnancy and lactation, the terminal end 
buds of the mammary gland undergo proliferation and differentiation to form 
secretory milk-producing alveoli (14,15). Post-lactational involution reverts the 
mammary gland back to its pre-lactation state, and is characterised by 
widespread apoptosis of alveolar epithelial tissue, stromal remodelling, and 
adipocyte replenishment (9,168). Studies have found that Nodal and members of 
the Nodal signalling pathway are cyclically expressed during mammary gland 
remodelling. In particular, one study found that Nodal, Cripto, ALK-4, and SMAD4 
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were upregulated during lactation, and downregulated during involution in BalbC 
mice (137,169). These results suggest that Nodal signalling may play a dynamic 
role during mammary gland remodelling, whereby Nodal upregulation correlates 
with proliferative alveolar expansion, and Nodal downregulation correlates with 
apoptosis.  
Nodal has also been studied in the human endometrium, which, like the 
mammary gland, undergoes many remodelling events during adulthood. 
Endometrium cycling consists of three phases: menstrual, proliferative (re-
epithelialization), and secretory (170). Studies by Harrison and colleagues have 
studied Nodal signalling in human endometrium during the various phases of 
remodelling. His group has shown that Lefty, formerly known as Endometrial 
Bleeding-Associated Factor (EBAF), is highly expressed during late secretory 
and menstrual phases, and is downregulated during the proliferative phase (170). 
In contrast, Nodal is highly expressed throughout the proliferative phase and 
early secretory phase, and is abruptly downregulated by the mid-secretory phase 
(170). Again, although the endometrium harbours a completely different 
microenvironment compared to the mammary gland, it seems that Nodal 
expression correlates with proliferative epithelial expansion during endometrial 
cycling.  
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1.6.3 Nodal in Cancer 
(See copyright release Appendix 1)
Nodal acts early in development, when the embryo consists of stem cell 
populations. Nodal is no longer expressed at later stages of development, when 
cells differentiate (130). Similar to its regulatory effects on embryonic stem cells, 
recent studies have suggested that Nodal is involved in maintaining the 
pluripotent phenotype of cancer cells, and that its actions result in increased 
cancer cell aggressiveness and tumourigenicity (127,131,171-173). When Nodal 
was inhibited with a small molecule inhibitory drug (SB431542) or morpholino 
oligonucleotides in melanoma cells, there was a marked reduction in tumour 
formation and metastasis, and a loss of cellular plasticity (127,172). This 
phenotypic transition occurred concomitant with an upregulation of Tyrosinase, 
and a downregulation of VE-Cadherin  and Keratin 18, indicating a distinct 
genetic transition toward a more differentiated melanocyte-like cell type (127).  
Similarly, one study reported a correlation between Nodal and invasive 
phenotypes in glioma (174). This group found that overexpression of Nodal in 
glioma cells that express low endogenous Nodal causes an increase in cellular 
invasion, MMP-2 secretion/activity, and proliferation in vitro, and tumour growth in
vivo (174). Conversely, Nodal knockdown with shRNA in glioma cells that 
express high endogenous Nodal causes a decrease in cellular invasion, MMP-2 
secretion/activity, and proliferation in vitro, and tumour growth in vivo (174). 
Importantly, this group found that Nodal expression is positively correlated with 
grade in human glioma tissue (174). 
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An article published in Cell Stem Cell by Heeschen and colleagues 
reported a correlation between Nodal and Activin signalling and pancreatic 
cancer. This study found that both Nodal and Activin were expressed at low 
levels in well-differentiated adherent pancreatic cancer cells, and at high levels in 
non-adherent pancreatic spheroids that express elevated pluripotency markers 
(called “cancer stem cells” (CSCs) in this study) (175). Treatment of CSCs with 
recombinant Nodal was found to increase spheroid formation, size, and invasion 
in vitro (175). Conversely, Activin/Nodal signalling inhibition in pancreatic cancer 
cells with an ALK4/7 inhibitor eliminated the CSC subpopulation and rendered 
cells receptive to gemcitabine chemotherapy in vitro, and in an orthotopic mouse 
model (175). Together, the results from this study demonstrate the robust effects 
of Nodal during disease progression and in promoting stem cell-like phenotypes 
in pancreatic cancer.  
Nodal has been implicated in male-cancer types, such as testicular cancer 
and prostate cancer (176,177). Both Cripto and Nodal have been shown to be 
present in tumourigenic testicular cancer cells, such as NCCIT cells (177). One 
study by Adkins et al. (2003) demonstrated that inhibition of Cripto-Nodal 
signalling via an anti-EGF antibody (A27.F6.1) was able to inhibit tumour growth 
of NCCIT testicular cancer cells in nude mice (177). In prostate cancer, Nodal is 
correlated with invasive phenotypes (176). Compared to poorly aggressive 
LNCaP prostate cancer cells that express low levels of Nodal, aggressive DU145 
prostate cancer cells express high levels of Nodal, and undergo anchorage-
independent growth and invasion in vitro (176). Furthermore, transfection of 
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LNCaP cells with a Nodal expression vector increases clonogenicity in vitro 
(176). 
Nodal signalling has also been implicated in female cancer types, such as 
endometrial cancer (170). As mentioned, the female endometrium undergoes 
constant remodelling and turnover during adult life, and Nodal has been 
positively correlated with proliferation during normal endometrial cycling (170). 
Interestingly, patient biopsies of endometrial carcinoma that ranged from Grade 1 
to Grade 3 in severity showed a positive correlation between Nodal and Cripto 
expression, and cancer progression (170).  Lefty, a potent inhibitor of Nodal 
signalling in embryonic stem cells, was absent in all endometrial cancer biopsies 
(170). These results are important for understanding normal mechanisms of 
proliferation in the endometrium, and aberrant mechanisms of endometrial 
carcinoma progression, in order to reveal new prognostic indicators of 
metastasis.  
Several studies have linked Nodal with apoptosis in ovarian cancer (178). 
One study by Peng and colleagues from York University in Toronto found that 
Nodal overexpression in ovarian cancer cells was associated with decreased 
metabolic activity and proliferation (178). Although prima facie this finding seems 
to contradict the metastasis-promoting effects of Nodal in other forms of cancer, 
Peng’s experimental designs employ gain of function, over-expressing strategies 
(178,179). Overexpression of Nodal in cancer cells that already express Nodal 
tends to induce apoptosis, while overexpression of Nodal in cancer cells that do 
not normally express Nodal tends to promote metastasis. This trend is quite 
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interesting, as it highlights the concentration-dependent multi-functionality of 
Nodal signalling and timing in metastatic progression. This is not surprising, since 
other members of the TGF-β superfamily tend to have variable concentration-
dependent effects during embryology and cancer progression, depending on 
temporal and spatial location (180-185). 
Ongoing studies in our laboratory have demonstrated a role for Nodal in 
choriocarcinoma (186). Specifically, we have found that poorly-invasive BeWo 
cells have lower levels of Nodal protein compared to highly-invasive JAR and 
JEG-3 cells, and that Nodal protein expression is positively correlated with 
invasive capacity of these cell lines through Transwell chambers (186). In 
agreement with results from our laboratory, previous reports by Peng and 
colleagues have confirmed that Nodal and its receptors are present in BeWo, 
JAR and JEG-3 cells (167,179). However, in accordance with their results in 
ovarian cancer cell lines, Peng’s research group has reported that Nodal-
overexpression in JAR and JEG-3 cell lines causes a decrease in proliferation 
and an induction of apoptosis (179), indicating that Nodal may elicits different 
effects in different contexts/conditions in this cancer type as well. 
Recent studies have demonstrated a pro-metastatic role for Nodal and 
Cripto in breast cancer (131). Tissue microarray analyses of human breast tissue 
samples revealed a positive correlation between Nodal and breast cancer 
progression (187). Furthermore, Nodal was absent in normal breast tissue 
samples from these experiments. When MDA-MB-231 breast cancer cells were 
treated with Lefty from human embryonic stem cells, invasion and clonogenicity 
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was reduced concomitant with a downregulation of Nodal gene and protein 
expression (187).    
Al-Hajj et al. identified breast cancer stem cells as CD44+/24-, which have 
since been used to demonstrate the plastic potential of aggressive breast tumour 
subpopulations (188). As mentioned, Meyer et al. was recently able to 
demonstrate that although CD44+/24- cells are accepted as the stem cell 
population within tumours, CD44+/24+ isolated populations are able to convert to 
CD44+/CD24- cells (and vise versa) both in vitro and in vivo, associated with a 
downregulation of E-Cadherin and an upregulation of stem cell associated 
genes, such as Slug (125). When isolated CD44+/24+ cell populations were 
transplanted into nude mice mammary fat pads,  tumours were locally invasive, 
and did contain CD44+/24- populations upon examination (125). Interestingly, 
this suggests that differentiated cells outside the breast cancer stem cell 
subpopulation classically defined by Al-Hajj, exhibit a dynamic plastic phenotype. 
It was found that the central regulator of this dynamic phenotypic switching in 
CD44+/24+ and CD44+/24- cell populations was the Activin/Nodal pathway 
(125). When the ALK receptor was inhibited with SB431542 in either of these 
populations, phenotypic switching was significantly impaired, implying an 
important role for Nodal-associated signalling pathways in mediating plasticity in 
cancer (125). It is possible that Nodal is promoting these plastic phenotypes 
through mediating the transitions that occur during processes like EMT. 
Examining Nodal’s normal role in maintaining embryonic pluripotency may lend 
insight towards its actions in cancer plasticity. 
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 1.6.4 Hypoxia promotes Nodal expression 
In light of the attention awarded to embryonic proteins in cancer, one 
important question is how do cancer cells re-express embryonic proteins that are 
supposed to be silenced? Oxygen is a microenvironmental factor that plays a 
pivotal role in regulating gene expression and cell fate during both embryological 
development and cancer progression. Interestingly, hypoxia constitutes both 
embryonic and tumour microenvironments, and mediates the activation of 
embryonic stem cell-associated programmes. HIF is the dominant mediator of the 
hypoxic response, and its fundamental nature is typified by its ubiquitous 
expression in nearly all cell types (189). Studies have shown that hypoxia 
promotes metastatic phenotypes including EMT, invasion and angiogenesis 
(83,190-192). These processes are mediated by an upregulation of factors such 
as TCF3 (which causes repression of E-Cadherin), VEGF (pro-angiogenic 
factor), and Twist (inducer of EMT) under hypoxic conditions (83,191,192).  
Interestingly, our laboratory has recently shown that hypoxia causes 
upregulation of Nodal in breast and melanoma cell lines through HIF-1 (190). 
Specifically, HIF-1 was shown to bind to the NDE upstream of the Nodal gene 
locus, to promote transcription. Following Nodal upregulation, Nodal expression 
was shown to persist even after re-oxygenation, via an autoregulatory positive 
feedback loop. Although our work has uncovered a mechanism of Nodal 
expression in breast cancer cells, little is known about the role that Nodal plays 
during breast cancer progression after it has been re-expressed.  
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 1.7  Hypothesis and Rationale 
Given the role that Nodal plays in multiple types of cancer, and given that 
Nodal is re-expressed in breast cancer, the following study opts to resolve the 
question: What role does Nodal play during various aspects of the metastatic 
cascade? My hypothesis is that Nodal promotes metastatic phenotypes in breast 
cancer, including tumour growth, vascularization and invasion. Throughout my 
thesis, I have used multiple breast cancer cell lines: the highly-aggressive MDA-
MB-231, MDA-MB-468, and Hs578t breast cancer cell lines, and the poorly-
aggressive T47D and MCF-7 breast cancer cell lines. As will be evident in the 
following chapters, the highly-aggressive cell lines express high levels of Nodal 
and will be used for Nodal loss-of-function experiments, whereas the poorly-
aggressive cell lines express relatively low levels of Nodal and will be used for 
Nodal gain-of-function experiments.
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CHAPTER 2 
Nodal inhibition impairs breast cancer growth and progression 
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2.1 Abstract 
Breast cancer progression is in part marked by the ability of tumour cells 
to exhibit uncontrolled growth. Tumours that display human embryonic stem cell 
(hESC)-associated gene expression signatures are more likely to progress than 
well-differentiated cancers and are thus associated with poor patient prognosis. 
Elevated proliferation and evasion of growth control are similarly associated with 
disease progression, and are classical hallmarks of cancer. In the current study 
we demonstrate that the hESC-associated factor, Nodal, promotes breast cancer 
growth. Specifically, we show that Nodal is elevated in aggressive MDA-MB-231, 
MDA-MB-468 and Hs578t human breast cancer cell lines, compared to poorly 
aggressive MCF-7 and T47D breast cancer cell lines. In a nude mouse model of 
tumourigenesis, Nodal knockdown via shRNA reduces tumour incidence and 
significantly blunts tumour growth at primary sites. In vitro, using Trypan Blue 
exclusion assays, Western blot analysis of phosphorylated histone H3 and 
cleaved caspase-9, and real time RT-PCR analysis of BAX and BCL2 gene 
expression, we demonstrate that Nodal promotes expansion of breast cancer 
cells, likely via a combinatorial mechanism involving increased proliferation and 
decreased apopotosis. In an experimental model of metastasis using beta-
glucuronidase (GUSB)-deficient NOD/SCID/mucopolysaccharidosis type VII 
(MPSVII) mice, we show that although Nodal is not required for the formation of 
small (<100 cells) micrometastases at secondary sites, it supports an elevated 
proliferation:apoptosis ratio (Ki67:TUNEL) in micrometastatic lesions. Indeed, at 
longer time points (8 weeks), we determined that Nodal is necessary for the 
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subsequent development of macrometastatic lesions ( 100 cells). Our findings 
demonstrate that Nodal supports tumour growth at both primary and secondary 
sites by altering the ratio of proliferation to apoptosis in breast cancer cells. As 
Nodal expression is limited to embryonic systems and cancer, this study 
establishes Nodal as a potential tumour-specific target for the treatment of breast 
cancer. 
2.2 Introduction 
Tumour growth is dictated by elevated cellular proliferation and reduced 
apoptosis, to yield a net increase in cellular expansion. Accordingly, two classical 
and fundamental hallmarks of cancer include enhanced proliferation and evasion 
of apoptotic signals (1,2). Normally, epithelial cells require signals from their 
microenvironment to trigger entrance into a proliferative state. In contrast, cancer 
cells exhibit a reduced dependence on mitogenic factors from their 
microenvironment, and can enter a proliferative state in response to their own 
deregulated growth signals. In breast cancer, patients bearing tumours that 
express high levels of the proliferation marker nuclear antigen Ki67, concomitant 
with mutations in apoptotic programmes, exhibit accelerated disease progression 
and poor prognosis (3-6). Elucidating factors that regulate proliferative 
programmes and that, therefore, cause susceptibility to tumour cell expansion is 
of interest in order to develop effective targeted cancer therapies. 
In addition to enhanced proliferation and evasion of apoptosis during 
cancer progression, aberrant expression of stem cell factors within breast 
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tumours has been shown to promote aggressive phenotypes, and is associated 
with growth-promoting profiles in tumour cells and their microenvironments. One 
example of a stem cell factor that is associated with cancer progression is Nodal, 
an embryonic morphogen and member of the Transforming Growth Factor-Beta 
(TGF-β) superfamily. Nodal expression is limited to pluripotent stem cells during 
embryonic development and to specialized dynamic adult tissue (such as the 
cycling endometrium), but is re-expressed to induce growth programmes in 
cancers such as melanoma, glioma, and prostate cancer (7-10). The role of 
Nodal during breast cancer progression has been minimally investigated; 
however, it has been reported that transient inhibition of Nodal in MDA-MB-231 
breast cancer cells with morpholino oligonucleotides delays tumourigenesis in 
nude mice, concomitant with reduced proliferation (by Ki67 staining) and elevated 
apoptosis (by TUNEL staining) (11).  
In accordance with its documented contribution to tumour growth, Nodal 
has recently been linked to proliferation in a variety of normal physiological 
systems. For example, Harrison and colleagues have studied Nodal signalling in 
human endometrium during the various phases of remodelling, and found that 
Nodal is highly expressed throughout the proliferative and early secretory 
phases, and is abruptly downregulated by the mid-secretory phase (12). In 
addition, Salomon and colleagues have found that Nodal and members of the 
Nodal signalling pathway are cyclically expressed during mammary gland 
remodelling. In particular, Nodal, Cripto, ALK4, and SMAD4 are upregulated 
during lactational expansion of alveolar epithelial tissue, and downregulated 
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during involution (marked by widespread apoptosis) in BalbC mice (13,14). 
Together, these studies suggest that Nodal may play a role in promoting 
proliferative phenotypes in dynamic epithelial cell types.  
Given the role of Nodal in promoting cancer progression, and that Nodal is 
correlated with proliferative adult tissues, we wanted to investigate the role of 
Nodal during breast cancer growth. First, we demonstrate that stable Nodal 
knockdown significantly blunts tumour growth in an orthotopic mouse model of 
tumourigenesis. In vitro, we found that Nodal promotes proliferation whilst 
preventing apoptosis in breast cancer cell lines.  Overtime, we found that Nodal 
elevated the ratio of live:dead cells in vitro, indicating that this embryonic protein 
supports a net cellular expansion. Lastly, we evaluated the effect of Nodal on 
growth of secondary metastases. Using a unique experimental metastasis assay, 
we discovered that although Nodal does not affect the number of 
micrometastasis in the lung (i.e. seeding efficiency), it enhances 
proliferation:apoptosis ratios in micrometastases in favour of tumourigenic 
growth. Indeed, we found that Nodal is required for growth progression to 
macrometastases at secondary sites.  
2.3 Methods 
2.3.1 Cell lines and treatments 
Two well-differentiated poorly-metastatic luminal-like breast cancer cell lines 
expressing low levels of Nodal (MCF-7 and T47D) and two highly-metastatic 
basal-like breast cancer cell lines expressing high levels of Nodal (MDA-MB-231 
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and MDA-MB-468) were used for Nodal gain-of-function and Nodal loss-of-
function experiments, respectively. All cancer cell lines were obtained from the 
American Type Culture Collection (ATCC) and were maintained as per 
instructions.  To increase Nodal signalling, we used a Nodal expression vector 
(versus an empty pcDNA3.3 vector; pcDNA 3.3-TOPO  cloning kit; Invitrogen). 
To decrease Nodal signalling, we used Nodal-targeted shRNAs (versus 
scrambled control shRNAs). Two Nodal-targeted shRNAs were used, a HuSH-
29mer (Id: GI311711; Origene) and a GIPZ lentiviral shRNAmir (Id: 
V2LHS 155453; Open Biosystems) to rule-out off-target effects. Transfection 
was performed with Arrest-In (Open Biosystems) or Lipofectamine (Invitrogen) as 
per manufacturer instructions. For stable selection, Puromycin (200-450 ng/mL) 
or Geneticin (G418; 800 ng/mL) was used. 
2.3.2 RNA extraction and real-time PCR 
RNA isolation was performed using the Perfect Pure RNA cultured cell kit (5 
Prime), and DNAse was used to degrade genomic DNA.  Reverse transcription 
was performed using 2 g of RNA and a High Capacity cDNA Reverse 
Transcription kit (Applied Biosystems). Real-time PCR was performed with 
TaqMan  gene expression human primer/probe sets. For a list of primer/probes, 
see Table 2.1. For analysis of Nodal receptor expression across cell types, 
primer/probes included ALK4 (ACVR1B), ALK7 (ACVR1C), and Cripto-1 
(TDGF1). Raw Ct values are presented, since housekeeping genes were often 
different between cell lines and therefore delta Ct values misleadingly 
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Target Probe ID 
ALK4 (ACVR1B) Hs00244715_m1 
ALK7 (ACVR1C) Hs00377065_m1 
Cripto-1 (TDGF1) Hs02339499_g1 
BAX  
BCL2  
HPRT1 4333768-0904021 
 
Table 2.1 Primer/Probe information for real time PCR 
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exaggerated differences. For analysis of BAX and BCL2 gene expression in 
response to treatments, Ct values were normalized to HPRT1, and compared 
using the ΔΔCt method. 
2.3.3 Western blotting 
Protein lysates were prepared using Mammalian Protein Extraction Reagent (M-
PER; Thermo Scientific) and Halt Protease Inhibitor Cocktail (Thermo Scientific) 
as per manufacturer’s instructions.  Equal amounts of protein were reduced and 
separated by SDS-polyacrylamide gel electrophoresis, and transferred onto 
Immobilon-P membranes (Millipore).  Membranes were blocked in 5% milk, 
incubated with primary antibody, washed with TBS-T 0.1% Tween, and incubated 
with horseradish peroxidase-conjugated secondary antibody. For a list of primary 
antibodies see Table 2.2. Enzyme activity was detected by enhanced 
chemiluminescence (Super Signal; Pierce). Images were obtained using film. 
In accordance with previous studies (7,15-17), three banding locations 
were detected for Nodal:  Pro-Nodal at 39 kDa, fully processed Nodal at 50 
kDa, and mature Nodal at 15 kDa. The 50 kDa species is highly variable due to 
differences in post-translational modifications and protein lysate handling, and 
the 15 kDa band is typically in low abundance in both cell lysates and 
conditioned media due to low protein stability (16). For consistency, we used the 
39 kDa band to assess Nodal expression in lysates, as we have previously 
shown that it is proportional to 15 kDa mature Nodal in both lysate and 
conditioned media (17).  
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Table 2.2 List of primary antibodies used for Western blot analyses.  
Primary Antibody Clone Company Dilution 
Monoclonal mouse anti-Nodal WS65 Santa Cruz 1:500 
Monoclonal rabbit anti-phospho-SMAD2 A5S Millipore 1:1000 
Polyclonal rabbit anti-SMAD2/3  Millipore 1:1000 
Monoclonal mouse anti-β-Actin C4 Santa Cruz 1:5000 
Polyclonal rabbit anti-Caspase-9  Cell Signalling 1:1000 
Polyclonal rabbit anti-Cleaved Caspase-9  Cell Signalling 1:1000 
Monoclonal rabbit anti-phospho Histone 
H3 (Ser10) D2C8 Cell Signalling 1:1000 
Polyclonal rabbit anti-phospho Histone 
H3 (Ser28)  Cell Signalling 1:1000 
Polyclonal rabbit anti-phospho Histone 
H3 (Thr3)  Cell Signalling 1:1000 
Polyclonal rabbit anti-phospho Histone 
H3 (Thr11)  Cell Signalling 1:1000 
Monoclonal rabbit anti-Histone H3 D1H2 Cell Signalling 1:1000 
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 2.3.4 Tumour assay in nude mice 
Two nude mouse models (Crl:NU-Foxn1nu; Charles River) were used to evaluate 
the effects of Nodal knockdown (in highly aggressive MDA-MB-468 or MDA-MB-
231 cells) on tumourigenesis in vivo. All experiments involving animals were 
approved by the Animal Use Subcommittee at the University of Western Ontario, 
Protocol No. 2008-101 (Appendix 2). 
 Flank tumour assay: MDA-MB-468 cells were transfected with a Control 
HuSH shRNA, or a Nodal-targeted HuSH shRNA and stably selected with 
Puromycin. 2,500,000 cells in 100 L of RPMI + Matrigel (1:1) were injected into 
the right flank of 6-8 week old female mice. Twice per week, the longest 
dimension of the tumour that could be seen through the mouse skin was 
measured using a digital caliper. We choose to use only one dimension as an 
indication of growth rate, since the volume of an irregularly shaped tumour 
cannot be accurately calculated until it is excised and the depth can be 
quantified. Of note, following tumour excision, the total volume of the tumour was 
calculated by measuring all three growth dimensions (length x width x depth).  
Orthotopic tumour assay: MDA-MB-231 cells were transfected with a 
Control GIPZ shRNA or a Nodal-targeted GIPZ shRNA, and stably selected with 
Puromycin. 500,000 cells in 50 L of RPMI were injected into the mammary fat 
pad of 6-8 week old female mice. Twice per week, the longest dimension of the 
tumour that could be seen through the mouse skin was measured using a digital 
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caliper. Following tumour excision, the total volume of the tumour was calculated 
(length x width x depth). 
 
2.3.5 In vitro growth curves and cell death analyses 
Cells were seeded into 6-well plates (100,000 cells/well) and counted over 3 
days. Media containing dead and live cells was collected. Attached cells were 
harvested using Trypsin, combined with media, spun down, and resuspended 
with Trypan Blue to demarcate non-viable cells. A Countess automated cell 
counter (Invitrogen) was used to calculate total cell number, live cells, and dead 
cells. Growth curves and Live:Dead ratios were calculated from this data. 
2.3.6 Experimental metastasis assay in NOD/SCID/MPSVII mice 
500,000 cells in 700 L Ca2+-free HBSS were injected into the tail vein of
NOD/SCID/MPSVII mice. Mice were sacrificed at 4 weeks (to assess 
micrometastases) or 8 weeks (to assess macrometastases). Lung, brain, and 
liver from transplanted NOD/SCID/MPSVII mice were either frozen in OCT 
embedding medium (Sakura Finetek, Torrance, CA) for histochemical analysis of 
GUSB activity, or were fixed in 4% formaldehyde and paraffin-embedded for 
analysis of TUNEL and Ki67: 
GUSB staining and assessment of metastases from frozen tissue: 
Frozen serial sections of 10 μm thickness were fixed with 10% buffered formalin 
(Sigma Aldrich, St. Louis, MO), and blocked with mouse-on-mouse reagent 
(Vector Laboratories, Burlingame, CA).  Sections were analyzed for human cells 
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by colourimetric detection of ubiquitous GUSB activity in human cells as 
previously described using napthol AS-BI β-D-glucuronide substrate (Sigma-
Aldrich) (18), and counterstained with haematoxylin. Within one section, 
metastases that were <100 cells were considered micro’, while metastases that 
were 100 cells were considered macro’. Micrometastases versus 
macrometastases were counted manually under a microscope. It should be noted 
that, usually, micrometastases were much less than 100 cells, and 
macrometastases were much more than 100 cells, and therefore, differentiating 
between these two types of lesions was clear. For each mouse organ, 3-6 
sections were acquired from evenly spaced areas through the tissue, and the 
average number of metastases per mouse organ (i.e. per 3 sections) was 
calculated. 
Ki67 and TUNEL staining and assessment of Proliferation:Apoptosis 
from paraffin-embedded tissue: Serial sections of 4 μm thickness were 
obtained, and immunohistochemical staining was conducted using a human-
specific Ki67 antibody (Monoclonal rabbit anti-hKi67, clone SP6; Ready to use; 
Thermo Scientific) as per manufacturer’s instructions. The DeadEnd colorimetric 
TUNEL system (Promega) was used to measure apoptosis as per instructions.  
The proliferation:apoptosis ratio was determined by counting Ki67-positive and 
TUNEL-positive nuclei in matched serial sections.  At least 3 pairs of serial 
sections, evenly spaced through the tissue, were averaged per mouse to yield 
one proliferation-to-apoptosis score for that animal. 
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2.3.7 Statistical analyses 
Statistics were performed using SigmaStat (Dundas Software), and validated 
through the biostatistical support unit at the University of Western Ontario. All 
parametric data was analysed using a one-way ANOVA and a Tukey Kramer 
Comparisons Post-Hoc test, and expressed as mean  S.E.M. for replicate 
values. All non-parametric data was analyzed using an ANOVA on Ranks 
followed by the Mann-Whitney rank-sum test, and expressed as median  
interquartile range. A student’s t-test was used to compare two items.  All 
statistical tests were two-sided, and data were considered statistically significant 
at p<0.05.   
2.4 Results and Discussion 
2.4.1 Nodal is elevated in aggressive (c.f. poorly aggressive) breast cancer 
cell lines 
Through Western blot analyses, we determined that Nodal protein is 
elevated in poorly-differentiated, basal-like, metastatic Hs578t, MDA-MB-231 and 
MDA-MB-468 breast cancer cell lines compared to well-differentiated luminal-like 
MCF-7 and T47D cell lines (Figure 2.1A) (19). This is consistent with previous 
reports that show high Nodal expression in aggressive melanoma, prostate, and 
breast cancer cell lines compared to poorly aggressive lines, supporting the 
hypothesis that Nodal expression is elevated during cancer progression (9,15). 
Nodal signals through interactions with Cripto-1 (TDGF1) and the Activin-
Like Kinase type I (ALK4/7) and type II (ActRIIB) receptor complex. Activation of 
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Figure 2.1 Nodal is associated with aggressive breast cancer cells.
(A) Western blot analysis of Nodal in poorly-differentiated (MDA-MB-
231, MDA-MB-468, Hs578t) and well-differentiated (MCF-7, T47D)
breast cancer cells. Nodal expression is elevated in highly aggressive
MDA-MB-231, MDA-MB-468 and Hs578t breast cancer cells compared
to poorly aggressive MCF-7 and T47D breast cancer cells. ~39 kDa
Pro-Nodal band is depicted and Actin is used as a loading control. (B)
Raw Ct values from real time RT-PCR analysis of equal amounts of
cDNA demonstrating that all members of the Nodal receptor complex,
including ALK-4, ALK-7 and Cripto (TDGF1), are expressed in MDA-
MB-231, MDA-MB-468, Hs578t, MCF-7 and T47D breast cancer cell
lines (n=4). Lower Ct values are indicative of exponentially higher levels
of expression.
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this receptor complex leads to SMAD2/3 phosphorylation, and subsequent 
Nodal-mediated gene expression (20).  It has been reported that Nodal receptor 
components are expressed at varying levels in prostate cancer cell lines (10). 
Similarly, we wanted to determine whether the cell lines used in this study 
expressed Nodal receptor components, in order to ensure our cell lines had the 
potential to respond to treatment conditions. Using real time RT-PCR, we 
determined that all members of the Nodal receptor complex, including ALK4, 
ALK7 and TDGF1, are expressed in Hs578t, MDA-MB-231, MDA-MB-468, T47D 
and MCF-7 breast cancer cell lines at varying levels (Figure 2.1B). This suggests 
that these cell lines are able to respond to and carry out Nodal-induced signal 
transduction, providing a context upon which to study both Nodal gain-of-function 
and Nodal loss-of-function effects.  
2.4.2 Nodal promotes breast cancer tumourigenesis 
Given that Nodal is associated with aggressive cancers and breast cancer 
cell lines, we first sought to determine whether stable Nodal knockdown regulates 
breast cancer tumourigenesis in vivo. Previous studies demonstrated that 
transient inhibition of Nodal with morpholinos or exposure to its antagonist, Lefty, 
diminished tumour initiation in breast cancer and melanoma models (7,15). In 
order to better understand the role of Nodal in tumour growth over an extended 
period of time, we stably knocked down Nodal expression in aggressive MDA-
MB-468 and MDA-MB-231 breast cancer cells using puromycin-selectable 
shRNAs. In our first model, we injected 2.5 million MDA-MB-468 cells transfected 
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with a Control shRNA (468+shControl) or a Nodal-targeted shRNA 
(468+shNodal) into the flanks of nude mice, and measured tumour growth over 6 
weeks. This approach revealed that Nodal knockdown significantly impaired 
MDA-MB-468 tumour growth, and resulted in 2-fold reduction in tumour volume 
following excision (p<0.05) (Figure 2.2A-C).  
As a corollary to this experiment, in our second model, we injected 
500,000 MDA-MB-231 cells transfected with a Control shRNA (231+shControl) or 
Nodal-targeted shRNA (231+shNodal) through the nipple into the mammary fat 
pad of nude mice, and measured tumour growth over 9 weeks. Compared to the 
flank model, this model was more stringent since we injected fewer cells (0.5 
versus 2.5 million), Matrigel was not used to help tumours initiate, and the breast 
cancer cells were injected into the mammary environment to recapitulate a 
relevant physiological context. We found that Nodal knockdown significantly 
impaired tumour growth compared to controls (p<0.05, n=10) (Figure 2.2D,E). 
Furthermore, there was a 5-fold reduction in tumour volume following excision 
(p<0.05) (Figure 2.2F). Importantly, we observed a phenomenon that was not 
apparent in our flank model. We found that unlike 231+shControl tumours which 
continued to grow over time, the 231+shNodal tumours experienced a plateau in 
growth at a diameter of approximately 1.5 mm. This suggested to us that Nodal 
inhibition may alter cell viability, proliferation or death to counteract tumour 
growth. It should be noted that Nodal knockdown in the MDA-MB-231 cell line 
was more robust than knockdown in the MDA-MB-468 cell line (by Western blot 
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Figure 2.2 Nodal promotes tumorigenesis in vivo. (A) Western blot
confirming Nodal knock-down by shRNA in MDA-MB-468 cells. The ~39
kDa Pro-Nodal band is presented and Actin is used as a loading control.
(B) 2.5 million MDA-MB-468 cells transfected with Control shRNA
(468+shControl) or a Nodal-targeted shRNA (468+shNodal) were
injected with Matrigel into the flanks of nude mice, and tumor diameter
was measured over the course of 6 weeks. 468+shControl cells formed
significantly larger tumors compared to 468+shNodal cells (n=8,
p<0.05). Values represent mean tumor diameter (mm) ± S.E.M. (C)
Tumor volume of MDA-MB-468-derived tumors excised after 6 weeks.
Bars represent mean tumor volume (mm3) ± S.E.M. (D) Western blot
confirming Nodal knock-down by shRNA in MDA-MB-231 cells. The ~39
kDa Pro-Nodal band is presented and Actin is used as a loading control.
(E) 0.5 million MDA-MB-231 cells transfected with Control shRNA
(231+shControl) or Nodal-targeted shRNA (231+shNodal) were
orthotopically injected into the mammary fat pads of nude mice, and
tumor diameter was measured over the course of 9 weeks.
231+shControl cells formed significantly larger tumors compared to
231+shNodal cells (n=10, p<0.05). Values represent mean tumor
diameter (mm) ± S.E.M. (F) Tumor volume of MDA-MB-231-derived
tumors excised after 9 weeks. Bars represent mean tumor volume
(mm3) ± S.E.M.
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validation in Figure 2.2A compared to Figure 2.2D). This may also explain why 
the plateau effect was not apparent in the flank model.
2.4.3 The effects of Nodal on proliferation in vitro 
Given our finding that Nodal inhibition causes a reduction in tumour growth 
in vivo, we wanted to examine the effects of Nodal on cell proliferation in vitro. 
We used Trypan Blue exclusion assays to generate growth curves for breast 
cancer cells in response to alterations in Nodal expression. As a Nodal gain-of-
function model, we used T47D cells stably transfected with a Nodal expression 
construct (T47D+Nodal) versus an empty vector control (T47D+EV) (Figure
2.3A). We found that T47D+Nodal cells displayed a significant increase in 
proliferation after 3 days compared to T47D+EV cells (n=3; p=0.046) (Figure
2.3B). As a Nodal loss-of-function model, we compared growth curves for 
468+shNodal cells versus 468+shControl cells, or 231+shNodal cells versus 
231+shControl cells. We found that Nodal inhibition by shRNA significantly 
reduced proliferation in MDA-MB-468 cells (n=3; p=0.046) and in MDA-MB-231 
cells (n=3, p=0.047) compared to controls after 3 days (Figure 2.3C,D). In 
accordance with these results, Western blot analyses confirmed that histone H3 
phosphorylation at 4 different sites, including Ser10, Ser28, Thr3, and Thr11, was 
lower in 231+shNodal cells compared to 231+shControl cells, indicative of 
reduced mitosis (Figure 2.3E). In general, although the growth curves showed 
changes in response to altered Nodal expression, the changes were small and 
likely do not solely account for the robust effects seen on tumour growth in vivo.  
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Figure 2.3 Nodal promotes proliferation of breast cancer cells in
vitro. (A) Western blot validating elevated Nodal expression in T47D
cells transfected with a Nodal expression vector (T47D+Nodal) versus
an empty vector control (T47D+EV). (B-D) Trypan Blue exclusion was
used to count live cells daily to generate growth curves over 3 days, in
response to altered Nodal expression. (B) T47D+Nodal cells exhibited a
significant increase in proliferation compared to T47D+EV cells over 3
days (n=3, p=0.046). (C) MDA-MB-468 cells transfected with a Nodal-
targeted shRNA (468+shNodal) exhibited a significant decrease in
proliferation over 3 days compared to cells transfected with a scrambled
Control shRNA (468+shControl) (n=3; p=0.046). (D) MDA-MB-231 cells
transfected with a Nodal-targeted shRNA (231+shNodal) exhibited a
significant decrease in proliferation over 3 days compared to cells
transfected with a scrambled Control shRNA (231+shControl) (n=3;
p=0.047). (E) Western blot demonstrating decreased phosphorylated
histone H3 at 4 different sites, including Thr11, Ser10, Ser28 and Thr3
in 231+shNodal cells compared to 231+shControl cells. Total histone H3
and β-Actin are used as controls. All data are presented as mean
S.E.M. for replicate values. Asterisks indicate a significant difference
compared to controls.
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2.4.4 The effects of Nodal on apoptosis in vitro 
Given that Nodal had a small effect on proliferation in vitro, we 
hypothesized that perhaps Nodal could also regulate apoptotic phenotypes, 
which might help to explain the large differences observed during in vivo tumour 
growth. In order to explore the effects of Nodal on apoptosis, we performed 
Western blot analyses for activated (cleaved) caspase-9 in T47D+EV cells 
versus T47D+Nodal cells. We found that cleaved caspase-9 was present at lower 
levels in T47D+Nodal cells compared controls, indicative of reduced apoptosis in 
the presence of Nodal (Figure 2.4A). Given that caspase-9 is frequently 
associated with mitochondria-mediated apoptosis (refer to Section 1.4.1.3), we 
decided to quantify BAX and BCL2 mRNA expression in T47D+EV cells versus 
T47D+Nodal cells. Real time RT-PCR analysis indicated that there was a 
significant decrease in BAX expression (n=5, p=0.016) and a significant increase 
in BCL2 expression (n=5, p=0.016) in T47D+Nodal cells compared to controls 
(Figure 2.4B,C). 
As a corollary, caspase-9 cleavage, and BAX and BCL2 gene expression 
were measured in 231+shNodal versus 231+shControl cells. We found that 
cleaved caspase-9 was present at higher levels in 231+shNodal cells compared 
to controls, indicative of elevated apoptosis in the absence of Nodal (Figure
2.4D). Consistently, real time RT-PCR indicated that there was a significant 
increase in BAX expression (n=4, p=0.029) and a significant decrease in BCL2 
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Figure 2.4 Nodal reduces apoptosis of breast cancer cells in vitro.
(A) Western blot demonstrating that cleavage of caspase-9 is reduced
in T47D cells transfected with a Nodal overexpression construct
(T47D+Nodal) compared to cells transfected with an empty vector
control (T47D+EV). Uncleaved caspase-9 and β-Actin are used as
controls. (B) Real time RT-PCR analysis demonstrating that BAX mRNA
expression is significantly lower in T47D+Nodal cells compared to
T47D+EV cells (n=5, p=0.016). (C) Real time RT-PCR analysis
demonstrating that BCL2 mRNA expression is significantly higher in
T47D+Nodal cells compared to T47D+EV cells (n=5, p=0.016). (D)
Western blot demonstrating that cleavage of caspase-9 is elevated in
MDA-MB-231 cells transfected with a Nodal-targeted shRNA
(231+shNodal) compared to cells transfected with a scrambled Control
shRNA (231+shControl). Uncleaved caspase-9 and β-Actin are used as
controls. (E) Real time RT-PCR analysis demonstrating that BAX mRNA
expression is significantly higher in 231+shNodal cells compared to
231+shControl cells (n=4, p=0.029). (F) Real time RT-PCR analysis
demonstrating that BCL2 mRNA expression is significantly lower in
231+shNodal cells compared to 231+shControl cells (n=4, p=0.029). All
data are presented as mean S.E.M. for replicate values. Asterisks
indicate a significant difference compared to controls.
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expression (n=4, p=0.029) in 231+shNodal cells compared to controls (Figure
2.4E,F).
 
2.4.5 The effects of Nodal on Live:Dead cell ratios in vitro 
As previously mentioned, tumour growth is dictated by elevated cellular 
proliferation and reduced apoptosis, to yield a net increase in cellular expansion 
(1,2). Therefore, the ratio of live:dead cells at any given time is an important 
indicator of growth potential. Given our findings that Nodal affects both 
proliferation and apoptosis in 3 day-old cultures, we wanted to verify that Nodal 
did indeed have an effect on the overall ratio of live:dead cells at this time. As a 
Nodal gain-of-function model, we found that T47D+Nodal cells exhibited a 
significant increase in the ratio of live:dead cells after 3 days compared to 
T47D+EV cells (n=3, p=0.038) (Figure 2.5A). As a Nodal loss-of-function model, 
we compared live:dead cell ratios for 468+shNodal cells versus 468+shControl 
cells, or 231+shNodal cells versus 231+shControl cells. We found that after 3 
days, 468+shNodal cells exhibited a significant decrease in the ratio of live:dead 
cells (n=3; p=0.033) compared to 468+shControls (Figure 2.5B). Consistently, 
231+shNodal cells exhibited a significant decrease in the ratio of live:dead cells 
(n=3, p=0.024) compared to 231+shControls (Figure 2.5C).  
 
Taken together, our results demonstrate that Nodal promotes elevated net 
growth in culture. This in part explains the observation that Nodal inhibition blunts 
tumour growth in vivo. Interestingly, it has been reported that Notch4, which 
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Figure 2.5 Nodal promotes an elevated Live:Dead cell ratio in
breast cancer cells in vitro. Trypan blue exclusion was used to
calculate the Live:Dead cell ratio of breast cancer cell lines after 3 days
in culture, in response to altered Nodal expression. (A) T47D cells
transfected with a Nodal overexpression construct (T47D+Nodal)
exhibited an elevated Live:Dead cell ratio after 3 days compared to
T47D cells transfected with an empty vector control (T47D+EV) (n=3,
p=0.038). (B) MDA-MB-468 cells transfected with a Nodal-targeted
shRNA (468+shNodal) exhibited a decreased Live:Dead cell ratio after 3
days compared to cells transfected with a scrambled Control shRNA
(468+shControl) (n=3; p=0.033). (C) MDA-MB-231 cells transfected with
a Nodal-targeted shRNA (231+shNodal) exhibited a decreased
Live:Dead cell ratio after 3 days compared to cells transfected with a
scrambled Control shRNA (231+shControl) (n=3, p=0.024). All data are
presented as mean ± S.E.M. for replicate values. Asterisks indicate a
significant difference compared to controls.
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regulates Nodal expression in melanoma models, promotes proliferation and 
inhibits apoptosis in C8161, MV3, and SK-MEL-28 melanoma cell lines (21). 
Furthermore, Nodal over-expression in GBM glioma cells causes an increase in 
proliferation concomitant with elevated tumourigenesis in mice (8). In contrast to 
the results shown here, studies by Peng and colleagues have reported that over-
expression of Nodal promotes apoptosis and inhibits proliferation in MDA-MB-
231 breast cancer cell lines (22,23). However, one key difference in Peng’s 
experimental design is that Nodal was over-expressed in MDA-MB-231 cells 
(which express high endogenous Nodal), whereas here, Nodal was inhibited in 
MDA-MB-231 cells. Furthermore, the dose of recombinant Nodal that was used 
in Peng’s study was 500 ng/mL, which is more than 5-fold higher than the dose 
of Nodal necessary to sustain its role in maintaining pluripotency in hESC 
cultures (23-25). This brings light to the possibility that Nodal exhibits a 
concentration-dependent biphasic effect on breast cancer progression, similar to 
the function of TGF-β (26,27). 
 
2.4.6 Nodal promotes growth from micro to macrometastases 
Cancer becomes a fatal disease once it has metastasized and grown into 
a sufficient secondary tumour mass. However, the metastatic cascade is a highly 
inefficient process overall, and it has been reported that one of the most 
inefficient steps is growth at the secondary site (28,29). Given that Nodal 
inhibition causes a plateau in primary tumour growth in vivo, and that it alters 
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proliferation and cell death in vitro, we opted to test the effect of Nodal inhibition 
on secondary tumour growth.  
Accordingly, we developed a model that takes advantage of a simple 
experimental metastasis assay using NOD/SCID/mucopolysaccharidosis type VII 
(NOD/SCID/MPSVII) mice, which are deficient in the lysosomal enzyme beta-
glucuronidase (GUSB) (18). The GUSB model allowed us to attain single-cell 
resolution of transplanted human tumour cells by virtue of their constitutive GUSB 
activity within the GUSB-deficient mouse, thereby enabling the identification of 
lesions down to single-cell level that would be undetectable using conventional 
histology. We sacrificed mice at two different time points, at 4 weeks and 8 
weeks, following tail vein injection of 231+shControl or 231+shNodal cells. At 
both 4 and 8 weeks, brain and liver tissue were also evaluated for evidence of 
metastasis (Figure 2.6). Using this high-resolution experimental metastasis 
model, we found only micrometastases of <100 cells at 4 weeks post-injection, 
and discovered that Nodal knockdown did not cause a significant change in the 
number of micrometastases that formed in the lung (Figure 2.7A,B). This 
suggested that Nodal does not affect seeding at secondary sites.  
In addition to seeding, another important step in the metastatic cascade is 
growth at the secondary site. Indeed, metastatic tumour cells can reside and 
survive at secondary sites in the body while circumventing a need for growth or 
progression; an aspect of carcinogenesis called tumour dormancy. Tumour mass 
dormancy, in particular, refers to metastases that remain asymptomatic due to an 
inability to expand in size, and is often attributed to a counterbalance of 
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Figure 2.6 Experimental design for examination of the transition
from micro- to macro-metastases. Schematic depicting experimental
process for GUSB metastasis model. Briefly, MDA-MB-231 cells
transfected with a Nodal-targeted shRNA (231+shNodal) or a Control
shRNA (231+shControl) were injected through the tail vein of
NOD/SCID/MPSVII mice, which exhibit GUSB deficiency. After 4 weeks,
micrometastasis formation from human cells was assessed in the lung,
liver and brain of animals, marked by positive GUSB enzymatic staining.
At 8 weeks, macrometastasis formation from human cells was assessed
in the lung, liver and brain of animals, by GUSB enzymatic staining and
H&E. Ki67 and TUNEL were used to assess proliferation:apoptosis
ratios.
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Figure 2.7 Nodal inhibition alters proliferation-to-apoptosis ratios
in micrometastases. (A) GUSB staining of pulmonary
micrometastases from MDA-MB-231 cells transfected with a Control
shRNA (231+shControl) or a shRNA to Nodal (231+shNodal) in
NOD/SCID/MPSVII mice 4 weeks post-intravenous injection (red and
outlined with white dotted line). (B) Scatter plot representing the
average number of micrometastases (<100 cells) per section of lung
from NOD/SCID/MPSVII mice 4 weeks after injection with
231+shControl or 231+shNodal cells. The number of 231+shNodal
micrometastases that formed after 4 weeks in NOD/SCID/MPSVII mice
was not significantly reduced compared to the number of 231+shControl
micrometastases (n≥5, p 0.05). Each point represents the average
mean number of micrometastases per section per mouse. Black bars
represent the median number of micrometastases per section per
mouse. (C) Immunohistochemical analysis of Ki67 expression (brown)
and TUNEL (brown) staining in pulmonary micrometastases from
231+shControl cells or 231+shNodal cells in NOD/SCID/MPSVII mice 4
weeks post-intravenous injection. Proliferation is indicated by Ki67
staining and apoptotic nuclei were detected with TUNEL. (D)
Proliferation:apoptosis ratios in 4 week micrometastases were
determined with immunohistochemical localization of Ki67 and TUNEL.
At 4 weeks, lesions from 231+shControl cells had a positive proliferation
ratio (1.57) whereas lesions from 231+shNodal cells had a negative
proliferation:apoptosis ratio (0.74) (n≥3, p<0.05). Values represent
mean average proliferation:apoptosis ratio in tumor lesions per mouse
S.E.M.
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proliferation and apoptosis (reviewed in (30)). Dormant tumours are often not 
dangerous; however, their potential to overcome their dormant state poses a 
threat to patient health. Accordingly, we measured proliferation:apoptosis ratios 
in the 4-week micro-lesions via immunohistochemical staining for Ki67:TUNEL. 
We found that 231+shControl lesions had a proliferation:apoptosis ratio greater 
than 1, indicating a potential for tumour growth, whereas 231+shNodal lesions 
had a proliferation:apoptosis ratio less than 1, indicating a state of tumour mass 
dormancy or regression (Figure 2.7C,D).   
Given these results, we expected that tumours that exhibited a potential 
for growth at 4 weeks would progress to macrometastases by 8 weeks, and far 
exceed the 100-cell limit observed in the 4-week lesions. Of note, by 8 weeks the 
231+shControl lesions formed overt pulmonary macrometastases in all of the 
mice injected with these cells (Figure 2.8A,B).  In contrast, the 231+shNodal 
cells did not form macrometastases.  Rather, at 8 weeks there was a significant 
accumulation of micrometastases in the lung compared to 231+shNodal cells at 
the 4 week time point (n≥8, p<0.05) (Figure 2.8C).  We also detected 
metastases in the brain of 1/5 231+shControl injected mice at 4 weeks and in the 
liver of 1/4 231+shControl injected mice at 8 weeks (Figure 2.9).  However, 
metastases to the brain or the liver were not detected in any of the 16 
231+shNodal-injected mice.  
Taken together, the results from our experimental metastasis assay 
illustrate the importance of Nodal in regulating the transition between 
micrometastatic and macrometastatic growth, in part through its ability to alter 
114
100 μm 100 μm
231+shControl
0.0
1.0
2.0
3.0
4.0
5.0
6.0
231+
shNodal
(4 wks)
231+
shNodal
(8 wks)
N
um
be
r o
f M
icr
om
et
s 
(A
ve
ra
ge
 o
f 3
 lu
ng
 s
ec
o
ns
/m
ou
se
) *
231+shControl 231+shNodal
231+shNodal
100 μm 100 μm
A
B
C
115
Figure 2.8 Nodal promotes progression to macrometastases. (A)
H&E staining demonstrates macrometastasis formation after 8 weeks
post-intravenous injection in NOD/SCID/MPSVII mice for 231+shControl
cells, but not 231+shNodal cells. 100% of lungs seeded with
231+shControl cells (4/4) contained macroscopic lesions at 8 weeks,
whereas 0/8 lungs seeded with 231+shNodal cells contained
macroscopic lesions. (B) GUSB staining to confirm human origin of
lesions showing 231+shControl macrometastasis formation after 8
weeks. Although macrometastases were not detected in mice injected
with 231+shNodal cells, micrometastases were detected with GUSB
staining. (C) The number of 231+shNodal micrometastases that formed
after 8 weeks in NOD/SCID/MPSVII mice was significantly higher than
those that formed after 4 weeks (n=8, p<0.05). Bars represent the
average mean number of micrometastases per section per mouse ±
S.E.M.
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Figure 2.9 Nodal supports tumour metastasis. (A) GUSB staining of
a brain metastasis from MDA-MB-231 cells transfected with a Control
shRNA (231+shControl) in NOD/SCID/MPSVII mice 4 weeks post-
intravenous injection (red). (B) GUSB staining demonstrates a liver
macrometastasis from 231+shControl cells after 8 weeks. No tumours
were found in either brain or liver from 231+shNodal cells at either 4 or
8 weeks.
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proliferation:apoptosis ratios necessary for normal tissue homeostasis. Similar 
phenomena have been reported in C57BL6/J mouse models of Lewis lung 
carcinoma mice, whereby poor tumour vascularization caused tumour dormancy 
marked by equal rates of mitosis and apoptosis (31). Interestingly, previous 
findings from our laboratory have implicated Nodal in regulating tumour 
angiogenesis both in vitro and in vivo (32). Thus, in addition to directly regulating 
cell proliferation and/or apoptosis, Nodal may indirectly promote tumour growth 
by facilitating vascular recruitment, a possibility worth investigating in future 
studies (see Chapter 3). Finally, although Nodal did not affect seeding of the 
cells at the secondary site, micrometastases accumulated over time with Nodal-
deficient cells. Conventional tumour growth assays using histology and/or whole 
animal imaging do not permit the single cell resolution that we obtained with the 
GUSB model; hence, studies done using conventional methodologies may 
inadvertently overlook the seeding phenomenon uncovered here.  
 
Collectively, this study indicates that the stem cell-associated protein Nodal 
promotes breast cancer tumour growth at both primary and secondary tumour 
sites, by altering the balance between proliferation and apoptosis. Our results 
provide mechanistic insight into studies that demonstrate that cancer cells 
manifesting stem-cell like properties exhibit accelerated cancer growth and 
progression in vivo, compared to their well-differentiated counterparts (33,34).  
Since Nodal expression is limited to embryonic contexts, our discovery suggests 
a novel role for Nodal as a tumour-specific target against breast cancer 
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progression, and for maintenance of tumour dormancy following metastatic 
spread. 
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CHAPTER 3 
The embryonic protein Nodal promotes breast cancer vascularization 
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3.1 Abstract 
Tumour vascularization is requisite for breast cancer progression, and 
high microvascular density in tumours is a poor prognostic indicator. Patients 
bearing breast cancers expressing human embryonic stem cell (hESC)-
associated genes similarly exhibit high mortality rates, and the expression of 
embryonic proteins is associated with tumour progression. Here, we demonstrate 
that Nodal, a hESC-associated protein, promotes breast cancer vascularization. 
We show that high levels of Nodal are positively correlated with high vascular 
densities in human breast lesions (p=0.0078). In vitro, we demonstrate that Nodal 
facilitates breast cancer-induced endothelial cell migration and tube formation, 
largely by up-regulating the expression and secretion of pro-angiogenic factors 
by breast cancer cells. Using a directed in vivo angiogenesis assay, and a chick 
chorioallantoic membrane assay, we show that Nodal promotes vascular 
recruitment in vivo. In a clinically relevant in vivo model whereby Nodal 
expression was inhibited following tumour formation, we found a significant 
reduction in tumour vascularization concomitant with elevated hypoxia and 
tumour necrosis. These findings establish Nodal as a potential anti-angiogenic 
target for the treatment of breast cancer angiogenesis and progression.
 
 
3.2 Introduction 
Aggressive breast cancer cells exhibit stem cell-like properties that 
contribute to their plasticity and ability to metastasize (1,2). For instance, 
metastatic cancer cells over-express genes normally restricted to hESCs and the 
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expression of an embryonic signature is associated with poor prognosis (3,4). 
Nodal, an embryonic morphogen from the TGF-β superfamily, is a hESC-
associated protein that becomes re-expressed during cancer progression (1,5-7). 
Nodal signals through the ALK4/7 and ActRIIB receptor complex, and its 
signalling is enhanced by Cripto-1 co-receptor.  Receptor activation leads to 
phosphorylation and nuclear translocation of SMAD2/3. Recent studies 
demonstrate that Nodal promotes a dedifferentiated phenotype in melanoma, 
glioma and prostate cancer, and that it increases cancer cell invasion and 
tumourigenicity in these cancer types (5,7,8). Nodal expression is also correlated 
with breast cancer progression, such that Nodal is absent in normal breast 
tissues, yet is aberrantly expressed in invasive breast cancer lesions (6).  The 
functional consequences of Nodal in breast cancer remain elusive.   
Recent studies have linked the acquisition of stem cell markers to the 
enhancement of classical hallmarks of cancer, such as self-sufficiency in growth 
signals and the acquisition of invasive phenotypes, as these phenotypes tend to 
be key characteristics of stem cell functionality. Angiogenesis is another hallmark 
of cancer that has recently been correlated with the acquisition of stem cell 
markers. For example, CD105+ human renal carcinoma cells, expressing  
Nestin, Nanog, and Oct3/4, have been shown to shed microvesicles that contain 
mRNAs for pro-angiogenic growth factors (including, but not limited to, VEGF and 
FGF) to facilitate tumour angiogenesis (9). Stem cell-associated phenotypes 
have also been linked to angiogenic potential in gliomas.  A mesenchymal-like 
subclass of high-grade gliomas has been shown to exhibit elevated expression of 
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pro-angiogenic factors including VEGF and PECAM, and a recent study revealed 
that glioma stem cell-like populations promote vascularization via a combinatorial 
mechanism involving the secretion of VEGF and Stromal-Derived Factor-1 (SDF-
1) (10,11). Lastly, one study has reported that Nodal regulates VEGF expression 
and is correlated with vessel density in gliomas (12).  However, this latter study 
did not directly assess the role of Nodal in the regulation of angiogenesis or 
vasculogenesis. 
Here, we demonstrate that Nodal is a potential target for the treatment of 
breast cancer vascularization. We found that Nodal protein is positively 
associated with a high microvascular density in human breast cancer tissues, 
and that it causes vascular recruitment in vivo. In vitro, we found that Nodal 
increases the ability of breast cancer cells to promote tube formation by 
endothelial cells, and that it regulates the expression of VEGF and other pro-
angiogenic factors in these breast cancer cells.  Finally, using inducible shRNA 
technology, we determined that Nodal can be targeted in established tumours to 
decrease vascular density and induce necrosis.  Given that Nodal is not present 
in non-lactating normal adult breast tissue, it may be useful as a therapeutic 
target against breast cancer angiogenesis. 
 
 
3.3 Methods 
3.3.1 Ethics Statement 
Human archival tissue was obtained from the Ontario Institute for Cancer 
Research (OICR), Ontario Tumour Bank. All experiments involving animals were 
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approved by the Animal Use Subcommittee at the University of Western Ontario, 
Protocol No. 2008-101 (Appendix 2). 
 
3.3.2 Immunohistochemistry (IHC) of human tissue 
Formalin-fixed, paraffin-embedded archival tissue with clinical and pathological 
information was obtained from breast cancer patients (OICR).  In total, ninety 
tumour sections, predominately reflecting invasive disease, were procured.  
Following deparaffinization in xylene, ethanol degradation, antigen retrieval with 
citrate buffer, and peroxidase and serum-free protein blocks, Nodal or CD31 
specific antibodies were applied (Table 3.1). To verify the specificity of Nodal 
staining, a monoclonal versus a polyclonal antibody were compared (Figure 3.1).  
In confirmation of previous studies, these antibodies stained the same cell 
populations, and revealed comparable staining patterns (13). We proceeded with 
the monoclonal antibody, as it generated less background staining, and it has 
been shown to detect human Nodal in breast cancer, melanoma, and 
endometrial cancers in several previously published reports (5,6,14).  Slides were 
rinsed in TBS-T, and treated with Envison+ HRP anti-mouse IgG (Dako). Color 
was produced with DAB substrate and counterstained with Mayer’s 
haematoxylin. Samples were dehydrated in reagent grade alcohol and cover 
slipped with permanent mounting medium. Isotype-matched mouse IgG negative 
controls were used at the same concentration as Nodal and CD31 antibodies.   
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Figure 3.1 AbCAM Nodal antibody stains the same cells as R&D
Nodal antibody, but with less non-specific background staining.
Immunohistochemical staining (brown) of Nodal in serial sections of
human breast cancer tissue specimens. Three examples of patients
with low and high levels of Nodal expression are displayed, and 2
different antibodies are compared: A mouse anti-human Nodal
monoclonal antibody (mAb) from AbCAM, and a goat anti-mouse Nodal
polyclonal antibody (pAb) from R&D. The R&D antibody has been used
successfully in several publications, and has been shown to detect
human Nodal in breast cancer, melanoma and endometrial cancers (see
Methods). The AbCAM mAb shows a similar staining pattern as the
previously characterized antibody, but with less background staining.
Hence, the AbCAM mAb was chosen for our experiments. Bar equals
100 mm.
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3.3.3 Evaluation of Nodal IHC and tumour vascular density in breast cancer 
sections
Nodal IHC was evaluated under light microscopy. Cytoplasmic staining was seen 
in all cases. Cases were blindly and independently scored by two pathologists 
(S.J.D. and J.M.) to derive a total Allred score (15). Total Allred score is the sum 
of proportion score (percentage of cells stained: 0%=0, <1%= 1, 1-10%= 2, 10-
33%= 3, 34-66%= 4 and 67%= 5) and intensity score (No staining= 0, Weak= 1, 
Moderate= 2, Strong= 3). Values were dichotomized using a total Allred score of 
7 and 8 as high expression, and ≤6 as low expression.   
Vascular density was blindly and independently scored by two pathologists 
(S.J.D. and J.M.) based on CD31 IHC staining, following the recommendations 
from the International Consensus on Evaluation of Angiogenesis in Solid Human 
Tumours (16). Briefly, three “hotspots” in the stromal component of each tissue 
section were selected, the number of vessels in each “hotspot” was counted at 
200x magnification, and a final score was expressed as the mean vessel density 
per section. Data was dichotomized using the average number of vessels among 
all samples as the cut-off between high and low vascular density values.  All 
scoring values obtained by S.J.D. and J.M. had a Pearson Correlation Coefficient 
(rp) of 0.73 or higher.  83 out of 90 cases had both Nodal IHC and CD31 vascular 
density scores, and were used for statistical analyses.   
For clinical characteristics of these 83 patients, see Table 3.2.  The Allred 
scores for Nodal were used to assess correlations between Nodal, ER status, PR 
status, HER-2 status and tumour grade.  For these correlation analyses, positive 
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ER/PR/HER-2 staining was assigned a value of 1 and negative staining was 
assigned a value of 0. The disease grade was assigned a value of 1, 2, or 3.  
Assessment of correlations was performed using Pearson Correlation and a 2-
sided t-test.  
 
3.3.4 Cell culture and transfection 
Multiple cell types (both endothelial and breast cancer), treatments (drugs and 
recombinant proteins), and constructs (shRNA and expression vectors) were 
used throughout this study: 
Endothelial cells: Two endothelial cell lines were used, human umbilical 
vein endothelial cells (HUVECs; ATCC), and primary human adult microvascular 
endothelial cells (HMVECs; Invitrogen). We used both adult and umbilical 
sources to account for possible functional differences in response to Nodal. Cells 
were maintained with attachment factor, and Medium 131 + Microvascular 
Growth Supplement as per manufacturer suggestions (Invitrogen).   
Breast cancer cells: We used two highly aggressive breast cancer cell 
lines that express high endogenous Nodal for loss-of-function studies (MDA-MB-
231 and MDA-MB-468), and one poorly aggressive breast cancer cell line that 
expresses low endogenous Nodal for gain-of-function studies (T47D) (Figure
2.1A). All breast cancer cell lines were obtained from and validated by ATCC, 
and were maintained as per instructions.  Multiple constructs were used to 
knockdown or induce Nodal signalling in each of the cell lines used: 
Using shRNA or SB431542 for Nodal loss-of-function experiments: 
Nodal knockdown was achieved in MDA-MB-231 cells with a pGIPZ lentiviral 
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shRNAmir against Nodal’s 3rd exon (Clone: V2LHS 155453, Open Biosystems), 
or with a pTRIPZ lentiviral shRNAmir against Nodal’s 3rd exon (Clone: 
V2THS 155453) with Tet-On /Tet-Off  inducibility (Open Biosystems). 
Additionally, Nodal knockdown was achieved in MDA-MB-468 cells with a HuSH-
29mer shRNA against Nodal’s 3rd exon (Id: GI311711) (Origene). Scrambled 
Control and anti-Nodal shRNAs were transfected using Arrest-In (Open 
Biosystems) or Lipofectamine (Invitrogen) as per manufacturer instructions, and 
cells were stably selected using Puromycin (200-450 ng/mL). For all knockdown 
systems, shRNAs targeting at least 4 regions in the Nodal gene were tested for 
their ability to knockdown Nodal protein expression.  For each vector type, the 
shRNA achieving the best knockdown was chosen (as specified above). To 
inhibit Nodal signalling, the ALK4/5/7 inhibitor SB431542 (Sigma) was used at a 
concentration of up to 10 M. We chose to use 10 M of SB431542 in our 
experiment, since this dose consistently had the greatest inhibitory effect on 
SMAD2 phosphorylation, and has been used in previously published reports on 
hESCs to block Nodal signalling (17,18). 
Using expression vectors or recombinant protein for Nodal gain-of-
function experiments: For Nodal gain-of-function experiments, a Nodal 
expression vector was made with pcDNA 3.3-TOPO  cloning kit, and an empty 
pcDNA3.3 vector was used as a control.  Vectors were sequenced and validated, 
transfected into T47D cells using Lipofectamine (Invitrogen) as per manufacturer 
instructions, and stably selected with Geneticin (G418; 800 ng/mL). Additionally, 
for proof-of-principle, 50-100 ng/mL recombinant human Nodal (mature species) 
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was used to treat cells and activate phospho (P)-SMAD2 signalling (R D 
systems). We chose to test this concentration range since previous studies have 
shown that at least 50 ng/mL of Nodal is required for maintenance of pluripotency 
in hESCs (17,19). We chose to use 100 ng/mL of recombinant human Nodal 
(rhNodal) for our experiments (rather than 50 ng/mL), since we found there was 
substantial lot-to-lot variance, and 100 ng/mL most consistently induced 
phosphorylation of SMAD2. Furthermore, 100 ng/mL of rhNodal has been used 
effectively in multiple published studies related to Nodal in cancer (20,21).
 
3.3.5 RNA extraction and real time RT-PCR 
Total RNA was isolated from cells and tumour tissue using the Perfect Pure RNA 
cultured cell kit (5 Prime) and genomic DNA was degraded using DNAse.  
Reverse transcription was performed using 2 g RNA and the High Capacity 
cDNA Reverse Transcription kit (Applied Biosystems). Real-time PCR was 
performed using TaqMan  gene expression human primer/probe sets (Table 
3.3). Gene expression was normalized to the endogenous control genes HPRT1 
or RPLPO.   
 
 
3.3.6 Western blotting 
Protein lysates were prepared and quantified as previously described (6).  Equal 
amounts of protein were separated by SDS-polyacrylamide gel electrophoresis 
under reducing conditions, and resolved proteins were transferred onto 
Immobilon-P membranes (Millipore Corp.).  Membranes were incubated with 
primary antibody (Table 3.1) and the appropriate horseradish peroxidase-
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Target Probe ID 
PDGF-B Hs00234042_m1 
VEGF-A Hs00173626_m1 
RPLPO 4333761-0707014 
HPRT1 4333768-0904021 
 
Table 3.3 Primer/Probe information for real-time PCR 
(Applied Biosystems)
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conjugated secondary antibody.  Enzyme activity was detected by enhanced 
chemiluminescence (Super Signal; Pierce). Images were obtained using film. 
In accordance with previous studies (5,6,20,22), three banding locations 
were detected for Nodal:  Pro-Nodal at 39 kDa, fully processed Nodal at 50 
kDa, and mature Nodal at 15 kDa. The 50 kDa species is highly variable due to 
differences in post-translational modifications and protein lysate handling. The 15 
kDa band is typically in low abundance in both cell lysates and conditioned media 
due to low protein stability (22); however, it is slightly easier to pick up in 
condensed conditioned media. For consistency and accuracy, we used the 39 
kDa band to assess Nodal expression in lysates (as we have previously shown 
that it is proportional to 15 kDa mature Nodal in both lysate and conditioned 
media (20)), and the 15 kDa band to assess Nodal levels in conditioned media.  
 
 
3.3.7 In vitro functional assays 
Functional assays were performed on endothelial cell lines (HUVECs and 
HMVECs) in response to conditioned media from either (1) MDA-MB-231 cells 
transfected with a scramble control shRNA or a Nodal-targeted shRNA (pGIPZ 
constructs as specified in Section 3.3.4), or (2) T47D cells transfected with an 
empty control vector or a Nodal expression vector.  
Tube formation: Endothelial cell Medium 131 supplemented with 0.5% 
BSA was conditioned by cancer cells for 24 hours. Endothelial cells were seeded 
on Matrigel and treated with conditioned media. In some cases, rhNodal (100 
ng/mL; R D), VEGF (20 ng/mL; Invitrogen), and/or PDGF (20 ng/mL; Invitrogen) 
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were added to the conditioned medium after it was collected, during the course of 
the assay. 20 ng/mL of VEGF and PDGF was used because it is the minimum 
concentration consistently reported to stimulate endothelial cells in vitro (23,24), 
and it is much lower than concentrations used for most in vivo positive controls 
(for example, refer to DIVAA manufacturer protocol). Tube formation was 
quantified by counting the number of circular structures that formed from 
complete branching per field of view (20x magnification). A sum of 10 fields of 
view was used for each treatment replicate. 
Migration: Endothelial cells (50,000 cells) were seeded into a Transwell 
insert, and treated with conditioned media from cancer cells. Migration (24 hrs) 
was quantified by staining nuclei with DAPI and counting cells. In some cases, 
rhNodal, VEGF, and/or PDGF were added to the conditioned medium after it was 
collected, during the course of the assay. An average of 10 fields of view (20x 
magnification) was used for each treatment replicate. 
Viability: Viability of endothelial cells in response to conditioned media 
was assessed using the LIVE/DEAD  Viability/Cytotoxycity Kit as per 
manufacturer’s instructions (Invitrogen). 
 
3.3.8 SearchLight protein array
In some cases (as indicated) VEGF and PDGF protein levels were quantified by 
an Aushon SearchLight Chemiluminescent Angiogenesis Arrays ( 84694; 
Aushon Biosystems, Billerica, MA) as per manufacturer instructions. 
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3.3.9 Directed in vivo angiogenesis assay (DIVAA) 
A DIVAA kit was used for the in vivo angiogenesis assays (Trevigen, 
Gaithersburg, MD) (25,26). Angioreactor tubes were filled with Matrigel (negative 
control), Matrigel + cancer cells, or Matrigel + cancer cells + growth factors (for 
rescue analyses). As in our in vitro assays, rhNodal was added at a 
concentration of 100 ng/mL, and VEGF was added at a concentration of 20 
ng/mL. Angioreactors were inserted subcutaneously into nude mice. After 10 
days, mice were sacrificed and angioreactors were removed. Blood vessels that 
invaded the angioreactors were imaged under a microscope, and subsequently 
transferred into a 1.5 mL tube. Endothelial cells were incubated with FITC-Lectin 
overnight (provided in the DIVAA kit), and fluorescence was quantified using a 
plate reader.  
 
3.3.10 Chick chorioallantoic membrane (CAM) assays 
To assess angiogenesis, one collagen-enmeshed grid containing 2 X 106 cells 
was placed on each CAM, and newly formed blood vessels that appeared in the 
upper grids of the collagen onplants after 3 days were scored and quantified as 
previously described (27). To assess tumour formation, 100,000 cells were 
placed directly onto the CAM, and were left for 5 days prior to confocal imaging. 
Tumour cells were visualized with GFP expressed in the bicistronic pGIPZ 
shRNA constructs. In both cases, recombinant VEGF was added at a 
concentration of 20 ng/mL for rescue analysis. 
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3.3.11 In vivo inducible shRNA tumour assay 
MDA-MB-231 cells were transfected with a doxycyclin (Dox)-inducible control or 
Nodal-targeted shRNA. Both constructs expresses RFP upon induction by Dox.
500,000 cells in 100 L RPMI + Matrigel (1:1) were injected into the right flank of 
6-8 week old female Nude mice (Crl:NU-Foxn1nu; Charles River). Dox was 
administered 2 weeks following onset of palpable tumour growth via diet (0.625 g 
doxycyline hyclate per 1 kg chow). This diet is optimized to deliver Dox at 2-3 
mg/day, given that each mouse eats approximately 4-5 g/day (Harlan 
Laboratories). Excised tumours were cut in half: one half was subject to 
formaldehyde-fixation for H E and analysis of tumour necrosis, and the other half 
frozen and cryosectioned for IF and analysis of tumour hypoxia. Following 
cryosectioning, remaining tumour tissue was used for RNA extraction and PCR 
analysis. 
Immunofluorescence: Immunofluorescence was conducted using anti-
CD31 and anti-Nodal antibodies (Table 3.1) with the appropriate fluorochrome-
conjugated secondary antibodies. DAPI was used to stain nuclei and IgG isotype 
controls were performed. For each tumour section, CD31 was quantified by 
taking 5 random images of vascular hotspots around the tumour periphery 
(tumour cores were too necrotic to include), and then counting the number of 
vessels in each field of view across a 25-box grid overlay using ImageJ software. 
For each tumour, 3 serial sections were quantified by this method, and averaged 
to yield one value for CD31 expression per mouse replicate.
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Analysis of VEGF expression: After cryosectioning, remaining frozen 
tumour tissue was subject to RNA extraction as per manufacturer’s protocol 
(described in Section 3.3.5). VEGF mRNA expression was subsequently 
analyzed by real time RT-PCR, as described above. 
Analysis of tumour necrosis:  Three tumour sections spaced evenly 
throughout each tissue block were stained with H E. Each section was imaged 
such that the entire section was visible in one picture. Photoshop software was 
used to outline and quantify total tumour area, and area of necrosis. Necrosis 
was calculated as a percentage of the total tumour area. 
Analysis of tumour hypoxia: Animals were injected with hypoxyprobe-1 
(60 mg/kg body weight) prior to sacrificing. Excised tumours were frozen and IHC 
was performed as described above, with a few modifications as per manufacturer 
instructions. Acetone was used for fixation. Endogenous immunoglobulins in 
mouse tissue were blocked with the mouse-on-mouse (M.O.M. ) basic kit 
(Vector Laboratories). Sections were incubated with anti-hypoxyprobe-1 antibody 
(HPI, Inc) (Table 3.1), and a biotinylated anti-mouse IgG (H+L) secondary 
antibody (M.O.M.  kit, Vector Laboratories). Vectastain ABC kit (Vector 
Laboratories) was used to detect enzyme activity, DAB substrate (Dako) was 
used for color development, and haematoxylin was used to counterstain.  
 
3.3.12 Statistical analyses 
Statistical analyses of multiple comparisons for parametric data were performed 
using a one-way ANOVA followed by a Tukey Kramer Comparisons Post-Hoc 
test. An ANOVA on Ranks followed by the Mann-Whitney rank-sum test was 
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used for non-parametric data. When only two items were compared, a student’s 
t-test was used.  Parametric data were expressed as mean  S.E.M. for replicate 
values, and non-parametric data were expressed as median  interquartile range. 
All statistical tests were two-sided and data comparisons for all experiments were 
considered statistically significant at p<0.05.  Statistics were performed using 
SigmaStat (Dundas Software) in consultation with the biostatistical support unit at 
the University of Western Ontario. 
 
3.4 Results 
3.4.1 Nodal is correlated with CD31 in human breast cancer samples 
Angiogenesis is a rate-limiting step in the metastatic cascade and high 
microvascular density is correlated with a poor clinical outcome (28,29).  Given 
recent evidence linking tumour angiogenesis to stem cell markers, we sought to 
determine if Nodal expression correlates with microvascular density in human 
breast cancers.  Immunohistochemical analysis of Nodal and CD31 (to 
demarcate endothelial cells) in a cohort of breast cancer patients was examined 
in serial sections (29). Breast cancer tissue from 90 patients was procured from 
the primary tumour site; 89 via surgical resection and 1 via excisional biopsy. The 
average age of the patients was 61 years (ranging from 27 to 90) with a SD of 
16.5 years.  The majority of the cases were invasive disease, diagnosed as being 
Grade 3 (47%) or Grade 2 (37.4%).  Of the 90 samples, 83 could be scored for 
both Nodal and vascular density, and were used for statistical analyses.  Clinical 
characteristics of these patients are listed in Table 3.2.  IHC for both Nodal and 
CD31 was heterogeneous, varying between individuals and within sections in 
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extent, intensity and localization.  In these lesions, Nodal was generally confined 
to epithelial-like tumour cells (Figure 3.1, Figure 3.2A).  Nodal staining was not 
correlated to breast cancer Grade (p=0.140), or to Estrogen Receptor (ER) 
(p=0.682), Progesterone Receptor (PR) (p=0.801) or HER2 (p=0.589) status.  
However, high levels of Nodal were associated with a high vascular density 
(n=83; rp=0.3, p=0.0076), suggesting a clinical association between the 
acquisition of Nodal expression and vascular recruitment (Figure 3.2A,B). 
 
3.4.2 Nodal promotes endothelial cell tube formation in vitro 
To explore whether Nodal regulates breast cancer angiogenesis, we first 
tested the effects of Nodal on endothelial cell function. Specifically, we performed 
in vitro tube formation and migration assays using human umbilical vein 
endothelial cells (HUVECs), or primary human microvascular endothelial cell 
(HMVECs) treated with conditioned media from stably transfected breast cancer 
cells. For Nodal loss-of-function experiments, we used MDA-MB-231 cells, which 
express high levels of Nodal, and for Nodal gain-of-function experiments, we 
used T47D cells, which express relatively low levels of Nodal (Figure 2.1A) (6). 
We found that conditioned media from MDA-MB-231 cells transfected with a 
Nodal-targeted shRNA (231+shNodal) significantly reduced endothelial 
branching (HUVEC n=3, P<0.001; HMVEC n=3, P<0.001) and migration (HUVEC 
n=4, P<0.001; HMVEC n=3, P<0.001) of both HUVECs and HMVECs compared 
to conditioned media from MDA-MB-231 cells transfected with a Control shRNA 
(231+shControl) (Figure 3.3A-D, Figure 3.4A-C). This effect was not due to 
altered cell viability or proliferation (Figure 3.3E-F, Figure 3.4D). Similarly, in 
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Figure 3.2 High Nodal expression is associated with vascular
hotspots in breast cancer lesions. (A) Immunohistochemical staining
(brown) of Nodal and CD31 in serial sections of human breast cancer
tissue specimens. Examples of a patient with a low level of Nodal
expression and another patient with a high level of Nodal expression are
displayed. Sections stained with H&E or incubated with an isotype
control are also included. Bar equals 50 μm. (B) Entire sections of
each breast cancer case were analyzed to derive an Allred Score for
Nodal expression. A total Allred score of 7 and 8 represented high
Nodal expression and a score of 6 and below represented low Nodal
expression. In serial sections, vascular density was scored based on
CD31 staining. Following the recommendations from the International
Consensus on Evaluation of Angiogenesis in Solid Human Tumors,
three “hotspots” in the stromal component were selected, the number of
vessels in each “hotspot” was counted and a final score was expressed
as the mean vessel density. Data was dichotomized using the average
number of vessels among all the samples as the cut-off between high
and low vascular density values. High Nodal expression was found to
be associated with a high vascular density in human breast cancer
tissue (n=83 patients, rp=0.3, P=0.0076).
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Figure 3.3 Nodal inhibition in MDA-MB-231 cells reduces HUVEC
tube formation and migration in vitro. (A) Western blot analysis of
Nodal protein in conditioned medium of 231+shNodal cells or
231+shControl cells. The 15 kDa cleaved and secreted Nodal band is
presented. (B) Representative images of HUVEC Matrigel tube
formation assays treated with 0.5% BSA (negative control),
231+shControl-conditioned media, 231+shNodal-conditioned media, or
231+shNodal-conditioned media plus the addition of recombinant
human Nodal (rhNodal). Bar equals 100 m. (C) Quantified HUVEC
tube formation corresponding to (B). Nodal knockdown caused a
significant reduction in tube formation compared to 231+shControl, and
this effect was not rescued by addition of rhNodal to conditioned media.
Bars represent mean number of branch points S.E.M. (n=3, P<0.001).
(D) Transwell assay testing HUVEC cellular migration in response to
treatments from (B) and (C). Nodal knockdown caused a significant
reduction in HUVEC migration compared to 231+shControl, and this
effect was rescued by addition of rhNodal to conditioned media. Bars
represent mean number of migrated cells per field of view (FOV)
S.E.M. (n=4, P<0.001). (E) Viability assay testing the effects of
treatment conditions from (B-D) on HUVECs. Viability was not
compromised in response to conditioned media. Bars represent fold
change in fluorescence S.E.M. relative to 0.5% BSA control (n≥4,
P=0.2). (F) HUVEC cell proliferation assay over 4 days in response to
treatment with 100 ng/mL rhNodal. No significant difference was
observed for any of the time points (n=3, p 0.05). For all graphs,
different superscripted letters indicate a statistical difference as
specified.
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Figure 3.4 Nodal inhibition in MDA-MB-231 cells reduces HMVEC
tube formation and migration in vitro. (A) Representative images of
primary HMVEC Matrigel tube formation assays treated with 0.5% BSA
(negative control), 231+shControl-conditioned media, 231+shNodal-
conditioned media, or 231+shNodal-conditioned media plus the addition
of rhNodal. Bar equals 50 μm. (B) Quantified HMVEC tube formation
corresponding to (A). Nodal knockdown caused a significant reduction
in tube formation compared to 231+shControl, and this effect was not
rescued by addition of rhNodal to conditioned media. Bars represent
mean number of branch points ± S.E.M. (n=3, P<0.001). (C) Transwell
assay testing HMVEC cellular migration in response to treatments from
(A) and (B). Nodal knockdown caused a significant reduction in HMVEC
migration compared to 231+shControl, and this effect was not rescued
by addition of rhNodal to conditioned media. Bars represent mean
number of migrated cells per field of view (FOV) ± S.E.M. (n=4,
P<0.001). (D) Viability assay testing the effects of treatment conditions
from (A-C) on HMVECs. Viability was not compromised in response to
conditioned media. Bars represent fold change in fluorescence ± S.E.M.
relative to 0.5% BSA control (n=6, P>0.05).
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complementary Nodal gain-of-function experiments, we treated HUVECs with 
conditioned media from T47D cells transfected with an empty vector (T47D+EV) 
or a Nodal expression construct (T47D+Nodal) (Figure 3.5A). We found that 
tube formation (n=3, P<0.01) and migration (n=4, P<0.05) were significantly 
increased in response to conditioned media from T47D+Nodal cells, compared to 
T47D+EV cells (Figure 3.5B-D). This effect was not due to a change in HUVEC 
viability (Figure 3.5E).  
In order to determine if Nodal was acting directly on the endothelial cells, 
or indirectly by regulating the expression of angiogenic factors in the cancer cells, 
we added recombinant human Nodal (rhNodal) to the collected conditioned 
media during the course of the tube formation assays.  If Nodal was acting 
directly on the endothelial cells, rhNodal would restore endothelial cell function in 
231+shNodal-conditioned media. Although migration of HUVECs was rescued by 
rhNodal treatment, migration of HMVECs and tube formation for both endothelial 
cell types were not affected (Figure 3.3B-E, Figure 3.4A-D). This suggests that 
Nodal acts on some endothelial cells directly, but also that Nodal can promote 
angiogenesis indirectly, perhaps by up-regulating the secretion of pro-angiogenic 
proteins by the cancer cells.  
In support of this concept, using a SearchLight array and Western blot 
analysis, we found that Nodal inhibition with shRNA caused a significant 
reduction in Platelet Derived Growth Factor (PDGF) (n=3, p=0.018) and VEGF 
(n=3, p=0.007) protein expression (Figure 3.6A-D). Furthermore, addition of 
rhNodal (100 ng/mL) to 231+shNodal cells rescued VEGF expression as 
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Figure 3.5 Nodal overexpression in T47D cells promotes HUVEC
tube formation and migration in vitro. (A) Western blot validation of
elevated Nodal expression in T47D+Nodal conditioned media versus
T47D+EV stably transfected cells. The ~15 kDa mature Nodal band is
shown. (B) Representative images of HUVEC Matrigel tube formation
assays treated with 0.5% BSA (negative control), 20 ng/mL VEGF-A
(positive control), T47D+EV-conditioned media, or T47D+Nodal-
conditioned media. Bar equals 100 mm. (C) Quantified tube formation
corresponding to images in (B). HUVECs formed tubes more efficiently
when treated with T47D+Nodal-conditioned media compared to
T47D+EV-conditioned media. Bars represent mean number of branch
points ± S.E.M. (n=3, P<0.01). (D) Transwell assay testing HUVEC
cellular migration in response to treatments from (B) and (C). HUVEC
migration was significantly increased in response to T47D+Nodal-
conditioned media compared to T47D+EV-conditioned media (n=4,
P<0.05). Bars represent mean number of migrated cells per field of view
(FOV) ± S.E.M. (E) Viability assay testing the effects of treatment
conditions from (B-D) on HUVECs. Viability was not compromised in
response to conditioned media. Bars represent fold change in
fluorescence ± S.E.M. relative to 0.5% BSA control (n=3, P=0.48). For
all graphs, different superscripted letters indicate a statistical difference
as specified.
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Figure 3.6 Nodal inhibition in MDA-MB-231 and MDA-MB-468 cells
reduces expression and secretion of pro-angiogenic factors. (A)
Western blot validating Nodal knockdown in 231+shNodal versus
231+shControl cells, concomitant with a reduction in phosphorylated-
SMAD2 (indicative of decreased canonical Nodal signalling). The pro-
Nodal (~39 kDa) band is detected and SMAD2/3 and Actin are used as
loading controls. (B) Western blot demonstrating that VEGF protein in
231+shNodal lysate is lower than in 231+shControl lysate, but that
VEGF expression is rescued by the addition of 100 ng/mL rhNodal. (C)
PDGF protein expression (PDGF n=3, p=0.018), and (D) VEGF protein
expression (VEGF n=3, p=0.007) were reduced in 231+shNodal cells
compared to 231+shControl cells as measured with a protein array.
Bars represent mean protein expression ± S.E.M. (E) SearchLight
protein quantification of PDGF expression in conditioned media (n=3,
p=0.029) or (F) cell lysate (n=3, p<0.001) from 468+shControl versus
468+shNodal cells. (G) SearchLight protein quantification of VEGF
expression in conditioned media (n=3, p<0.001) or (H) cell lysate (n=3,
p<0.001) from 468+shControl versus 468+shNodal cells. (I) Western
blot demonstrating reduced VEGF expression in 468+shNodal cells
compared to 468+shControl cells. For all graphs, asterisks (*) indicate a
significant difference compared to controls as specified.
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measured by Western blot (Figure 3.6B). To validate these observations, we 
measured VEGF and PDGF protein in response to Nodal knockdown in MDA-
MB-468 cells. We found that Nodal inhibition caused decreased expression of 
PDGF in conditioned media (n=3, p=0.029) and cell lysate (n=3, p<0.001) 
(Figure 3.6E,F), and decreased expression of VEGF in conditioned media (n=3, 
p<0.001) and cell lysate (n=3, p<0.001) (Figure 3.6G-I). In complementary gain-
of-function experiments, treatment of T47D or MCF-7 cells with increasing 
concentrations of rhNodal (0, 50, or 100 ng/mL) resulted in an increase in VEGF 
and PDGF protein expression measured by Western blot (Figure 3.7A,B). 
Furthermore, treatment of T47D cells with rhNodal caused a significant increase 
in VEGF and PDGF mRNA expression (n=3, P<0.05) (Figure 3.7C). Similarly, 
using a SearchLight protein array, we found that T47D+Nodal cells displayed a 
significant increase in PDGF protein expression in conditioned media (n=3, 
p=0.045) and cell lysate (n=4, p=0.029) (Figure 3.7D,E), and a significant 
increased in VEGF protein expression in cell lysate (n=3, p=0.029) compared to 
T47D+EV cells (Figure 3.7F-H). Lastly, we found that activation of ALK4/7 is 
required for VEGF and PDGF regulation, since treatment of T47D cells with 
SB431542 inhibits rhNodal-induced up-regulation of these proteins (Figure 3.7I).  
Given that Nodal regulates pro-angiogenic proteins in breast cancer cells, 
we next investigated whether we could rescue the effects of 231+shNodal-
conditioned media on endothelial cells with recombinant VEGF and/or PDGF. We 
added these proteins to the conditioned media after it was collected from the 
cancer cells (i.e. during the incubation on endothelial cells). Unlike the addition of 
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Figure 3.7 Nodal overexpression in T47D cells increases
expression and secretion of pro-angiogenic factors. (A) Western
blot validating dose-dependent induction of Nodal signaling via
phospho-SMAD2 in T47D cells in response to vehicle or rhNodal (50 or
100 ng/mL) after 24 hrs. Actin was used as a loading control. (B)
Western blot analysis showing a dose-dependent increase in VEGF and
PDGF in T47D cells or MCF-7 cells treated with increasing
concentrations of rhNodal (0, 50, or 100 ng/mL). Actin is used as a
loading control. (C) Real-time RT-PCR analysis of VEGF and PDGF
expression in T47D cells treated for 24 hours with either vehicle or
rhNodal (50 ng/mL, 100 ng/mL). VEGF and PDGF mRNA expression
were significantly elevated in T47D cells treated with 50 or 100 ng/mL of
rhNodal. Expression levels are normalized to HPRT1. Bars represent
mean gene expression ± S.E.M. relative to 0 ng/mL rhNodal control
(n=3, P<0.05 for each). (D) SearchLight protein quantification of PDGF
expression in conditioned media (n=3, p=0.045) or (E) cell lysate (n=3,
p=0.029) from T47D+EV versus T47D+Nodal cells. (F) SearchLight
protein quantification of VEGF expression in conditioned media (n=3,
p>0.05) or (G) cell lysate (n=3, p=0.029) from T47D+EV versus
T47D+Nodal cells. (H) Western blot demonstrating elevated VEGF
expression in T47D+Nodal cells compared to T47D+EV cells. Actin is
used as a loading control. (I) Western blot demonstrating that VEGF
and PDGF are up-regulated in response to rhNodal treatment (100
ng/mL) in T47D cells, but that this is mitigated with the addition of
SB431542 (10 μM). Actin is used as a loading control. For all graphs,
asterisks (*) indicate a significant difference compared to controls as
specified.
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rhNodal, which did not rescue angiogenic phenotypes compared to controls, we 
found that addition of VEGF and/or PDGF to 231+shNodal conditioned media 
during the tube formation and migration assays did restore both phenotypes in 
HUVEC and HMVEC cultures (Figure 3.8A-C, Figure 3.9A-C). This was not due 
to a significant change in viability (Figure 3.8D, Figure 3.9D). 
 
3.4.3 Nodal promotes vascular recruitment in vivo 
To test the significance of our in vitro results we employed a directed in 
vivo angiogenesis assay (DIVAA). Stably transfected cancer cells were seeded 
into silicone matrix-containing angioreactors, which were implanted 
subcutaneously into nude mice, and endothelial cells that invaded the 
angioreactors were quantified using a FITC-lectin-based assay (25). We 
determined that 468+shControl cells (n=7, p=0.007) and 231+shControl cells 
(n=10, p=0.003) efficiently recruit vasculature within 10 days, and that this ability 
is mitigated when Nodal is knocked down (Figure 3.10A-D). Moreover, this in
vivo effect of Nodal knockdown on angiogenesis was fully rescued in 
468+shNodal cells by the addition of VEGF (Figure 3.10C,D). In contrast to our 
in vitro studies, we were able to partially recover the effects of Nodal knockdown 
with the addition of rhNodal (Figure 3.10C,D).  This may have been because the 
cancer cells in the implants responded to the rhNodal by re-expressing VEGF 
and PDGF. Alternatively, Nodal may affect other pro-angiogenic cell types in
vivo, such as hematopoietic stem cells, not accounted for in our endothelial cell 
assays. In accordance with our in vitro studies, T47D+Nodal transfected cells 
induced significantly higher vessel recruitment compared to controls (n=10, 
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Figure 3.8 VEGF and PDGF rescue the effects of Nodal knockdown
on HUVEC tube formation and migration. (A) Representative images
of HUVEC Matrigel tube formation assays treated with 0.5% BSA
(negative control), 231+shControl-conditioned media, 231+shNodal-
conditioned media, or 231+shNodal-conditioned media plus the addition
of VEGF and/or PDGF. Bar equals 100 mm. (B) Quantified HUVEC
tube formation corresponding to (A). The effects of Nodal knockdown on
tube formation are rescued by adding VEGF, or VEGF+PDGF to
conditioned media following collection from cancer cells. Bars represent
mean number of branch points S.E.M. (n=3, P<0.001). (C) Transwell
assay testing HUVEC cellular migration in response to treatments from
(A) and (B). The effects of Nodal knockdown on HUVEC migration are
rescued by adding VEGF, PDGF, or VEGF+PDGF to conditioned media
following collection from cancer cells. Bars represent mean number of
migrated cells per field of view (FOV) S.E.M. (n=4, P<0.001). (D)
Viability assay testing the effects of treatment conditions from (A-C) on
HUVECs. Viability was not compromised in response to conditioned
media. Bars represent fold change in fluorescence S.E.M. relative to
0.5% BSA control (n≥4, P=0.2). For all graphs, different superscripted
letters indicate a statistical difference as specified.
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Figure 3.9 VEGF and PDGF rescue the effects of Nodal knockdown
on HMVEC tube formation and migration. (A) Representative images
of primary HMVEC Matrigel tube formation assays treated with 0.5%
BSA (negative control), 231+shControl-conditioned media,
231+shNodal-conditioned media, or 231+shNodal-conditioned media
plus the addition of VEGF and/or PDGF. Bar equals 50 mm. (B)
Quantified HMVEC tube formation corresponding to (A). The effects of
Nodal knockdown on tube formation is rescued by adding VEGF, PDGF,
or VEGF+PDGF to conditioned media following collection from cancer
cells. Bars represent mean number of branch points ± S.E.M. (n=3,
P<0.001). (C) Transwell assay testing HMVEC cellular migration in
response to treatments from (A) and (B). The effects of Nodal
knockdown on HMVEC migration is rescued by adding VEGF+PDGF to
conditioned media following collection from cancer cells, and partially
rescued by adding VEGF alone. Bars represent mean number of
migrated cells per field of view (FOV) ± S.E.M. (n=4, P<0.001). (D)
Viability assay testing the effects of treatment conditions from (A-C) on
HMVECs. Viability was not compromised in response to conditioned
media. Bars represent fold change in fluorescence ± S.E.M. relative to
0.5% BSA control (n=6, P>0.05). For all graphs, different superscripted
letters indicate a statistical difference as specified.
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Figure 3.10 Nodal promotes vascular recruitment in a Directed In
Vivo Angiogenesis Assay (DIVAA). (A) 231+shNodal cells or
231+shControl cells were injected into silicon angioreactors and
implanted subcutaneously into nude mice. After 10 days, vascular
recruitment into the angioreactors was quantified using a FITC-lectin-
based assay. Nodal knockdown caused a significant reduction in
vascular recruitment compared to 231+shControl. Data are non-
parametric and are presented as median ± interquartile range (n=10,
P=0.003) (B) Images of representative angioreactors corresponding to
(A) following excision from mice. (C) 468+shNodal cells or
468+shControl cells were injected into silicon angioreactors and
implanted subcutaneously into nude mice for 10 days as described in
(A). 468+shNodal cells had significantly reduced vascular recruitment
compared to 468+shControl cells. This effect was partially rescued by
the addition of rhNodal to angioreactors containing 468+shNodal cells,
and was significantly rescued by the addition of VEGF. Recombinant
VEGF in Matrigel (no cells) was included as a control. Data are
parametric and are presented as mean relative fluorescent units ±
S.E.M. (n=7, P<0.007). (D) Images of representative angioreactors
corresponding to (C) following excision from mice. (E) T47D+Nodal or
T47D+EV transfected cells were injected into silicon angioreactors and
implanted subcutaneously into nude mice for 10 days as described in
(A). T47D+Nodal cells had significantly increased vascular recruitment
compared to T47D+EV cells (n=10, P<0.001). Bars represent mean
relative fluorescent units ± S.E.M. (F) Images of representative
angioreactors corresponding to (E) following excision from mice. For all
graphs, different superscripted letters have a statistical difference.
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P<0.001) (Figure 3.10E,F). Collectively, these data confirm that Nodal promotes 
tumour angiogenesis in vivo. 
As proof-of-principle of our DIVAA results, we used a Chick 
Chorioallantoic Membrane (CAM) assay as an additional method to assess the 
role of Nodal during vascularization in vivo. The CAM assay involves placing 
cells-of-interest on a collagen-enmeshed grid on the CAM and then scoring for 
newly formed blood vessels in the upper grids after 3 days (27). We found that 
231+shControl cells were able to induce angiogenesis significantly better than 
231+shNodal cells (n≥37, P<0.001) (Figure 3.11A). Furthermore, inclusion of 
recombinant VEGF with 231+shNodal cells on the CAM resulted in a rescue of 
the angiogenic phenotype (Figure 3.11A). Consistently, when we used the chick 
CAM to perform a tumour assay over 5 days, we found that 231+shNodal cells 
were unable to form tumours compared to controls by confocal analysis (Figure
3.11B). Furthermore, despite promoting vascularization, VEGF did not rescue 
231+shNodal tumour formation (Fig. 311B), suggesting that Nodal may regulate 
multiple aspects of tumourigenesis in this model. 
 
3.4.4 Inducible Nodal inhibition following tumour formation reduces 
vascularization
We next designed a clinically relevant model to evaluate the effects of 
targeting Nodal in established tumours.  MDA-MB-231 cells transfected with a 
Doxycyclin-inducible Nodal shRNA (231+ishN) or Control shRNA (231+ishC) 
were injected with Matrigel into the flanks of nude mice.  Dox treatment groups 
were given regular chow for the course of the experiment, whereas +Dox 
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Figure 3.11 Nodal promotes vascular recruitment in a Chick
Chorioallantoic Membrane (CAM) assay. (A) 231+shControl cells,
231+shNodal cells, or 231+shNodal cells +VEGF were inoculated onto
chick CAMs with a collagen mesh grid. After 3 days, 231+shControl
cells induced significantly more angiogenesis compared to 231+shNodal
cells. This effect was rescued by the addition of VEGF to 231+shNodal
cells. Bars represent mean angiogenesis relative to a PBS control
S.E.M. (n≥37, P<0.001). (B) Confocal images of a 5-day tumor assay
performed on chick CAMs. 231+shControl cells formed large tumors
compared to 231+shNodal cells. Addition of VEGF to 231+shNodal cells
did not rescue tumour formation. Vessels are shown in red, and cells
are GFP-labelled (green). For all graphs, different superscripted letters
have a statistical difference.
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treatment groups were given chow containing Doxycyclin during weeks 2-4 of the 
experiment (i.e. after the tumour had begun to form) (Figure 3.12A,B). We found 
that if we administered Dox after the tumour had already been established, we 
could avoid significant differences in tumour size between treatments over the 
course of the experiment, and thus minimize confounding effects of tumour 
growth on our analysis of angiogenesis. Of note, we found no significant 
difference in tumour size over time between treatments (n≥4, p=0.4) (Figure
3.12C). Following tumour excision, we performed immunofluorescence and 
noticed that the distribution of Nodal mirrored the distribution of CD31 across 
treatments, and that CD31 expression in 231+ishN +Dox tumours was often 
shallow and limited to the tumour periphery. Indeed, we found a 50% reduction 
in CD31 staining in 231+ishN +Dox tumours compared to all other treatments 
(n≥4, p=0.04) (Figure 3.13A,B).  Interestingly, in cases where Nodal expression 
rebounded following Dox treatment in 231+ishN mice (a common limitation of 
shRNA technology), CD31 expression was similarly restored (Figure 3.13C).  In 
accordance with these findings, we found that 231+ishN +Dox exhibited a 
significant reduction in VEGF expression compared to all other treatment groups 
(n≥3, p=0.003) (Figure 3.13D). Significant differences in PDGF expression were 
not, however, detected. 
As a corollary to our CD31 and VEGF measurements, we wanted to 
evaluate whether inducible Nodal inhibition affected tumour necrosis. Using H E 
analyses, we found that tumour necrosis was significantly higher and frequently 
extended closer to the tumour periphery in 231+ishN +Dox tumours compared to 
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Figure 3.12 Experimental design for inducible shRNA tumour
model in vivo. (A) Schematic representation of inducible shRNA tumor
model. Briefly, 500,000 doxycyclin-inducible 231+ishC or 213+ishN
stably transfected cells were injected with Matrigel into the flanks of
nude mice. Mice were given normal chow for the course of the
experiment (-Dox), or normal chow for 2 weeks followed by Doxycyclin-
chow for 2 weeks (+Dox). After 4 weeks, tumors were excised and
cryosectioned for immunofluorescence, or paraffin-embedded for H E.
(B) Western blot analysis confirmed that the shRNA constructs were
efficiently transfected and operated as expected in response to
Doxycyclin in vitro. The 39 kDa Pro-Nodal band is depicted and Actin
is used as a loading control. (C) Confocal images of 231+ishC cells and
231+ishN cells +/- Dox in culture, used to confirm the inducibility of the
transfected shRNA constructs. Doxycyclin induces the expression of
RFP in the transfected shRNA construct in both Control and Nodal-
knockdown cell lines. Nuclei are stained with DAPI (blue) and bars
equal 20 m. (D) Tumor diameter over the course of 4 weeks, following
flank injection with 231+ishC or 231+ishN cells. No significant
differences in tumor growth were found between 231+ishC or 231+ishN
treatments, regardless of Dox administration. Values represent mean
tumor diameter (mm) at each time point S.E.M. (n≥4, P=0.4). The
time at which Dox was administered is indicted by the dotted line.
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Figure 3.13 Inducible Nodal inhibition following tumour formation
reduces vascularization. (A) Representative immunofluorescence
images used to assess CD31 (green) and Nodal (far red) localization.
DAPI (blue) was used to stain the nuclei. Merged images are shown for
each treatment. Bar equals 50 mm. (B) Relative quantification of CD31
expression in excised 231+ishC and 231+ishN derived tumors. Values
represent mean CD31 expression relative to 231+ishC Dox tumors
S.E.M., and the asterisk ( ) indicates a significant difference compared
to 231+ishC Dox control (n≥4, P=0.04). (C) Representative
immunofluorescence images of a 231+shN +Dox tumor in which Nodal
was re-expressed. In this case CD31 (green) levels were high in the
regions where Nodal (red) was localized. DAPI (blue) was used to stain
the nuclei. Bar equals 50 mm. (D) Real time RT-PCR quantification of
VEGF expression in 231+ishC versus 231+ishN tumors (+/- Dox).
VEGF expression was significantly lower in 231+ishN+Dox tumours
compared to all other treatments. Values represent mean VEGF
expression relative to 231+ishC Dox tumors S.E.M., and the asterisk
( ) indicates a significant difference compared to 231+ishC Dox control
(n≥3, P=0.003).
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controls (n≥4, p<0.001) (Figure 3.14A,B).  Additionally, we determined the extent 
of hypoxia in the tumour sections.  For these studies, the mice were injected with 
Hypoxyprobe-1 (pimonidazole hydrochloride) before being sacrificed, and 
Hypoxyprobe-1 adducts, delineating areas of low oxygen, were detected in the 
tissue sections using immunostaining.  Using this method, we determined that 
hypoxic regions surrounded areas of necrosis, and that 231+ishN +Dox tumours 
stained more extensively than control tumours (Figure 3.15). 
 
3.5 Discussion 
This study demonstrates that expression of the embryonic protein Nodal 
correlates with microvascular density in human breast cancer tissue, and that 
Nodal enhances the angiogenic potential of breast cancer cells.  Importantly, we 
discovered that Nodal can be targeted within growing tumours to inhibit 
vascularization and promote necrosis. Since vascular density is correlated with 
metastasis and poor prognosis, our study strongly implicates Nodal as a potential 
prognostic indicator and a novel target for the treatment of breast cancer.  
In accordance with previous studies in glioma, Nodal promoted VEGF and 
PDGF expression in all of the human breast cancer cell lines tested (12). 
However, we did find that there were differences in protein expression between 
lysate and conditioned media. For example, T47D cells over-expressing Nodal 
had elevated VEGF expression in cell lysate, but not in conditioned media. This 
suggests that Nodal may be involved in regulating secretion of pro-angiogenic 
factors. Furthermore, although Nodal was consistent in promoting VEGF and 
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Figure 3.14 Inducible Nodal inhibition following tumour formation
increases necrosis. Doxycyclin-inducible 231+ishC or 213+ishN stably
transfected cells were injected with Matrigel into the flanks of nude
mice. Mice were given normal chow for the course of the experiment (-
Dox), or normal chow for 2 weeks followed by Doxycyclin-chow for 2
weeks (+Dox). After 4 weeks, tumour necrosis was evaluated. (A)
Representative H E images of tumours from 231+ishC and 231+ishN
cells, with or without Dox chow, demonstrating areas of tumour
necrosis. Bar equals 100 mm. (B) Quantification of necrosis
corresponding to (A). 231+shN +Dox tumours exhibited a significant
increase in tumour necrosis compared to all other treatment groups.
Bars represent mean percent necrosis of total tumour area S.E.M.,
and the asterisk ( ) indicates a significant difference compared to
231+ishC Dox control (n≥4, P<0.001).
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Figure 3.15 Inducible Nodal inhibition following tumour formation
increases tumour hypoxia. Doxycyclin-inducible 231+ishC or
213+ishN stably transfected cells were injected with Matrigel into the
flanks of nude mice. Mice were given normal chow for the course of the
experiment (-Dox), or normal chow for 2 weeks followed by Doxycyclin-
chow for 2 weeks (+Dox). Prior to sacrificing animals (at 4 weeks), mice
were injected with hypoxyprobe-1 to demarcate hypoxic tissue. Tumour
hypoxia was evaluated by staining serial sections with an anti-
hypoxyprobe-1 antibody. Images show stained regions of tumour
hypoxia (brown) across treatment groups.
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PDGF, a full analysis of a pro-angiogenic signature was not performed, leaving 
the possibility that Nodal may activate other cytokines to mediate vascularization. 
When comparing rhNodal rescue treatments from in vitro versus in vivo 
experiments, we found that rhNodal differentially rescued the angiogenic 
phenotype. For instance, addition of rhNodal to shNodal-conditioned media after 
it was collected from the cancer cells did not induce a rescue of endothelial cell 
tube formation in vitro. However, addition of rhNodal to shNodal-containing 
DIVAA angioreactors did induce a partial rescue of vascularization. This suggests 
that rhNodal is able to induce signalling and downstream targets when in contact 
with cancer cells or with other cell types in the animal, but is not able to 
propagate signalling when in contact with only endothelial cells.  We speculate 
that this is due to differential expression of Nodal receptor components, for 
example Cripto, across cell types. Although some studies indicate that Nodal 
may signal in a Cripto-independent manner (30), others suggest that Cripto is 
required for Nodal-induced phenomena. Moreover, Cripto has been linked to 
breast and colon tumourigenesis, and one study reported that Cripto promotes 
HUVEC migration in vitro and angiogenesis in vivo (31,32). Future studies 
exploring patterns of Cripto expression on endothelial cells or endothelial 
progenitors, and the role of Cripto in Nodal-induced angiogenesis would be 
valuable for developing relevant targeted therapies.  
Although we have demonstrated that Nodal induces angiogenesis by 
regulating classical pro-angiogenic factors and promoting endothelial cell 
recruitment, it is possible that additional mechanisms of neovascularization also 
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exist. One possibility is that in vivo, bone marrow derived (BMD) progenitor cells 
are recruited to the tumour. Indeed, BMD endothelial progenitors have been 
shown to incorporate into the luminal walls of neovessels during breast cancer 
progression (33). Furthermore, several studies have demonstrated that inhibition 
of BMD endothelial progenitor cell mobilization/function causes a decrease in 
tumour vascularization (33,34).  Given the role of Nodal in the regulation of stem 
cell fate and morphogenesis, it is conceivable that it may also regulate tumour 
vasculogenesis via the recruitment of such endothelial progenitor cells.  
In order to recapitulate therapeutic intervention, we designed an assay 
wherein Nodal was inhibited after tumour initiation. We were able to optimize the 
timing for activation of our inducible construct so that we minimized confounding 
factors such as tumour size. We found that there was a decrease in 
vascularization when Nodal was inhibited in these tumours. In accordance with 
these observations, one study in melanoma demonstrated a decrease in lung 
colonization following administration of a function-blocking antibody targeted to 
Nodal (35). Interestingly, colonies that did form in mice treated with the Nodal 
antibody exhibited signs of apoptosis inclusive of cytoplasmic swelling and 
vacuole expansion. However, this study did not include an examination of the 
anti-angiogenic effects of Nodal inhibition, nor did it explore the possibility that 
Nodal may be targetable in established lesions that are healthy and proliferative 
following colonization.   
It is not clear from our experiments whether vascular reduction via Nodal 
inhibition would yield a positive or negative response with respect to metastasis. 
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Indeed, it has been reported that tumour hypoxia is associated with cellular 
programmes that yield enhanced metastasis. For instance, it has been shown 
that tumour hypoxia is associated with elevated tumour initiating cell populations 
in breast cancer (36), and resistance to chemotherapy and radiation (reviewed in 
(37) and (38)). Furthermore, over-expression of hypoxia-inducible factor α (HIF-
1α) has been shown to promote metastatic phenotypes, and is associated with 
increased breast cancer relapse and decreased patient survival (39-41).  HIF 
proteins have been shown to up-regulate of a number of stem cell-associated 
transcription factors that induce tumour-promoting programmes, including 
TWIST1, TCF3, ZEB1 and ZEB2 (42-46). Paradoxically, although in the current 
study we show that Nodal inhibition causes decreased VEGF expression and 
increased tumour necrosis concomitant with tumour hypoxia, we have previously 
shown that hypoxia induces Nodal expression through HIF-1α (20), and VEGF is 
one of the best characterized targets of HIF proteins (47). The significance of 
these contrasting phenomena is unclear at this time. Accordingly, metastatic 
burden in response to Nodal inhibition, as well as possible combination therapies 
to circumvent the hypoxic response, should be investigated. 
Collectively, we have demonstrated that the stem cell-associated protein 
Nodal supports a pro-angiogenic niche. This discovery provides mechanistic 
insight into recent studies demonstrating that cancer cells expressing stem cell-
associated genes are better able to recruit vasculature than cancer cells that 
display a more differentiated phenotype (11).  Importantly, we have shown that 
Nodal is correlated with high vascular density in human breast cancer sections, 
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and that blocking Nodal expression in established tumours in mice results in a 
marked reduction in vascularization concomitant with tumour necrosis.  Since 
Nodal is not expressed in non-lactating normal adult breast tissue, our discovery 
suggests a novel role for Nodal as a tumour-specific target for the treatment of 
breast cancer angiogenesis. 
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CHAPTER 4 
Nodal promotes invasive phenotypes via a non-canonical Mitogen 
Activated Protein Kinase-dependent pathway 
187
4.1 Abstract 
The progression of cancer from localized to invasive disease is requisite 
for metastasis, and is often characterized by epithelial-to-mesenchymal transition 
(EMT) and alterations in cellular adhesion and migration. Studies have shown 
that this transition is associated with an up-regulation of embryonic stem cell-
associated genes, resulting in a dedifferentiated phenotype and poor patient 
prognosis. Nodal is an embryonic factor that plays a critical role in promoting 
early invasive events during development. Nodal is silenced as stem cells 
differentiate; however, it plays a specialized role in adult life during placentation 
and mammary gland development, and an aberrant role during cancer 
progression. Here, we show that Nodal over-expression in poorly invasive breast 
cancer and choriocarcinoma cell lines causes increased invasion and migration 
in vitro. Furthermore, we compare EMT-associated phenotypes in response to 
Nodal over-expression in both choriocarcinoma and breast cancer cells at the 
level of gene expression and protein localization. Using Western blot analyses, 
we show that Nodal promotes these invasive events in both cancer types in part 
through phosphorylation of ERK1/2. Since Nodal normally signals through 
SMADs, these findings lend insight into an alternative pathway that is hijacked by 
this protein in cancer. To evaluate the clinical implications of our results, we show 
that Nodal inhibition reduces liver tumour burden in a model of spontaneous 
breast cancer metastasis in vivo, and that Nodal loss-of-function in aggressive 
breast cancer lines results in a decrease in invasive phenotypes. Our results 
demonstrate that Nodal is involved in promoting invasion in multiple cellular 
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contexts, and that Nodal inhibition may be useful as a therapeutic target for 
patients with progressive disease.    
 
4.2 Introduction 
The progression of cancer from localized to invasive disease is requisite 
for metastasis, and is often characterized by epithelial-to-mesenchymal transition 
(EMT) and alterations in cellular adhesion and migration. EMT is associated with 
tissue remodelling during both normal physiological processes such as mammary 
gland development and placentation, and in cancers, including  breast cancer 
and choriocarcinoma (1,2). Interestingly, while EMT has been thoroughly 
investigated in breast cancer, its mechanisms are poorly understood in the 
context of choriocarcinoma. 
In many cancer types, cellular invasion and EMT have been linked to the 
over-expression of embryonic stem cell-associated genes (3,4). Moreover, this 
stem cell-like gene expression profile is associated with metastasis and poor 
prognosis. One possible mediator of this invasive cancer signature is Nodal (5,6). 
Nodal is a member of the transforming growth factor-beta (TGF-β) superfamily, 
and a morphogen during early embryonic development. Nodal plays an important 
role in promoting invasive events during primitive streak formation, mammary 
gland development, and trophoblast invasion during placentation (7,8). It has 
been postulated that the role that Nodal plays in mediating normal invasive 
events may similarly manifest during cancer progression.  
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Indeed, recent studies have shown that Nodal promotes cellular invasion 
and tumourigenicity in melanoma, prostate cancer, endometrial cancer, and 
glioma (6,9-14). The role of Nodal in breast cancer and choriocarcinoma is less-
characterized in the literature; however, there is evidence that  Nodal and its 
receptors are present in invasive human placental choricarcinoma cell lines and 
breast cancer cell lines (7,15-17). Furthermore, in breast cancer, Nodal is 
expressed in invasive and metastatic breast cancer lesions, but it is absent in 
normal breast tissues (6,7,18). Together these findings provide preliminary 
evidence that Nodal is correlated with invasive breast cancer and 
choriocarcinoma cell types; however, the significance of this correlation has not 
been investigated.  
Nodal signals through the activin-like kinase type I (ALK4/7) and type II 
(ActRIIB) receptor complex, and its signal is enhanced by EGF-CFC family GPI-
linked Cripto co-receptor. Activation of this receptor complex causes 
phosphorylation of SMAD2/3, which then associates with SMAD4. This 
SMAD2/3/4 complex translocates to the nucleus to regulate transcription of target 
genes, including NODAL and its inhibitors, LEFTY1/2 (5,19). LEFTY1/2 
expression is limited to embryonic contexts and is not expressed in cancer cells, 
resulting in uncontrolled positive feedback during cancer progression (17).  
Non-SMAD pathways activated by Nodal in cancer have been poorly 
investigated; however, non-SMAD pathway activation in embryology has been 
reported. For instance, Nodal-induced anterior visceral endoderm (AVE) 
specification during embryonic patterning is dependent on phosphorylation of p38 
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(20). Furthermore, phospho-p38 amplifies Nodal signalling during this process, 
through phosphorylation of the SMAD2 linker region leading to increased SMAD2 
activation (20). In cancer, non-SMAD pathway activation by other TGF-β-family 
proteins is better characterized, revealing possibilities for non-SMAD Nodal 
targets during disease progression. For instance, the type I receptor has been 
shown to activate MAPK signalling through ShcA phosphorylation and 
subsequent interaction with the GRB2/SOS complex in response to TGF-β 
signalling (21). In fact, both SMAD and ERK signalling are required for TGF-β-
induced EMT in keratinocytes (22). Cross-talk between these two pathways has 
been shown, whereby ERK substrates interact with SMADs to regulate nuclear 
translocation and gene expression (22). Interestingly, ERK1/2 phosphorylation 
has also been found to be crucial during trophoblast cell growth and invasion, 
and ERK activation promotes choriocarcinoma proliferation (23-25). Although 
Nodal and TGF-β share many signalling commonalities, it is unknown whether 
Nodal is capable of inducing non-SMAD pathways, like MAPKs, in cancer. 
Accordingly, the current study investigates the role of Nodal in breast 
cancer and choriocarcinoma invasion. First, we demonstrate that in poorly 
invasive breast cancer and choriocarcinoma cell lines, Nodal promotes cellular 
invasion and migration, concomitant with an EMT-like phenotype. Conversely, 
Nodal knock-down results in the opposite phenotype, marked by reduced cellular 
invasion and a loss of mesenchymal marker expression. Furthermore, we show 
that these Nodal-induced phenomena are mediated in part through ERK1/2 
signalling. In vivo, we demonstrate that inducible Nodal inhibition causes a 
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reduction in spontaneous metastasis to the liver in NOD/SCID/interleukin-2γ 
receptor null mice (NSG mice). Our study lends insight into prospective Nodal-
targeted therapies for the clinical management of cancer progression.  
 
4.3 Methods 
4.3.1 Cell lines and treatments 
BeWo human choriocarcinoma cells, and MDA-MB-231, Hs578t, T47D and MCF-
7 breast cancer cell lines were obtained from the ATCC and maintained as per 
instructions. BeWo, T47D and MCF-7 cells were used for gain-of-function models 
as these cells are poorly invasive and express relatively low levels of Nodal 
(Figure 2.1A) (26).  MDA-MB-231 and Hs578t cells were used for loss-of-
function models as these cell lines are highly invasive and express relatively high 
levels of Nodal (Figure 2.1A). Multiple constructs and reagents were used to 
knockdown or induce Nodal signalling:   
Using expression vectors or recombinant protein for Nodal gain-of-
function experiments: T47D and BeWo cells were transfected via 
Lipofectamine (Invitrogen) with a Nodal expression vector, made with 
pcDNA 3.3-TOPO  cloning kit, or a control pcDNA3.3 vector. H9 hESCs were 
used to clone the human Nodal open reading frame. Vectors were sequenced 
and validated, and transfected cells were selected with G418 to generate stable 
lines. For proof-of-principle, both T47D and MCF-7 cells were also subject to 
treatment with recombinant human Nodal (rhNodal; 50-100 ng/mL) to activate 
phospho (P)-SMAD2 signalling as an alternative gain-of-function model (R D 
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systems). We chose to test this concentration range since previous studies have 
shown that at least 50 ng/mL of Nodal is required for maintenance of pluripotency 
in hESCs (27,28). We chose to use 100 ng/mL of rhNodal for our experiments 
(rather than 50 ng/mL), since we found there was quite a bit of lot-to-lot variance 
and 100 ng/mL most consistently induced phosphorylation of SMAD2. 
Furthermore, 100 ng/mL of rhNodal has been used effectively in multiple 
published studies related to Nodal in cancer (29,30).
Using shRNA and SB431542 for Nodal loss-of-function experiments: 
MDA-MB-231 cells were transfected via Arrest-In (Open Biosystems) with a 
pGIPZ lentiviral shRNAmir against Nodal’s 3rd exon (Clone: V2LHS 155453) or a 
scrambled shRNA Control (Open Biosystems). As an additional loss-of-function 
model, MDA-MB-231 cells were transfected via Lipofectamine (Invitrogen) with a 
pTRIPZ lentiviral shRNAmir against Nodal’s 3rd exon (Clone: V2THS 155453) 
with Tet-On /Tet-Off  inducibility or a scrambled inducible shRNA Control 
(Open Biosystems). All transfected MDA-MB-231 cells were selected with 
Puromycin to generate stable lines. For both pGIPZ and pTRIPZ knockdown 
systems, shRNAs targeting at least 4 regions in the Nodal gene were tested for 
their ability to knockdown Nodal protein expression.  For each type of vector, the 
shRNA achieving the best knock down was chosen. To inhibit Nodal signalling, 
the ALK4/5/7 inhibitor SB431542 (Sigma) was used at a concentration of up to 
10 M. We chose to use 10 M of SB431542 in our experiment, since this dose 
consistently had the greatest inhibitory effect on SMAD2 phosphorylation, and 
193
has been used in previously published reports on hESCs to block Nodal 
signalling (27,31). 
Inhibition of the ERK signalling pathway: To inhibit ERK signalling, 
U0126 (Sigma), and MEK1/2 inhibitor, was used at a concentration of 10 M. 
U0126 was given to cells 30 min-1 hr before experiments were performed. To 
assess the effects of U0126, Western blot for phospho-ERK1/2 (phospho-p44 
and phospho-p42) was performed (Cell signalling; Table 4.1). 
 
4.3.2 In vitro functional assays 
Functional assays were performed on breast cancer or choriocarcinoma cell lines 
in response to alterations in Nodal and/or ERK1/2 signalling, as indicated in the 
main text and figure legends: 
2D migration and invasion: To assess cellular migration, 50,000 cells 
were seeded onto a Transwell insert, and incubated for 24 hours. Migration was 
quantified by staining nuclei with DAPI and manual counting of the entire 
membrane. To assess cellular invasion, the migration protocol was modified by 
coating Transwells with Matrigel (1:10 Matrigel:Serum-free RPMI) prior to 
seeding cells. The Matrigel layer was left to solidify overnight at room 
temperature, and then re-hydrated with serum-free RPMI for one hour before 
seeding cells.  
3D cell cluster invasion assay: One million cells (T47D or MDA-MB-231) 
suspended in 1 mL of complete media (RPMI +10% FBS) were loaded into a 
bioreactor (Synthecon Rotary Cell Culture SystemTM ). The bioreactor was placed 
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in an incubator and set to a rotation of approximately 7 RPM. After 3 days, cell 
clusters could be seen macroscopically. Clusters were gently removed from the 
bioreactor using a 10 mL pipette, and placed into a petri dish. Clusters were 
individually selected, and embedded in bovine collagen type 1 (Invitrogen). 
Collagen was allowed to solidify at 37 C for 30 min, and was then overlaid with 
RPMI +10% FBS +treatment (32). MDA-MB-231 clusters were treated with 
recombinant human Lefty (rhLefty; 1000 ng/mL (17)), an endogenous inhibitor of 
Nodal in hESCs, and incubated for 36 hours.  T47D clusters were treated with 
100 ng/mL rhNodal, or 100 ng/mL rhNodal +10 M U0126 MEK1/2 inhibitor, and 
incubated for 1 week. Following termination of the invasion assays, pictures were 
taken with an inverted microscope and camera in order to measure distance of 
invasion from core. 4 measurements evenly spaced around each cluster 
periphery were averaged to generate a distance score for each cluster. Adobe 
Photoshop was used to measure distance (Analysis tool). 
Viability: Viability of endothelial cells in response to conditioned media 
was assessed using the LIVE/DEAD  Viability/Cytotoxycity Kit as per 
manufacturer’s instructions (Invitrogen). 
 
4.3.3 Immunofluorescence 
Cells were seeded on glass coverslips, fixed with 4% paraformaldehyde, made 
permeable with 20 mM HEPES and 0.5% TritonX-100, and blocked with serum-
free protein block (Dako, Carpinteria, CA) (29). Cells were stained using anti-E-
Cadherin antibody (Table 4.1), and an Alexafluor secondary antibody 
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(Invitrogen). DAPI was used to stain nuclei. IgG isotype controls were also 
included.  
 
4.3.4 Real-time PCR 
Total RNA was isolated using the Perfect Pure RNA cultured cell kit (5 PRIME) 
and genomic DNA was degraded using DNAse. Reverse transcription was 
performed using the High Capacity cDNA Reverse Transcription kit (Applied 
Biosystems).  Real-time PCR was performed using 2 g cDNA with TaqMan  
gene expression human primer/probe sets (Table 4.2). All gene expression was 
normalized to HPRT1.   
 
4.3.5 Western blot analysis 
Protein lysate was prepared using Mammalian Protein Extraction Reagent 
(Thermo Scientific), Halt  Protease Inhibitor Cocktail (Thermo Scientific), and 
Phosphatase Inhibitor (Thermo Scientific). Protein was quantified by BCA  
protein assay (Thermo Scientific) as per manufacturer’s instructions.  Equal 
amounts of protein were separated by SDS-polyacrylamide gel electrophoresis 
under reducing conditions, and then transferred onto Immobilon-P membranes 
(Millipore). Membranes were blocked, and incubated with primary antibody 
(Table 4.1) and horseradish peroxidase-labelled secondary antibody. Secondary 
antibodies were detected by Immun-Star  Chemiluminescent Detection kit (Bio-
Rad) or SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific). 
Images were taken using the ChemiDoc  XRS+ System (Bio-Rad) or standard 
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film.  For Nodal Western blots, the 39 kDa species was used to assess protein 
expression as previously described (29). Densitometry was done with ImageJ. 
 
4.3.6 Spontaneous metastasis in vivo 
MDA-MB-231 cells were transfected with a doxycyclin (Dox)-inducible Control or 
Nodal-targeted shRNA. Both constructs expresses RFP upon induction by Dox.
500,000 cells in 100 L RPMI:Matrigel (1:1) were injected into the right thoracic 
mammary fat pad of 7-8 week old female NSG mice (from D.A.H.). Like 
NOD/SCID strains, these mice exhibit reduced innate immunity and complete T-
cell and B-cell deficiency; however, they also exhibit compromised NK-cell 
function due to the IL2γR mutation. Dox was administered in mouse chow (0.625 
g Dox/1 kg chow) 1 week following injection, after formation of palpable tumour 
growth. This chow is optimized to deliver 2-3 mg of Dox per day (Harlan 
Laboratories). Mice were sacrificed when tumours reached 1.3 cm in diameter 
(termination size varied slightly depending on mouse health or observed depth of 
tumour growth). Lung and liver were collected from each mouse, fixed with 4% 
formaldehyde, and stained with H E. All experiments involving animals were 
approved by the Animal Use Subcommittee at the University of Western Ontario 
Protocol No. 2008-101 (Appendix 2). 
Evaluation of tumour burden in secondary sites: Lung and liver were 
collected from mice that underwent the spontaneous metastasis assay. The 
number of mice with macroscopic liver metastases was recorded upon sacrificing 
animals, since clear differences could be seen in this organ. Tissues were fixed 
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with paraformaldehyde, paraffin-embedded, sectioned, and stained with H E. 
For each tissue section, the percent tumour burden was calculated by averaging 
the tumour area, and dividing it by the average total square area of tissue (Adobe 
Photoshop).  For each animal, an average of 2-3 sections spaced evenly through 
the tissue was subject to this analysis, to yield one replicate value for percent 
tumour burden.  
 
4.3.7 Statistical analyses 
Parametric data: Statistical analyses of multiple comparisons were performed 
using a one-way ANOVA followed by a Tukey Kramer Comparisons Post-Hoc 
test. Parametric data were expressed as mean  S.E.M. for replicate values. 
Non-parametric data: an ANOVA on Ranks followed by the Mann-Whitney rank-
sum test was used. Non-parametric data were expressed as median  
interquartile range. When only two items were compared, a student’s t-test was 
used. All statistical tests were two-sided, and data comparisons were considered 
statistically significant at p<0.05.  Statistics were performed using SigmaStat 
(Dundas Software) in consultation with the biostatistical support unit at the 
University of Western Ontario. 
 
4.4 Results 
4.4.1 Nodal promotes migration and invasion in vitro 
Cellular invasion is a complex process that involves active migration and 
breaching of the extracellular matrix (ECM).  We first examined the role of Nodal 
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signalling in the regulation of cellular migration by performing in vitro Transwell 
chamber assays using breast cancer and choriocarcinoma cell lines. In 
agreement with previous findings (6,9,29), we confirmed that rhNodal could 
induce SMAD2 phosphorylation in breast cancer cells (Figure 4.1A).  We found 
that both T47D cells (n=4, p<0.05) and MCF-7 breast cancer cells (n=4, p<0.05) 
displayed a significant increase in migration when treated with increasing 
concentrations of rhNodal (0, 50 or 100 ng/mL) (Figure 4.1B,C). In accordance 
with these findings, when poorly-invasive BeWo choriocarcinoma cells were 
transfected with a Nodal expression construct (BeWo+Nodal), there was a 
significant increase in migration through Transwell chambers (n=6, p=0.002) 
compared to controls (BeWo+Control) (Figure 4.1D,E).
In order to invade and metastasize, a cancer cell must be able to breach 
the basement membrane of the host organ tissue, and invade through the 
extracellular matrix (ECM). To test the effects of Nodal on cellular invasion 
(including ECM degradation), we used a Transwell chamber that was coated with 
Matrigel, which is a protein mixture used to mimic extracellular matrix and 
basement membrane. When T47D (n=3, p=0.0038) and MCF-7 (n=3, p=0.004) 
breast cancer cells were treated with rhNodal (0, 50 or 100 ng/mL), there was a 
significant increase in cellular invasion at 100 ng/mL rhNodal compared to 0 
ng/mL controls in both cases (Figure 4.2A,B). As an alternative method for 
testing cellular invasion, we employed a 3D invasion assay that more closely 
resembles an in vivo context. Briefly, cells were cultured into 3D clusters in a 
bioreactor, and then seeded into a collagen plug and treated with rhNodal (0 or 
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Figure 4.1 Nodal promotes cellular migration in vitro. (A) Western
blot validating increased P-SMAD2 in response to treatment with
rhNodal in T47D cells. Total SMAD2/3 and β-Actin are used as controls.
(B) T47D cells were seeded in Transwell chambers and treated with 0,
50 or 100 ng/mL of rhNodal for 24 hours to assess cellular migration.
Cells exhibited a significant dose-dependent upregulation of cellular
migration in response to rhNodal (n=4, p<0.05) (C) MCF-7 cells were
seeded in Transwell chambers and treated with 0, 50 or 100 ng/mL of
rhNodal for 24 hours to assess cellular migration. Cells exhibited a
significant dose-dependent upregulation of cellular migration in
response to rhNodal (n=4, p<0.05). (D) Western blot validating
increased Nodal expression in BeWo cells following transfection with a
Nodal expression vector (BeWo+Nodal) versus a control vector
(BeWo+Control). The pro-Nodal ( 39 kDa) band is presented and β-
Actin is used as a control. (E) BeWo+Nodal cells or BeWo+Control cells
were seeded in Transwell chambers to assess cellular migration after 24
hours. BeWo+Nodal cells exhibited elevated cellular migration
compared to BeWo+Control cells (n=6, p=0.002). Data are presented as
mean S.E.M for replicate values. Different letters indicate a significant
difference.
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Figure 4.2 Nodal promotes cellular invasion in vitro. (A) T47D cells
were seeded in Matrigel-coated Transwell chambers and treated with 0,
50 or 100 ng/mL of rhNodal for 24 hours to assess cellular invasion.
Cells exhibited a significant upregulation of cellular invasion at 100
ng/mL rhNodal (n=3, p=0.0038) (B) MCF-7 cells were seeded in
Matrigel-coated Transwell chambers and treated with 0, 50 or 100
ng/mL of rhNodal for 24 hours to assess cellular invasion. Cells
exhibited a significant upregulation of cellular invasion at 100 ng/mL
rhNodal (n=3, p=0.004). (C) T47D cells were harvested for 3 days in 3D
culture using a bioreactor, and then seeded into collagen type 1 in order
to assess 3D invasion over the course of 1 week. Cells treated with 100
ng/mL displayed a significant increase in 3D cellular invasion (measured
by the distance cells invaded away from the edge of the cluster)
compared to controls (n=10, p=0.032). (D) Representative image
showing in vitro 3D collagen invasion assay with T47D cells as
described in (C). Bar equals 50 μm and hatched lines delineate the
cluster boarder. Data are presented as mean ± S.E.M for replicate
values. Different letters indicate a significant difference.
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100 ng/mL) for 1 week. We found that T47D cells treated with rhNodal invaded 
through the collagen, away from the cluster edge, more readily than control cells 
(n=10, p=0.032) (Figure 4.2C,D). 
 
4.4.2 Nodal promotes an EMT-like phenotype 
One of the mechanisms underlying cellular invasion in both normal and 
cancer contexts is EMT.  EMT is characterized by a down-regulation of epithelial 
cell markers, such as E-Cadherin (CDH1), and an acquisition of mesenchymal 
cell markers, such as Vimentin (VIM), Twist (TWIST1) and N-Cadherin (CDH2) 
(33). In breast cancers, EMT is also associated with a reduction in Estrogen 
Receptor (ESR1) expression (34-36).  Collectively, this phenotype allows cells to 
break away from the primary tumour and to invade into secondary sites.  Given 
that Nodal plays a role in promoting morphogenesis in early development, we 
opted to determine whether Nodal promotes EMT in epithelial-like breast cancer 
and choriocarcinoma cell lines. Using real-time RT-PCR analysis, we found that 
rhNodal treatment (100 ng/mL) in T47D and MCF-7 cells caused a down-
regulation ESR1 (T47D: n=4, p=0.029; MCF-7: n=5, p=0.008), and an up-
regulation of the transcription factor TWIST1 (T47D: n=4, p=0.029; MCF-7: n=3, 
p=0.036) and the intermediate filament VIM (T47D: n=4, p=0.029; MCF-7: n=5, 
p=0.008) (Figure 4.3A,B). Similarly, transfection of T47D cells with a Nodal 
expression construct (T47D+Nodal) resulted in a significant down-regulation of 
ESR1 (n=3, p=0.030), and an up-regulation of TWIST1 (n=3, p=0.036) and VIM 
(T47D: n=3, p=0.018) compared to T47D cells transfected with a control vector 
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Figure 4.3 Nodal promotes EMT-like gene expression. (A) Real time
RT-PCR analysis of EMT markers in T47D cells treated with 0, 50, or
100 ng/mL rhNodal (48 hrs). In response to 100 ng/mL of Nodal, T47D
cells displayed a decrease in ESR1 (estrogen receptor) expression
(n=4, p=0.029), and an increase in TWIST1 (n=4, p=0.029) and VIM
(Vimentin) expression (n=4, p=0.029) compared to controls. CDH2 (N-
Cadherin) and CDH1 (E-Cadherin) expression did not change (n=4,
p 0.05). (B) Real time RT-PCR analysis of EMT markers in MCF-7 cells
treated with 0 or 100 ng/mL rhNodal. In response to 100 ng/mL of
Nodal, MCF-7 cells displayed a decrease in ESR1 expression (n=5,
p=0.008), and an increase in TWIST1 (n=5, p=0.036) and VIM
expression (n=5, p=0.008) compared to controls. CDH2 and CDH1
expression did not change (n=5, p 0.05). (C) Western blot validating
that Nodal is elevated in T47D cells transfected with a Nodal expression
vector (T47D+Nodal) versus a control vector (T47D+Control). The pro-
Nodal ( 39 kDa) band is presented and β-Actin is used as a control. (D)
Real time RT-PCR analysis of EMT markers in T47D+Control cells
versus T47D+Nodal cells. T47D+Nodal cells displayed a decrease in
ESR1 expression (n=3, p=0.030), and an increase in TWIST1 (n=3,
p=0.036) and VIM expression (n=3, p=0.018) compared to
T47D+Control cells. CDH2 and CDH1 expression did not change (n=3,
p 0.05). (E) PCR analysis of EMT markers in BeWo cells transfected
with a Nodal expression vector (BeWo+Nodal) versus a control vector
(BeWo+Control). BeWo+Nodal cells displayed a decrease in CDH1
expression (n=4, p<0.001), and an increase in CDH2 (n=4, p<0.001)
and VIM expression (n=3, p<0.001) compared to BeWo+Control cells.
TWIST1 expression did not change (n=4, p 0.05). Data are presented
as mean S.E.M. for replicate values. Asterisks ( ) indicate a significant
different compared to control cells as specified. Expression levels are
normalized to HPRT1.
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(T47D+Control) (Figure 4.3C,D). In addition, BeWo+Nodal cells displayed a 
significant decrease in CDH1 expression (n=4, p<0.001), and an increase in both 
CDH2 (n=4, p<0.001) and VIM (n=3, p<0.001) expression compared to 
BeWo+Control cells (Figure 4.3E).  
In many instances, EMT is marked by deregulated E-cadherin protein 
localization, rather than by changes in transcript or protein production. 
Accordingly, we performed immunofluorescence to determine the localization of 
E-Cadherin, a pivotal cell-cell adhesion protein in epithelial cells. We found that 
when T47D or MCF-7 cells were treated with increasing concentrations of 
rhNodal for 48 hrs, E-Cadherin translocated from the cell membrane to the 
cytoplasm of the cells (Figure 4.4A,B). Over-expression of Nodal in BeWo cells 
similarly induced the cytoplasmic localization of E-Cadherin, in addition to down-
regulating gene expression (Figure 4.4C).  
 
4.4.3 Nodal activates non-SMAD pathways to mediate invasive phenotypes 
Given the emerging evidence that implicates Nodal during cancer 
progression, improving our understanding of both classical and non-classical 
Nodal signalling mechanisms will be imperative for developing future targeted 
therapies. As such, we decided to investigate whether Nodal signalling can 
activate the ERK pathway, as this pathway is highly involved in cellular invasion, 
proliferation, migration, and differentiation, during both cancer progression and 
placentation. We first treated T47D cells with rhNodal (100 ng/mL) for 0, 1, 2, 5, 
10, or 20 min, and found that Nodal increases P-ERK1/2 in as little as 2 min 
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Figure 4.4 Nodal promotes cytoplasmic localization of E-Cadherin.
(A) Immunofluorescence (IF) showing localization of E-Cadherin (green)
in T47D cells or (B) MCF-7 cells after treatment with 0, 50 or 100 ng/mL
rhNodal. (C) Immunofluorescence showing localization of E-Cadherin
(green) in BeWo cells transfected with a Nodal expression vector
(BeWo+Nodal) versus a control vector (BeWo+Control). Nuclei are
stained with DAPI (blue) and bars equal 20 μm. All IFwas performed 3-
4 times.
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when replicates were analysed by densitometry (Figure 4.5A,B). Similarly, we 
treated BeWo cells with rhNodal (100 ng/mL) for 0, 1, 2, 5, 10 or 20 min, and 
found that Nodal significantly increases P-ERK1/2 by 5 min when replicates were 
analysed by densitometry (Figure 4.5C,D). In order to determine whether 
phosphorylation of ERK was dependent on activation of the type I receptor 
(similar to what has been reported in the literature for TGF-β), we examined the 
effects of an ALK4/7 inhibitor (SB431542; 10 M, 1 hr) on Nodal-induced ERK1/2 
phosphorylation in T47D and BeWo cells. We found that in both cell lines, 
SB431542 reduced Nodal-induced phosphorylation of ERK1/2 (Figure 4.5E,F). 
In order to determine if ERK activity may reciprocally regulate SMAD signalling, 
we treated T47D+Nodal and BeWo+Nodal cells with a MEK inhibitor (U0126; 10 
M, 1 hr).  We determined that U0126 decreased Nodal-mediated P-SMAD2 in 
both cases (Figure 4.5G,H). Collectively, our results suggest that through the 
ALK4/7 receptor, Nodal induces the activation of the ERK1/2 MAPK pathway in 
breast cancer and choriocarcinoma cell lines. Moreover, Nodal-induced SMAD2 
phosphorylation is dependent upon the activation of the ERK1/2 MAPK pathway.  
We next wanted to determine the functional significance of Nodal-induced 
ERK activation. We seeded T47D or BeWo cells into Transwell chambers with 
Matrigel (for invasion) or without Matrigel (for migration), and treated them with 
rhNodal alone (100 ng/mL), or with both rhNodal (100 ng/mL) and U0126 (10 
M). We found that invasion (T47D: n=3, p=0.017; BeWo: n=3, p=0.022) and 
migration (T47D: n=3, p=0.010; BeWo: n=3, p=0.005) both increased significantly 
in response to treatment with rhNodal compared to controls, and this effect was 
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Figure 4.5 Nodal activates ERK signalling. (A) Western blot time
course analysis of ERK1/2 activation in T47D cells following treatment
with 100 ng/mL rhNodal for 0, 1, 2, 5, 10, or 20 minutes. P-ERK1/2
increases compared to controls after 2 minutes of rhNodal treatment.
Total ERK1/2 and β-Actin are used as controls. (B) Densitometry
analysis for all replicate experiments corresponding to (A). ImageJ was
used to calculate band density of P-ERK1/2 /band density of total
ERK1/2. Data are presented as mean fold change S.E.M. for replicate
values. Different letters indicate a significant difference compared to
controls (n=4, p=0.029). (C) Western blot time course analysis of
ERK1/2 activation in BeWo cells following treatment with 100 ng/mL
rhNodal for 0, 1, 2, 5, 10, or 20 minutes. P-ERK1/2 increases compared
to controls after 5 minutes of rhNodal treatment. Total ERK1/2 and β-
Actin are used as controls. (D) Densitometry analysis for all replicate
experiments corresponding to (C). ImageJ was used to calculate band
density of P-ERK1/2 /band density of total ERK1/2. Data are presented
as mean fold change S.E.M. for replicate values. Different letters
indicate a significant difference compared to controls (n=4, p=0.029).
(E) Western blot demonstrating that P-ERK1/2 is elevated in T47D cells
transfected with a Nodal expression vector (T47D+Nodal) versus a
control vector (T47D+Control), and that phosphorylation is reduced
when T47D+Nodal cells are treated with SB431542 (10 M). Total
ERK1/2 and β-Actin are used as controls. (F) Western blot
demonstrating that P-ERK1/2 is elevated in BeWo cells transfected with
a Nodal expression vector (BeWo+Nodal) versus a control vector
(BeWo+Control), and that phosphorylation is reduced when
BeWo+Nodal cells are treated with SB431542 (10 M). Total ERK1/2
and β-Actin are used as controls. (G) Western blot demonstrating that
P-SMAD2 is elevated in T47D+Nodal cells compared to T47D+Control
cells, and that this effect is abrogated by treating T47D+Nodal cells with
10 M U0126 (1 hr). Total SMAD2/3 and β-Actin are used as controls.
(H) Western blot demonstrating that P-SMAD2 is elevated in
BeWo+Nodal cells compared to BeWo+Control cells, and that this effect
is abrogated by treating BeWo+Nodal cells with 10 M U0126 (1 hr).
Total SMAD2/3 and β-Actin are used as controls.
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mitigated by addition of U0126 (Figure 4.6A-D). Importantly, we observed no 
significant differences in the number of viable cells between treatments for the 
duration of the invasion and migration assays (24 hrs) (Figure 4.6E-F). In 
accordance with these results, MCF-7 cells showed similar phenomena in 
response to rhNodal and U0126 treatments (n=3, p=0.005 for both migration and 
invasion) (Figure 4.6G,H). Finally, we employed a 3D invasion assay in which a 
bioreactor was used to generate T47D cell clusters that were subsequently 
seeded into collagen type 1. Consistent with previous experiments, we found that 
treatment of clusters with rhNodal caused a significant increase in invasion 
distance compared to controls, and that this effect was prevented with U0126 
(n=14, p<0.001) (Figure 4.7A,B).  
 In addition to cellular migration and invasion, we wanted to determine 
whether ERK-activation was involved in Nodal-mediated EMT. First, we added 
U0126 to MCF-7 cells prior to being treated with rhNodal (100 ng/mL) (extension 
of experiment represented in Figure 4.3B) and found that U0126 prevented 
Nodal-mediated induction of TWIST1 and VIM expression as quantified by real 
time RT-PCR. (Figure 4.8A). Interestingly, ESR1 expression was still 
upregulated by rhNodal in the presence of U0126 (Figure 4.8A). In accordance 
with these results, in choriocarcinoma cells, addition of U0126 to BeWo+Nodal 
cells (extension of experiment represented in Figure 4.3E) resulted in a decrease 
of Nodal-induced CDH2 and VIM expression, and an increase of CDH1 
expression back to control levels (n=4, p 0.05) (Figure 4.8B). To complement 
these studies, we also performed immunofluorescence to determine the 
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Figure 4.6 Nodal-induced cellular invasion and migration is
mediated by ERK. (A) T47D cellular invasion through a Matrigel-coated
Transwell chamber increased in response to 100 ng/mL rhNodal (n=3,
p=0.017), and this effect was mitigated back to control levels by the
addition of 10 μM U0126. (B) BeWo cellular invasion through a Matrigel-
coated Transwell chamber increased in response to 100 ng/mL rhNodal
(n=3, p=0.022), and this effect was mitigated back to control levels by
the addition of 10 μM U0126. (C) T47D cellular migration through a
Transwell chamber (without Matrigel) increased in response to 100
ng/mL rhNodal (n=3, p=0.010), and this effect was mitigated back to
control levels by the addition of 10 μM U0126. (D) BeWo cellular
migration through a Transwell chamber (without Matrigel) increased in
response to 100 ng/mL rhNodal (n=3, p=0.005), and this effect was
reduced by the addition of 10 μM U0126 (n=3, p=0.008, b vs. c). (E)
T47D viability assay and (F) BeWo viability assay demonstrating equal
cell viability after 24 hours between treatments corresponding to (A-D).
(G) MCF-7 cellular invasion through a Matrigel-coated Transwell
chamber increased in response to 100 ng/mL rhNodal (n=3, p=0.005),
and this effect was mitigated by the addition of 10 μM U0126. (H) MCF-
7 cellular migration through a Transwell chamber (without Matrigel)
increased in response to 100 ng/mL rhNodal (n=3, p=0.005), and this
effect was mitigated by the addition of 10 μM U0126. Data are
presented as mean ± S.E.M. for replicate values. Different letters
indicate a significant difference as specified.
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Figure 4.7 Nodal-induced cellular invasion through collagen is
mediated by ERK. T47D cells were harvested for 3 days in 3D culture
using a bioreactor, and then seeded into collagen type 1 in order to
assess 3D invasion over the course of 1 week. Distance of invasion was
recorded as an average of 4 measurements evenly spaced around the
cluster periphery. (A) Cells treated with 100 ng/mL rhNodal displayed a
significant increase in 3D cellular invasion compared to controls (n=14,
p<0.001), and this effect was reduced back to control levels in response
to treatment with 10 μM U0126. Data are presented as mean ± S.E.M
for replicate values, and different letters indicate a significant difference.
(B) Representative images from 3D invasion assay corresponding to
data presented in (A). Bar equals 50 μm and hatched lines delineate the
cluster boarder.
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Figure 4.8 Nodal-induced changes in EMT marker expression are
mediated by ERK. (A) Real time RT-PCR analysis of EMT markers in
MCF-7 cells exposed to 100 ng/mL rhNodal alone, or 100 ng/mL
rhNodal + 10 μM U0126 (48 hrs). Treatment with rhNodal alone caused
decreased ESR1 expression (n=5, p=0.008), and increased TWIST1
(n=3, p=0.036) and VIM expression (n=5, p=0.008). Addition of U0126
rescued TWIST1 and VIM expression back to control levels. ESR1
expression was not rescued with the addition of U0126 (n=5, p=0.008).
CDH2 and CDH1 expression did not change with any of the treatments.
(B) Real time RT-PCR analysis of EMT markers in BeWo cells
transfected with a Nodal expression vector (BeWo+Nodal) versus a
control vector (BeWo+Control), or in BeWo+Nodal cells treated with 10
μM U0126 (48 hrs). BeWo cells expressing Nodal displayed a decrease
in CDH1 expression (n=4, p<0.001), and an increase in CDH2 (n=4,
p<0.001) and VIM expression (n=3, p<0.001) compared to
BeWo+Control cells. Treatment of BeWo+Nodal cells with U0126
rescued CDH2 and VIM expression back to BeWo+Control levels, and
significantly reverted CDH1 expression to near-control levels (n=4,
p=0.029). TWIST1 expression did not change with any of the
treatments. Data are presented as mean ± S.E.M. for replicate values.
Asterisks (*) indicate a significant different compared to control cells as
specified. Expression levels are normalized to HPRT1.
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localization of E-Cadherin in response to U0126. We found that pre-treatment of 
T47D cells and MCF-7 cells with U0126 (10 M) followed by the addition of 100 
ng/mL rhNodal (1 hour) resulted in a full (T47D) or partial (MCF-7) rescue of E-
Cadherin from the cytoplasm to the cell membrane (Figure 4.9A,B).  
 
4.4.4 Nodal inhibition impairs invasion in vitro in part through decreased P-
ERK
In a complementary set of loss-of-function experiments, we wanted to 
determine if Nodal inhibition could decrease the invasiveness of more basal-like 
breast cancer cells, which express high levels of endogenous Nodal.  Using a 
Transwell chamber assay with Matrigel (for invasion) or without Matrigel (for 
migration), we found that knocking down Nodal expression in MDA-MB-231 cells 
with shRNA (231+shNodal) resulted in a significant decrease in both migration 
(n=5, p<0.001) and invasion (n=5, p=0.016) compared to 231+shControl cells 
(Figure 4.10A-C). When MDA-MB-231 cells or Hs578t cells were treated with 
SB431542 ALK4/7 inhibitor (0, 1, or 10 M), a similar reduction in cellular 
invasion was observed (n=5, p<0.05 for both cell types) (Figure 4.10D-F). Lastly, 
when we performed a 3D invasion assay through collagen using MDA-MB-231 
cells treated with rhLefty (1000 ng/mL), we found that the distance of invasion 
was significantly reduced compared to controls (n=7, p=0.001) (Figure 4.10G,H).  
We also investigated whether Nodal inhibition in MDA-MB-231 cells could 
alter phosphorylation of ERK to mediate the observed changes in cellular 
invasion and migration. We confirmed via Western blot that 231+shNodal cells 
222
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Figure 4.9 Nodal-induced cytoplasmic localization of E-Cadherin is
mediated by ERK. (A) Immunofluorescence (IF) showing localization of
E-Cadherin (green) in T47D cells and (B) MCF-7 cells after treatment
with 0 ng/mL rhNodal, 100 ng/mL rhNodal, or 100 ng/mL rhNodal + 10
μM U0126. Nuclei are stained with DAPI (blue) and bars equal 20 μm.
All IF was performed 3-4 times.
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Figure 4.10 Nodal inhibition impairs invasion and migration in
vitro. (A) Western blot validating decreased Nodal expression in MDA-
MB-231 cells transfected with a Nodal-targeted shRNA (231+shNodal)
versus a scramble control shRNA (231+shControl). The pro-Nodal ( 39
kDa) band is presented and β-Actin is used as a control. (B) Cellular
migration and (C) invasion through Matrigel of 231+shControl versus
231+shNodal cells was quantified following a 24 hr incubation. Cellular
migration and invasion were significantly reduced in response to Nodal
knockdown compared to controls (n=5, p<0.02). (D) Western blot
validating that treatment of MDA-MB-231 cells with SB431542 (0, 1, or
10 M) causes a dose-dependent decrease in SMAD2 phosphorylation.
SMAD2/3 and β-Actin are used as loading controls. (E,F) Cellular
invasion assay (24 hours) through a Matrigel-coated Transwell chamber
of (E) MDA-MB-231 cells or (F) Hs578t cells treated with 0, 1 or 10 M
of SB431542. Cellular invasion was significantly reduced in both cell
lines in response to SB431542 (n=5, p<0.05). (G) 3D invasion assay
demonstrating that rhLefty (1000 ng/mL) inhibits invasion in MDA-MB-
231 cells. Bars represent relative invasion relative to untreated controls.
(H) Representative images corresponding to (G). Bar equals 50 m and
hatched lines delineate the cluster boarder. All data are presented as
mean S.E.M for replicate values, and different letters indicate a
significant difference.
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displayed reduced P-ERK1/2 compared to 231+Control cells, and that addition of 
rhNodal (100 ng/mL) to 231+shNodal cells rescued P-ERK1/2 (Figure 4.11A). In 
accordance with these results, we found that rhNodal (100 ng/mL) could restore 
cellular invasion and migration in 231+shNodal cells to levels observed in 
231+shControl cells, but that this ability of rhNodal to rescue invasion and 
migration was mitigated when downstream ERK1/2 activation was prevented with 
U0126 (10 M) (Figure 4.11B-D). Furthermore, we found that inhibition of 
ERK1/2 phosphorylation in 231+shControl cells with U0126 resulted in a 
significant decrease in cellular invasion (n=3, p<0.001) and migration (n=3, 
p=0.002), and that these effects of U0126 were not rescued by the addition of 
rhNodal (Figure 4.11B-D). It should be noted that the number of viable cells did 
not change across treatments (Figure 4.11E). Hence our results indicate that 
Nodal regulates breast cancer invasion via a downstream ERK1/2-dependent 
pathway.   
Since Nodal over-expression caused an EMT-like event in poorly 
aggressive cell types, we tested whether Nodal inhibition could affect the 
expression of mesenchymal phenotypes in MDA-MB-231 cells. Using PCR 
analysis we found that treatment of MDA-MB-231 cells with SB431542 (10 M) 
resulted in a decrease in TWIST1 (n=3, p<0.001), CDH2 (n=3, p<0.001), and 
VIM (n=3, p=0.001) expression, but did not affect epithelial marker expression 
(including CDH1 or ESR1) (Figure 4.12A). Similarly, 231+shNodal cells 
displayed a significant reduction in TWIST1 (n=3, p<0.001), CDH2 (n=3, 
p<0.001), and VIM (n=3, p=0.031) expression, but did not display altered CDH1 
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Figure 4.11 Nodal inhibition impairs invasion in vitro in part
through decreased P-ERK1/2. (A) Western blot analysis of MDA-MB-
231 cells transfected with a Control (231+shControl) or a Nodal-
targeted shRNA (231+shNodal) showing that phosphorylation of
ERK1/2 decreases when Nodal is reduced. Addition of recombinant
human Nodal (rhNodal; 100 ng/mL) restores ERK1/2 phosphorylation in
231+shNodal cells. Total ERK1/2 and β-Actin are used as controls. (B)
Western blot analysis validating that U0126 reduces phosphorylation of
ERK1/2 in parental MDA-MB-231 cells. Total ERK1/2 and β-Actin are
used as controls. (C) Cellular invasion (through Matrigel) and (D)
cellular migration (no Matrigel) of 231+shControl or 231+shNodal cells
through a Transwell chamber in the presence or absence of rhNodal
(100 ng/ml) U0126 (10 M) (24 hrs). Cellular invasion and migration
were significantly reduced in 231+shControl cells treated with U0126,
and this was not rescued with rhNodal. Cellular invasion and migration
were significantly decreased in 231+shNodal cells as compared to
231+shControl cells, and the inclusion of rhNodal rescued invasion and
migration in 231+shNodal cells to control levels. This ability of rhNodal
to rescue the effects of shNodal on invasion and migration was
mitigated by U0126 (n=3, different letters are significantly different,
p<0.001). (E) Bar graph summarizing the results of LIVE/DEAD
Cytotoxicity/Viability assays (Invitrogen). Viability was constant across
all MDA-MB-231 treatment conditions after 24 hours (corresponding to
C and D) (n=8).
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Figure 4.12 Nodal inhibition reduces expression of mesenchymal
markers in MDA-MB-231 cells. (A) Real time RT-PCR analysis of EMT
markers in MDA-MB-231 cells treated with SB431542 small molecule
inhibitor (0 or 10 M, 48 hrs). In response to SB431542, which inhibits
ALK4/7, MDA-MB-231 cells displayed reduced expression of TWIST1
(n=3, p<0.001), CDH2 (n=3, p<0.001), and VIM (n=3, p=0.001). CDH1
and ESR1 did not change in response to SB431542. All data are
presented as mean S.E.M for replicate values, and asterisks ( )
indicate a significant difference compared to 0 M controls as specified.
(B) Real time RT-PCR analysis of EMT markers in MDA-MB-231 cells
stably transfected with a Nodal-targeted shRNA (231+shNodal) or a
scrambled Control shRNA (231+shControl). 231+Nodal cells displayed
reduced expression of TWIST1 (n=3, p<0.001), CDH2 (n=3, p<0.001),
and VIM (n=3, p=0.031). CDH1 and ESR1 were not significantly
different between 231+shNodal cells and 231+shControl cells. All data
are presented as mean S.E.M for replicate values, and asterisks ( )
indicate a significant difference compared to 231+shControls as
specified. (C) Western blot showing that 231+shNodal cells exhibit
lower protein expression for mesenchymal markers N-Cadherin,
Vimentin, and Slug, compared to 231+shControls. β-Actin is used as a
control.
231
or ESR1 expression compared to 231+shControl cells (Figure 4.12B). In 
accordance with these results, Western blot analysis revealed that mesenchymal 
markers N-Cadherin, Vimentin and Slug were lower in 231+shNodal cells 
compared to 231+shControl cells (Figure 4.12C). Taken together, while we did 
find that Nodal inhibition reduced mesenchymal marker expression in highly 
aggressive MDA-MB-231 cells, we did not find any alterations in epithelial marker 
expression, indicating that Nodal knockdown is not enough to induce a full 
mesenchymal-to-epithelial transition in poorly differentiated cell lines.  
 
4.4.5 Nodal inhibition reduces spontaneous metastasis of breast cancer to 
the liver 
In corroboration with our in vitro assays, we performed a spontaneous 
metastasis assay using highly invasive MDA-MB-231 breast cancer cells that 
express high basal levels of Nodal. MDA-MB-231 cells were transfected with a 
Nodal-targeted doxycyclin (Dox)-inducible shRNA construct (231+ishN), or a 
control Dox-inducible shRNA construct (231+ishC) (Figure 4.13A,B), and 
injected into the mammary fat pads of 7-8 week old NSG mice. Dox was 
administered in mouse chow one week after injections.  Tumours were palpable 
( 2 mm diameter) at this time. Once tumours reached 1.3 cm in diameter (end 
point varied depending on depth of tumour), which took approximately 5 weeks, 
mice were sacrificed, and lungs and livers were collected.  
Upon examination of lung tissue stained with H E, we saw no difference 
in the percentage of tumour burden in the lung across treatments (Figure 
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Figure 4.13 Validation of inducible shRNA transfection into MDA-
MB-231 cell lines. (A) Western blot analysis demonstrating that MDA-
MB-231 cells transfected with a Nodal-targeted doxycyclin (Dox)-
inducible shRNA (231+ishN) downregulate Nodal protein expression
upon administration of Dox compared to MDA-MB-231 cells transfected
with a scrambled control Dox-inducible shRNA (231+ishC). (B) Confocal
images of 231+ishC cells and 231+ishN cells +/- Dox in culture, used to
confirm the inducibility of the transfected shRNA constructs. Doxycyclin
induces the expression of RFP in the transfected shRNA construct in
both control and Nodal-knockdown cell lines. Nuclei are stained with
DAPI (blue) and bars equal 20 μm.
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4.14A,B). Interestingly, tumour burden ranged from approximately 10%-95%, 
indicating that in many cases, lung tissue was not over-saturated with tumour. 
Although macroscopically, we found no difference in lung tissue upon sacrificing 
the mice, we did see robust differences in liver metastases, whereby 231+ishN 
+Dox groups had macroscopically observable lesions in only 1/10 mice 
(compared to 7/11 for 231+ishC Dox, 6/10 for 231+ishC +Dox, and 11/15 for 
231+ishN Dox) (Figure 4.15A). Accordingly, we stained liver tissue with H E 
and measured the percentage of tumour burden per liver section across 
treatments. We found that there was a significant decrease in extent of liver 
metastases in 231+ishN +Dox mice compared to all other treatment groups 
(Figure 4.15B). 
 
4.5 Discussion 
Here we show for the first time that Nodal promotes invasive phenotypes 
in both breast cancer and choriocarcinoma cell lines. We reveal a link between 
Nodal and the induction of EMT-like phenomena in multiple cell types to yield a 
more aggressive phenotype both in vitro and in vivo. These observations are in 
accordance with others that have found a link between Nodal and cancer 
invasion, for example, during glioma invasion or melanoma progression (10,12), 
and with previous work from our laboratory demonstrating a link between Nodal 
and breast cancer progression in xenograft models (37). Indeed, previous studies 
have found that Nodal is rare in radial growth phase melanoma, but is frequently 
expressed during vertical growth phase melanomas and in melanoma 
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Figure 4.14 Nodal inhibition does not affect spontaneous
metastasis of breast cancer to the lung. 500,000 231+ishC or
231+ishN cells were injected into the right thoracic mammary fat pad of
NSG mice. Doxycyclin was administered 1 week following injection.
Mice were sacrificed when tumors reached 1.0-1.5 cm in diameter and
lung and livers were analysed macrosopically or using H&E stained
sections. (A) Images of lung sections stained with H&E across
treatment groups. Bar equals 1 mm. (B) Quantification of tumor burden
in lungs show no significant differences between treatment groups
(n=10). Each point represents the average tumor burden for one animal
and the filled diamond indicates the median value. Different letters
indicate a significant difference.
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Figure 4.15 Nodal inhibition reduces spontaneous metastasis of
breast cancer to the liver. 500,000 231+ishC or 231+ishN cells were
injected into the right thoracic mammary fat pad of NSG mice.
Doxycyclin was administered 1 week following injection. Mice were
sacrificed when tumors reached 1.0-1.5 cm in diameter and lung and
livers were analysed macrosopically or using H&E stained sections. (A)
Images of livers from mice injected with 231+ishC or 231+ishN cells and
fed either normal or Dox-containing chow. Metastases have been
outlined by a white dashed line and bar equals 1 mm. (B) Quantification
of tumor burden in livers shows a significant decrease in metastasis in
231+ishN +Dox mice compared to all other groups (n=10, p<0.05).
Each point represents the average tumor burden for one animal and the
filled diamond indicates the median value. Different letters indicate a
significant difference.
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metastases (12). Furthermore, Nodal is highly expressed in invasive breast 
cancer lesions (7).  The current study mechanistically addresses these previous 
correlations by demonstrating that Nodal promotes and sustains invasive 
phenotypes.  
We found that Nodal supports cellular invasion through altered expression 
of epithelial and mesenchymal cell markers in both choriocarcinoma and breast 
cancer cell lines. This adds Nodal to a growing list of TGF-β family members that 
have been shown to regulate EMT in normal epithelial cells and during cancer 
progression. For example, TGF-β promotes EMT in a variety of cell types 
including breast cancer cells, pulmonary epithelial cells and keratinocytes (38), 
and differentiation factor-9 (GDF-9) has been shown to induce EMT in prostate 
cancer (39). Interestingly, GDF is a member of the TGF-β family that has been 
shown to dimerize with Nodal in the embryonic node to mediate Left-Right 
asymmetry (40). As it has been shown that EMT is associated with invasive 
phenotypes, and that EMT is often induced by stem cell-associated proteins, it 
fits that our findings implicate Nodal during this complex transition. 
We determined that Nodal promotes cellular invasion and EMT-like 
phenomena via the activation of the ERK1/2 MAPK pathway in breast cancer and 
choriocarcinoma. Prior to this study, the effects of Nodal on cellular behavior 
during development and in cancer were largely attributable to the induction of 
SMAD signalling. However, many TGF-β superfamily proteins, which share 
similarities between type I and type II receptor components, employ non-SMAD 
pathways during signal propagation. Specifically, TGF-β has a profound effect on 
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activation of ERK signalling, through phosphorylation of ShcA and activation of 
the GRB2/SOS complex via its type I receptor (21). Moreover, TGF-β promotes 
EMT at least in part via ERK1/2 MAPK signalling (38). For example, TGF-β was 
shown to induce ERK and p38 signalling in human skin keratinocyte cells 
(HaCaT), ras-transfected H357 keratinocytes, and malignant Il-3 keratinocytes to 
induce EMT (22); and inhibition of MEK with U0126 reversed TGF-β-induced 
EMT in H357 and Il-3 cell lines (22). Cripto, Nodal’s co-receptor protein, can also 
signal through ERK (41). In one study, NCCIT teratocarcinoma cells were shown 
to have high basal levels of P-ERK1/2 as well as high Cripto expression. Cripto 
knockdown in these cells significantly impaired P-ERK1/2, and this was rescued 
with the inclusion of soluble Cripto (41). Moreover, treatment of MCF-10A cells 
(which exhibit undetectable Cripto) with rhNodal did not stimulate proliferation 
(indicative of ERK signalling); however, over-expression of Cripto in MCF-10As 
rendered cells susceptible to rhNodal-induced proliferation (41). Together, these 
studies suggest that multiple mechanisms of MAPK activation, perhaps receptor-
mediated either through ALK or Cripto proteins, may explain our findings that 
Nodal can activate non-SMAD pathways, specifically ERK, to elicit its effects.  
Our results suggest there may be multiple points of crosstalk between the 
SMAD2/3 and ERK1/2 pathways. First, we demonstrate that addition of rhNodal 
to cells causes an upregulation of phosphorylated ERK1/2. Based on reports of 
TGF-β-induced ERK activation, this may be an indirect effect via receptor 
phosphorylation of an upstream mediator of the ERK cascade (such as ShcA) 
(21), or a direct effect via receptor phosphorylation of ERK1/2 (42). Second, we 
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show that MEK inhibition leads to a decrease in Nodal-induced phosphorylation 
of SMAD2. As mentioned, previous studies in development have shown that the 
SMAD2/3 linker region is receptive to phosphorylation by MAPK pathways, 
specifically phospho-p38 (20). ERK1/2 MAPKs may similarly phosphorylate 
SMAD2/3 to facilitate Nodal-induced signalling. Third, we show that MEK 
inhibition reduces transcription of Nodal-induced TWIST1. In agreement with 
previous findings, this suggests that ERK may alter SMAD-mediated gene 
expression, either through regulating translocation of SMAD proteins to the 
nucleus, or by directly interfering with gene transcription (43). We also found that 
MEK inhibition rescued Nodal-induced mislocalization of E-Cadherin. In 
accordance with these observations, previous reports have shown that inhibition 
of the ERK pathway is required for relocalization of E-Cadherin to the plasma 
membrane after internalization during EMT (44,45). 
An important finding in our study is that Nodal inhibition in highly invasive 
breast cancer cells can revert cellular behavior to a less-aggressive state, and 
impair breast cancer metastasis to secondary organs. These results mirror the 
effects observed in our gain-of-function models, suggesting that Nodal-induced 
phenotypes may be reversible in advanced disease. In accordance with these 
observations, one group found that tumour supressor zinc-α2-glycoprotein (ZAG) 
was able to reduce cellular invasion through induction of TGF-β-mediated MET in 
pancreatic ductal adenocarcinoma, marked by a downregulation of VIM, and 
upregulation of KRT19 (Keratin19) and CDH1 expression (46). Interestingly, 
ZAG-induced MET was mediated via modulation of TGF-β-mediated ERK2 
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phosphorylation (46). These findings closely mirror our findings with Nodal 
inhibition in MDA-MB-231 cells, whereby invasion is correlated with Nodal 
expression, and Nodal inhibition causes a reduction in mesenchymal markers 
concomitant with a decrease in Nodal-induced P-ERK1/2. These findings provide 
multiple possible targets and time points for clinical intervention in patients with 
Nodal-positive tumours.  
In our NSG mouse model, we observed a marked difference in Nodal-
mediated tumour burden between lung and liver breast cancer metastases. 
Specifically, we saw that alterations in Nodal expression in MDA-MB-231 cells 
had no effect on lung metastasis, while it did for liver metastasis. There are a 
number of possibilities for this outcome. First, Nodal may regulate factors that 
differentially mediate organ-specific metastasis. For example, it has been shown 
that Claudin-2 is required for the initiation and growth of breast cancer liver 
metastases; however, interestingly, cell lines generated from aggressive breast 
cancer liver metastases with elevated Claudin-2 expression show decreased 
spontaneous metastasis to the lung by more than 3-fold (47). Other studies have 
reported differences in expression of chemotactic signalling axes between cancer 
cells and specific organ destinations. For example, CXCR4 is known to be 
elevated in breast cancer, while its ligand, CXCL12, is elevated in common sites 
of breast cancer metastasis, including liver, bone marrow and lung (48,49). It is 
possible that Nodal supports tumour metastasis to specific sites through 
regulating factors associated with organ-specific metastasis.  
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Another possible explanation for the differences in lung versus liver 
metastasis is that the NSG mouse model is highly permissive to metastasis due 
to a severely reduced immune system. In the human condition, this hypothesis is 
supported by the fact that organ transplant recipients undergoing immune-
suppression therapies have an elevated incidence of cancer (50,51). Moreover, 
differences in tumour-initiation have been reported between different model 
organisms with different immune system backgrounds. For example, Morrison 
and colleagues have shown that melanoma cells have elevated tumour growth 
and tumour-initiating frequency in NSG mice (approximately 25% of cells 
injected) compared to NOD/SCID mice (approximately 0.0001% of cells injected) 
(52,53). In accordance with these findings, it has been reported that tumour cells 
generated in immunocompromised mice do not form tumours in syngeneic 
immuno-competent mice; whereas, tumour cells generated in immuno-competent 
mice can form tumours in both immuno-competent or immunocompromised mice 
(54). Whether there is a connection between Nodal expression and immune 
surveillance during cancer progression is currently unknown. 
 Taken together, our results demonstrate that Nodal promotes invasive 
phenotypes in both breast cancer and choriocarcinoma cell lines. We found that 
Nodal supports cellular invasion through altered expression of epithelial and/or 
mesenchymal cell markers, and that Nodal can activate non-SMAD pathways, 
specifically ERK, to elicit its effects. Most importantly, we show that Nodal 
inhibition in highly invasive cells can revert cellular behaviour to a less-
aggressive state, and reduces breast cancer metastasis to the liver. Our findings 
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lend insight to recent studies that implicate Nodal in the progression of various 
types of cancer, and provide multiple possible targets to which clinical 
intervention might be effective.   
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5.0 General Discussion and Conclusions 
This study reveals, for the first time, that the embryonic protein Nodal mediates 
metastatic phenotypes in breast cancer. It is well-documented that the acquisition of 
embryonic signatures is associated with cancer progression. Although previous studies 
have shown that Nodal contributes to a malignant phenotype (1-5), the studies in this 
thesis link Nodal to a unique variety of cellular functions that have not been previously 
explored, including novel mechanisms of non-SMAD signalling. I have also 
demonstrated that cellular functions classically attributed to Nodal in embryonic 
contexts, such as cellular invasion, are maintained in breast cancer (6).  I have also 
demonstrated that Nodal mediates multiple phenotypes that are mechanistically 
divergent, albeit interconnected, in accordance with the principle that embryonic 
proteins can have widespread and adverse effects when they usurp adult tissue 
homeostasis. Taken together, my research has elucidated novel contributions of the 
embryonic protein Nodal to the metastatic dissemination of breast cancer, and has 
exposed many interesting new questions about Nodal-mediated events in breast 
cancer. 
 
5.1 Novel roles for Nodal in cancer 
This study demonstrates multiple novel roles for Nodal during cancer 
progression. First, I have shown that Nodal has a robust effect on breast cancer 
angiogenesis, and that the expression of Nodal correlates positively with vascular 
density in human breast cancer lesions. A previous report by Hueng et al., titled 
“Inhibition of Nodal suppresses angiogenesis and growth of human gliomas”, 
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demonstrated that Nodal is correlated with VEGF in human gliomas, and that Nodal 
knockdown leads to reduced tumour size and vessel length (measured in tissue 
sections) in vivo (7). However, this report did not demonstrate the effects of Nodal on 
angiogenesis, as the title and contents of the paper suggest (7). Angiogenesis is a 
process, and although a tumour’s vascular density and VEGF expression are indicative 
of angiogenic potential, they are not a measure of functionality. Moreover, 
measurements of vessel length in random fields of view do not necessarily account for 
vessel density. Rather, according to the International Consensus on Evaluation of 
Angiogenesis in Solid Human Tumors, grading of angiogenic “hotspots” is a more 
accurate method to assess tumour vascularization. By this consensus, vessel grading is 
based on the number of vessels in one hotspot, and is evaluated irrespective of vessel 
length. Although the hotspot method is admittedly simplified (8), there is little evidence 
to support the notion that longer vessels are worse for cancer outcome than smaller 
vessels, or that vessel length alone is a reliable prognostic indicator. In fact, studies 
have reported the opposite correlation, that vessel length is significantly lower in 
tumours compared to corresponding normal tissue (9). Indeed, all studies that explore 
the relevance of vessel length quantify per unit volume of tissue, since 2D sections are 
not appropriate for assessing a 3D phenomenon (such as length) (8,9). In this study, the 
hotspot method was used to determine that Nodal is correlated with high tumour 
vascular density, thereby providing more reliable and clinically-relevant evidence that 
Nodal is associated with the angiogenic progress.  
In light of these arguments, I have shown here for the first time, a functional 
connection between Nodal and angiogenesis. In vitro, Nodal promotes tube formation 
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and migration of multiple endothelial cell types, including human adult microvascular 
endothelial cells (HMVECs) and human umbilical vein endothelial cells (HUVECs). In 
vivo, Nodal promotes vascular recruitment in multiple animal models, and inducible 
Nodal inhibition following tumour formation significantly reduces vascular density. We 
found that Nodal elicited its angiogenic effects through production of pro-angiogenic 
proteins; however, the effects we saw in vivo were quite robust, and therefore may be 
mediated by additional unexplored mechanisms. One possibility is that Nodal promotes 
mobilization of bone marrow derived cells (BMDCs) to contribute to de novo vessel 
formation. Indeed, it has been reported that endothelial progenitor cells from bone 
marrow incorporate into breast tumour-associated neovessels (10). Furthermore, many 
studies have demonstrated that impaired BMDC recruitment disrupts tumour 
vascularization in vivo (10,11). Given that Nodal mediates stem cell fate and plays a 
directive role during embryonic morphogenesis, it is conceivable that it may also 
regulate progenitor mobilization from the bone marrow to support tumour 
vascularization.  
Another novel finding in this study is that Nodal potentiates ERK signalling in 
breast cancer and choriocarcinoma cells. I have demonstrated that Nodal induces 
phosphorylation of ERK1/2 in poorly invasive breast cancer and choriocarcinoma cell 
lines, and that phosphorylation is mitigated when the Nodal type I receptor is inhibited.  
Conversely, when ERK signalling is inhibited with a MEK inhibitor, Nodal-induced 
phosphorylation of SMAD2 is reduced. This demonstrates a link between canonical 
Nodal signalling and ERK in cancer. In accordance with these results, studies have 
reported signalling crosstalk between SMAD2/3 and ERK pathways. Studies with TGF-β 
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have shown that the type I receptor can phosphorylate both ShcA and ERK1/2 (12,13). 
Furthermore, the linker region of SMAD2/3 has been shown to be receptive to 
phosphorylation by p38 MAPK signalling (14): It is possible that ERK can phosphorylate 
SMAD2/3 by a similar mechanism.  
Functionally, I have demonstrated that Nodal-induced ERK signalling in part 
mediates invasive phenotypes and EMT in breast cancer and choriocarcinoma cell lines 
that are otherwise poorly invasive and well-differentiated. In accordance with these 
findings, in normal mammary gland epithelial cells TGF-β-induced EMT has been 
shown to be dependent on ERK signalling inclusive of a reduction of cell surface E-
Cadherin (15). However, my studies are the first to report a link between Nodal, ERK 
and EMT in both breast cancer and in choriocarcinoma. Future studies should examine 
if this fundamental discovery also applies to other phenomena where Nodal is present 
and when cellular migration and EMT occurs, such as embryonic morphogenesis, 
mammary gland development, and endometrial cycling (3,16).  
 
5.2 Classical Nodal-associated phenotypes are recapitulated in breast cancer 
In addition to the novel roles for Nodal revealed in this study, phenotypes that 
have been previously associated with Nodal in other cancer types were confirmed for 
the first time in breast cancer. For example, I show here that Nodal promotes elevated 
proliferation:apoptosis ratios in breast cancer cell lines, both in vitro and in vivo. In 
accordance with these findings, Hardy et al. showed that Nodal was correlated with 
aggressive phenotypes in melanoma, and that Nodal expression was induced by 
Notch4. Interestingly, this study demonstrated that the Notch4/Nodal relationship alters 
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proliferation:apoptosis ratios in favour of growth, and supports the acquisition of 
aggressive phenotypes in poorly aggressive melanoma cells (17). This study did not 
investigate whether Nodal could alter proliferation:apoptosis ratios irrespective of 
Notch4 status (17). Interestingly, it has been shown that Notch4 is not expressed in 
T47D breast cancer cells (18), yet I have shown that Nodal does indeed mediate 
changes in proliferation:apoptosis ratios in this cell line. This suggests that Nodal may 
regulate the proliferative capacity of these cells in a Notch-independent manner. 
In contradiction with these results, several studies by Peng and colleagues have 
reported that Nodal promotes apoptosis and inhibits proliferation in trophoblast, breast 
cancer, and ovarian cancer cells (19-21). The key experimental difference in these 
studies is that Nodal was overexpressed in cells that express high endogenous Nodal, 
whereas here, Nodal was inhibited in cells that express high endogenous Nodal. 
Furthermore, Peng and colleagues use 500 ng/mL of recombinant mouse Nodal on 
cells that express high Nodal, which is 5-fold higher than the dose of recombinant 
human Nodal (rhNodal) used in this thesis on cells that express low Nodal (21). 500 
ng/mL is also more than 5-fold higher than the dose of Nodal required to maintain 
pluripotency in hESC cultures (22,23), indicating that this concentration may be beyond 
physiological relevance. Alternatively, assuming that cell viability was incorporated as a 
control (as it should always be), these data raise the curious possibility that a 
concentration-dependent biphasic mechanism might be at play, similar to the function of 
TGF-β (24,25). To address this possibility, I performed Transwell migration assays on 
T47D and MCF-7 breast cancer cells treated with 0, 50, 100, or 500 ng/mL of rhNodal, 
and I found that migration was mitigated at 500 ng/mL (Figure 5.1). In agreement with 
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Figure 5.1 Nodal has a biphasic concentration-dependent effect on
cellular migration. (A) Experiment corresponding to Figure 4.1B, with
an additional treatment (500 ng/mL rhNodal) incorporated into the data
set. T47D migration through a Transwell chamber was significantly
lower in response to 500 ng/mL rhNodal, compared to 100 ng/mL
(p=0.015, n=4). (B) Experiment corresponding to Figure 4.1C, with an
additional treatment (500 ng/mL rhNodal) incorporated into the data
set. MCF-7 migration through a Transwell chamber was significantly
lower in response to 500 ng/mL rhNodal, compared to 100 ng/mL
(p=0.005, n=4). Different letters indicate a significant difference of
p<0.05 (unless indicated otherwise). Bars represent mean ± S.E.M. for
replicate values.
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these findings, another member of our lab performed the same experiment on HTR-
8/SVneo trophoblast cells, and found similar results (16). This suggests that although 
high Nodal expression is correlated with tumour growth, very high doses of Nodal may 
have the opposite effect. A wider range of Nodal concentrations should be used in 
future experiments to improve our understanding of this impending phenomenon. 
However, again, it should be noted that it is unclear whether these high doses of Nodal 
are physiologically relevant. 
Invasion is another phenotype associated with Nodal in multiple contexts, that has 
likewise been linked to Nodal in breast cancer and choriocarcinoma in this study. I have 
shown that Nodal promotes cellular invasion and migration in poorly aggressive breast 
cancer and choriocarcinoma cell lines. Conversely, I have shown that Nodal inhibition 
reverts invasive phenotypes in highly aggressive breast cancer cell lines. In accordance 
with these observations, Nodal has been linked to cellular invasion in melanoma and 
glioma (1,2), and previous studies from our laboratory have shown that Nodal is 
correlated with invasion in trophoblast cell lines (16). Interestingly, Peng and colleagues 
have reported seemingly contradictory results, whereby Nodal was shown to inhibit 
trophoblast cell migration and invasion (26). However, as mentioned in the previous 
discussion about proliferation:apoptosis, this may be explained by the possibility that 
Nodal may induce a biphasic effect on cell invasion and migration (16). However, future 
experiments ought to be performed to validate these speculations. 
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5.3 Cancer phenotypes are connected 
Phenotypes associated with cancer progression work in concert, and 
connections between the phenotypes explored here have been reported at length in the 
literature. Bone marrow-derived cells, in particular, seem to be a major driving force that 
connects multiple aspects of tumourigenesis, as they contribute to the composition of 
the tumour stroma and the pre-metastatic niche (27-30). Given that Nodal has a 
widespread effect on breast cancer phenotypes, it is valuable to consider what “master 
regulators” of disease progression might be receptive to Nodal signalling. Note that the 
following discussion is based largely on breast cancer, since breast cancer constitutes 
the majority of this thesis, and a large portion of the choriocarcinoma study was 
contributed by Guihua Zhang. 
 
5.3.1 Links between tumour growth and angiogenesis 
5.3.1.1 Tumour mass dormancy and the angiogenic switch 
That tumour growth is dependent on the ability to recruit a vasculature has been 
reported extensively in the literature with respect to multiple different tumour types, at 
both primary and secondary sites (11,31-34). The inability of tumours to growth beyond 
a certain size due to insufficient vascularization is called Angiogenic Dormancy, or 
Tumour Mass Dormancy (35). At secondary sites, tumour mass dormancy is 
characterized by metabolically active avascular micrometastatic lesions that do not grow 
beyond 1-2 mm in diameter (in accordance with the diffusion limit of oxygen (36)) due to 
a balance between proliferation and apoptosis. The angiogenic switch marks the 
transition out of this dormant state, at which point metastases are said to be “macro” 
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(i.e. larger than 1-2 mm due to vascular infiltration), and exhibit elevated proliferation 
rates compared to apoptosis (31,35,36). In this study (Chapter 2), I have demonstrated 
that Nodal is required for the transition from micro to macrometastatic growth, marked 
by a switch to a proliferation:apoptosis ratio (quantified by Ki67:TUNEL) greater than 1. 
Furthermore, I have shown that Nodal promotes a robust angiogenic phenotype in 
breast cancer (Chapter 3). It is possible that the mechanism of growth transition at 
secondary sites is due to a transition in angiogenic switching, mediated by Nodal 
expression. Indeed, when von Willebrand factor (vWF) was used to qualify 
vascularization in micrometastases (data not shown), I noticed that metastases formed 
by cells in which Nodal was knocked down frequently exhibited lower vascular 
infiltration. These data are in accordance with those reported by several research 
programmes, including those of Judah Folkman, Shahin Rafii, Vivek Mittal, and David 
Lyden (note: these names have been listed without permission from the individuals). 
 
5.3.1.2 Bone marrow-derived cells mediate the angiogenic switch 
One mediator of tumour mass dormancy is recruitment of bone marrow derived 
cells. Based on the finding that Nodal promotes angiogenesis, it is plausible that Nodal 
mediates recruitment of bone marrow-derived progenitor cell types to promote an 
angiogenic phenotype. In an elegant experiment by Gao et al. published in Science in 
2008, MMTV-PyMT mice were reconstituted with GFP+ bone marrow, and pulmonary 
metastases were analysed. Results showed that micrometastases were avascular, 
while macometastases exhibited high vascularity with GFP+ EPC incorporation (11). 
Interestingly, inhibition of one protein, Id1, prevented the transition from micro to 
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macrometastatic growth, by blocking EPC recruitment and the angiogenic switch (11). 
These results mirror my finding that Nodal inhibition prevents the switch from micro to 
macrometastic growth in the lung (Chapter 2). It is possible that like Id1, Nodal 
mediates the angiogenic switch at secondary sites through recruitment of EPCs. 
Indeed, based on my results, BMDC mobilization is now being investigated in our 
laboratory.   
 
5.3.2 Links between angiogenesis and invasion
5.3.2.1 Bone marrow-derived myeloid cells promote MET  
In this study I have shown that Nodal promotes EMT in poorly aggressive breast 
cancer and choriocarcinoma cell lines, and that Nodal inhibition promotes a loss of 
mesenchymal markers (a partial MET) in highly aggressive breast cancer cell lines. 
Furthermore, Nodal was associated with increased liver metastases in a mouse model 
of spontaneous metastasis. Although it is well-documented that EMT mediates invasion 
and metastasis to secondary sites, studies have (paradoxically) shown that secondary 
metastases often display an epithelial-like phenotype (37-39). This suggests that while 
EMT events early in the metastatic cascade are requisite for dissemination and 
translocation of tumour cells, MET events later in the metastatic cascade are important 
for secondary tumour growth. In other words, phenotypic switching by tumour cells, 
rather than EMT specifically, is a necessary component of successful metastasis. Gao 
et al. recently published an article in Cancer Research that examined this phenomenon, 
in light of the fact that bone marrow derived cells play a critical role in the angiogenic 
switch to macrometastases. They found that during breast cancer metastasis, bone 
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marrow derived myeloid progenitor cells were recruited to the pre-metastatic lung. Upon 
the arrival of breast cancer cells, these myeloid progenitor cells were able to induce 
mesenchymal-to-epithelial transition of tumour cells through downregulation of SMAD2 
signalling, to promote a switch to macrometastatic growth (37). Given that Nodal is a 
marker of pluripotency in embryos, and that Gao showed that downregualtion of SMAD2 
signalling mediated MET in secondary lesions, it is possible that Nodal regulates these 
switching events in cancer cells. Consistent with this hypothesis and with Gao’s 
observations, studies have reported that subpopulations of breast cancer cell lines 
undergo phenotypic switching, marked by shifts in CD44 and CD24 expression, in a 
Nodal/Activin-dependent manner (40).  
 
5.3.2.2 Tumour-associated macrophages promote vascularization and secrete 
proteolytic enzymes 
Macrophages are another tumour-associated cell type (also known as TAMs) 
that have a profound effect on both cellular invasion and angiogenesis (41-44). In a 
study published in Cancer Cell by Hanahan and colleagues, gene expression analyses 
were performed at progressive stages of pancreatic cancer in RIP1-Tag2 mice (which 
spontaneously develop pancreatic islet tumours due to expression of the SV40 T 
antigen) (42). They found that macrophage-derived cysteine cathepsins were 
upregulated during disease progression, and played a major role during the angiogenic 
switch and tumour cell invasion (42). In another study by Condeelis’ research group, 
gene expression analyses were performed on breast TAMs, which revealed that TAM-
expression profiles resembled developmental signatures (45). Condeelis’ group also 
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demonstrated that triple-clustering of TAMs, endothelial cells, and a pro-invasive protein 
called MENA is predictive of metastatic disease, a prognostic indicator Condeelis calls 
TMEM (29). In accordance with these findings, I have shown here that Nodal regulates 
both angiogenesis and tumour cell invasion in breast cancer. Furthermore, I have 
shown that Nodal expression is correlated with vascular density in human tissue 
sections demarcated by CD31. It is possible that Nodal mediates these phenotypes 
through regulation of tumour-TAM interactions, especially since TAM recruitment is 
often associated with an embryonic signature (45).  
 
5.3.2.3 Proteolytic enzymes
One connective feature of both cellular invasion and angiogenesis that was not 
explored in this study, but that would be worth investigating in the future, is proteolytic 
degradation. I have demonstrated that although Nodal promotes both migration and 
invasion through Transwell chambers, higher doses of rhNodal are required to affect 
invasion. This finding was recapitulated in both T47D and MCF-7 poorly aggressive 
breast cancer line, treated with increasing doses of rhNodal (Chapter 4). The key 
difference between migration and invasion assays is that invasion requires proteolytic 
degradation through the Matrigel layer on the Transwell membrane. Proteolysis is a key 
step in cellular invasion to mediate degradation of the basement membrane and the 
ECM. Proteolytic degradation of the ECM is also important during angiogenesis to make 
room for sprouting vasculature. It is plausible that Nodal regulates proteolytic networks 
(at higher concentrations than are required for migration) to dually mediate its invasive 
and angiogenic effects. In support of this hypothesis, studies have shown that TGF-β1 
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promotes MMP expression in highly aggressive MDA-MB-231 breast cancer cells and 
inhibits expression of MMP-inhibitor, RECK, in an ERK-dependent manner (46). Given 
the similarities between Nodal and TGF-β, and that Nodal regulates ERK signalling in 
breast cancer cells, a similar mechanism might be used by Nodal to regulate invasion 
and/or angiogeneis; however, this has yet to be investigated. 
 
5.3.2.4 Tumour hypoxia 
 Hypoxia is a phenomenon that occurs once tumours grow beyond the limits of 
oxygen diffusion (36), that upregulates both pro-invasive and pro-angiogenic 
programmes. Indeed, cellular invasion and angiogenesis are two of the most commonly 
studied hypoxia-induced phenotypes. In a previous report from our laboratory published 
in Molecular Biology of the Cell, we showed that hypoxia induces Nodal expression to 
upregulate invasion, migration, and tube formation in otherwise poorly-aggressive 
breast cancer cell lines (47). Furthermore, Nodal knockdown by shRNA prevented the 
induction of these phenotypes under hypoxic conditions. It is possible that in my in vivo 
studies, tumour hypoxia increased the expression of Nodal thereby promoting 
metastasis and angiogenesis. Furthermore, given the ability of Nodal knockdown to 
prevent angiogenesis and metastasis (hypoxia-induced phenomena), it is possible that 
Nodal is a pivotal regulator of certain hypoxia-induced phenotypes.  
265
5.3.3 Links between tumour growth and invasion
5.3.3.1 ERK regulates migration and proliferation 
MAPK signalling has long been associated with promoting proliferation and 
invasion in breast cancer (48). Here I have shown that Nodal induces a non-canonical 
ERK MAPK signalling pathway to promote cellular invasion. This is not surprising given 
the role of TGF-β in promoting invasion and proliferation through SMAD-ERK crosstalk 
in keratinocytes and epithelial cells (12,49). I have also shown that Nodal-induction of 
ERK causes invasion through EMT and upregulation of TWIST1 and VIM. In 
accordance with these findings, a previous study reported that TGF-β-induction of 
MAPKs, including ERK, causes phosphorylation and stabilization of TWIST1, resulting 
in EMT of breast cancer cells (50). Of note, Massagu  and colleagues have published 
extensively on the topic of non-canonical TGF-β signalling in cancer, and have found 
that MAPKs are major mediators of TGF-β’s tumourigenic effects (51). In cancer, 
mutations in the ERK pathway have been associated with progression of colon cancer, 
leukemias, and skin cancers, among others (52-54). Although I have shown that Nodal 
promotes invasive phenotypes in part through ERK signalling, whether Nodal also 
mediates its proliferative effects through alterations in ERK signalling remains elusive. 
 
5.3.3.2 Integrins and adhesion proteins 
In an experiment that was not included in this study, I performed an adhesion 
assay that revealed a significant decrease in ECM-adhesion in 231+shNodal cells 
compared to 231+shControls (Figure 5.2). In particular, adhesion to fibronection 
changed significantly, suggesting, perhaps, a shift in integrin expression in Nodal-
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Figure 5.2 Nodal inhibition alters cellular adhesion to ECM
proteins. MDA-MB-231 cells were transfected with a control shRNA
(231+shControl) or a Nodal-targeted shRNA (231+shNodal) and
subjected to a CytoSelect™ ECM Cell Adhesion Assay (CellBiolabs).
There was a significant decrease in adhesion to Fibronectin (p=0.001),
Collagen I (p=0.001) and Collagen IV (p=0.001) in 231+shNodal cells
compared to 231+shControl cells. No significant changes in adhesion to
Laminin I (p=0.062) or Fibrinogen (p=0.105) were seen between
treatments (n=4). Data are presented as mean ± S.E.M for replicate
values.
268
expressing versus Nodal-knockdown cell lines. Integrins are a family of cell surface 
adhesion proteins that are associated with cellular migration, proliferation, and 
apoptosis (55). Several studies have demonstrated that breast cancer progression is 
associated with increased expression of β3 integrin (56-58). One such study reported 
that the pro-tumourigenic effects of TGF-β during breast cancer progression, including 
EMT and metastasis, was mediated in part by interactions between the TGF-β Type II 
receptor and β3 integrin (56). Another study demonstrated that αvβ1 was correlated 
with lymph node metastases in breast and pancreatic cancer patients (59). Given that 
integrins play a regulatory role in both proliferation and invasion of cancer cells, these 
reports suggest that Nodal and integrin regulation may be worth future investigation.  
 
5.3.3.3 Cripto is associated with invasion and proliferation in cancer 
One important aspect of Nodal signalling is Cripto, and it is likely that the effects 
of Nodal signalling in breast cancer depend on the presence of this co-receptor on 
tumour cells and/or tumour-associated cell types. During embryonic axis patterning, 
Cripto mediates Nodal signalling, differentiating its promiscuous SMAD2/3 pathway from 
other TGF-β and Activin ligands (60,61). Studies have shown that Cripto is 
overexpressed in a subset of primary melanomas and cell lines, and that Cripto 
expression is correlated with invasive and proliferative phenotypes (62). Cripto 
expression is also associated with tumourigenesis in breast and oral cancers (63-66). 
Cripto mediates its mitogenic and invasive effects through activation of Nodal-
independent Ras/MAPK and PI3K/Akt signalling pathways, in addition to stimulating 
Nodal-dependent SMAD2/3 (63). Given that Nodal signals in cancer depend on Cripto 
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expression, consideration of Cripto functionality may be useful for understanding how to 
effectively target Nodal during cancer progression.   
 
5.4 Conclusions 
Nodal is an embryonic protein that links multiple aspects of tumourigenesis at 
both primary and secondary sites. In this study I have demonstrated both novel and 
classical roles for Nodal during breast cancer: I have revealed a novel link between 
Nodal and angiogenesis, ERK signalling and EMT. I have also shown that classical 
Nodal-induced phenotypes, such as cellular invasion, exist in breast cancer and 
choriocarcinoma as they do in other types of cancer. My research has raised many 
curious questions that are worth further investigation, including the role of Nodal in 
regulating BMDC recruitment, proteolytic degradation, integrin expression, and tumour-
stroma interactions. Given that Nodal is normally restricted to embryonic or highly 
specialized adult contexts, targeting Nodal expression in breast cancer poses an 
exciting avenue for therapeutic intervention.  
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